TMF-13966464  CONFIDENTIAL   
GlaxoSmithKline group of companies   209348  
 Protocol Amd 01  
 1 
 TITLE PAGE  
Protocol Title: A Phase IIb Multi -Center, Randomised, Open Label Study to Assess the 
Efficacy and Safety of Sequential Treatment with [COMPANY_004]3228836 followed by P egylated 
Interferon Alpha 2a  in Participants with Chronic Hepatitis B Virus (B -Together)  
Protocol Number : 209348 / Amendment 01  
 
Compound  Number:  [COMPANY_004]3228836  
Brief  Title: Phase IIb Study of Sequential [COMPANY_004]3228836 and Peginterferon Treatment in 
Participants with Chronic Hepatitis B (B -Together)  
Study Phase:  Phase  IIB 
Acronym:  B-Together  
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline Research & Development Limited  
[ADDRESS_936951]  
Middlesex, TW8 9GS  
[LOCATION_006] 
Regulatory Agency Identifying Number(s):   
EudraCT:  2020 -002979 -35 
IND: IND 122685  
Approval Date:  24-SEP-[ADDRESS_936952] Informatio n:  
Can be found in the Study Reference Manual (SRM)  
Copyright 2021 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised copying or use of this information is prohibited.  
 
 

TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 2 
 SPONSOR SIGNATORY:  
Protocol Title: A Phase IIb Multi -Center, Randomised, Open Label Study to Assess the 
Efficacy and Safety of Sequential Treatment with [COMPANY_004]3228836 followed by [CONTACT_690617] 2a in Participants with Chronic Hepatitis B Virus (B -Together)  
Protocol Number : 209348  / Amendment 0 1 
Compound Number or Name:  [CONTACT_23983]3228836  
 
 
 
 
Dickens Theodore, MD, MPH  
Senior Director, Clinical Development  
Immunology and Fibrosis  
GlaxoSmithKline   Date  
The signed page is a separate document.  
 
 
 
 
Medical Monitor Name [CONTACT_9352] [CONTACT_126701] . 
 
TMF-[ADDRESS_936953] -2020  2020N427224_00  
 
Amendment 01 24-SEP-2021  
This amendment is considered to be non -substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the  Council of the 
European Union because it neither significantly impacts the safety or physical/mental 
integrity of participants nor the scientific value of the study . 
Overall Rationale for the Amendment:   
The primary drivers for this amendment were non -substantial changes, mostly for 
clarification , alignment with Study 209668, and to incorporate recommendations 
suggested in regulatory feedback.  
In addition, minor typographical errors and inconsistencies have been corrected and 
minor editorial changes have b een made. Changes made to the text body have been made 
concurrently in the synopsis.  
Section # and 
Name  [CONTACT_9353] 1.3  
Schedule of 
Activities,  
Table 2, Table 2  Added thyroxine ( T4) to thyroid 
assessments.  Correction.  
Section 1.3  
Schedule of 
Activities  
tables, as required 
and applicable text 
throughout  Changed “anti -HBsAb” to “anti -
HBsAg” and “anti -HBeAb” to 
“anti -HBeAg.”  Correction.  
Section 1.3  
Schedule of 
Activities,  
Table 4, Table 5 Removed separate bilirubin 
assessment as this is included within 
the chemistry assessments.  Correction.  
Section 1.3  
Schedule of 
Activities  
tables, as required Specified that hepatitis B virus 
e-antigen ( HBeAg ) assessment is 
only for participants who are HBeAg -
positive at Screening.  Correction.  
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 4 
 Section # and 
Name  [CONTACT_690663] 1.3  
Schedule of 
Activities , Table 7 Added footnote to specify that 
neuropsychiatric assessments 
(Columbia Suicide -Severity Rating 
Scale [ C-SSRS ] and Beck Depression 
Inventory -II [BDI-II]) only need to b e 
completed for participants who 
received at least 1 dose of PegIFN.  Correction.  
Section 1.3  
Schedule of 
Activities , Table 7 Added pharmacokinetic ( PK) 
assessment at early termination visit 
for PegIFN  Correction.  
Section 3  
Objectives  and 
Estimands and 
where applicable 
throughout  Updated text defining the population 
for the efficacy objectives to align 
with the definition of intent -to-treat 
(ITT) population which will be used 
in efficacy analyses and is defined as 
all randomized subjec ts. To align with Study 209668 
(B-Clear).  
Section 3  
Objectives and 
Estimand s and 
Section  [IP_ADDRESS] 
Secondary 
Estimands  Secondary Efficacy Endpoints:  
moved HBe  antibody (anti -HBeAg) 
levels from a continuous variable to a 
categorical variable.  Correction.  
Section 5.2  
Exclusion Criteria  Medical Conditions Number 3:  
provide clarity that liver biopsy and 
stiffness are historical measurements.  Provide clarity to investigators 
that these are for historical 
measurements, if available, not 
to be performed for ass essment.  
Section 5.3  
Inclusion and 
Exclusion Criteria 
for PegIFN  Added text to clarify  eligibility 
criteria for patients who  meet  
[COMPANY_004]3228836 liver monitoring hold 
or stoppi[INVESTIGATOR_690580] .  Clarification requested per the 
Food  and Drug Administration 
(FDA ). 
Section 5.3  
Table 8 
Eligibility Criteria 
to start PegIFN  Added “vii)” before “Ocular Exam .” Correction.  
Section  6.1 
Study 
Intervention(s) 
Administered  Changed the address of 
manufacturer /source of PegIFN 
([COMPANY_002]).  Correction.  
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 5 
 Section # and 
Name  [CONTACT_9353] 7.1.1  
[COMPANY_004]3228836 Liver 
Chemistry Stoppi[INVESTIGATOR_165761]:  
Cases such as Gilbert syndrome, 
where baseline bilirubin values are 
high, should be discussed with the 
Medical Monitor, to assess if it is a 
case of drug-induced liver inj ury 
(DILI ) or the participant may 
continue with dosing.  To clarify and identify 
instance s where medical 
monitor should be consulted.  
Section 7.1.[ADDRESS_936954] high performance l iquid 
chromatography (HPLC) assay 
(quantifies potential acetaminophen 
contribution to liver injury in 
participants with definite or likely 
acetaminophen use in the preceding 
week) should be conducted if 
available.  Serum acetaminophen adduct 
high performanc e liquid 
chromatography assay may not 
be available in all countries.  
Section 7.1. 2 
[COMPANY_004]3228863 
Haematological 
Stoppi[INVESTIGATOR_690581]:  
If the platelet count is uninterpretable 
or a decreasing trend is noted below 
lower limit of normal ( LLN ) 
reference range, re -check the platelet 
counts as soon as possible (the 
investigator may, at their discretion, 
opt to have the participant come to 
their next scheduled visit OR ask the 
participant to come earlier than their 
scheduled visit, as they feel 
appropriate based on review of the 
participant’s clinical presentation and 
laboratory results).  Samples showing 
platelet clumpi[INVESTIGATOR_690582].  Clarification and to provide 
guidance to investigator.  
Section 7.1.3  
[COMPANY_004]3228836 Drug 
Induced Kidney 
Injury (Renal) 
Stoppi[INVESTIGATOR_690583]3228836 drug induced 
kidney injury (renal) treatment 
hold/treatment discontinuation  
criteria  to identify changes in albumin 
to creatinine  ratio ( ACR ) and 
estimated glomerular filtration rate 
(eGFR ) relative to the pre -dose range 
instead of baseline.  Clarification and to provide 
guidance to investigator.  
Section [IP_ADDRESS]  
Columbia Suicide 
Severity Rating 
Scale  (C-SSRS)  Removed timeframe  from  C-SSRS 
screening questions.  Correction.  
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 6 
 Section # and 
Name  [CONTACT_9353] 9.5  
Inter im Analysis  Removed interim analysis 1.  Interim analysis 1 was 
originally planned  to determine 
futility and stop enrolment in 
the study . At the time of this 
protocol amendment, i t was no 
longer applicable because 
complete enrolment ha d already 
occurred.    
Section 10.2  
Appendix 2: 
Clinical Laboratory 
Tests  
Table 1 7 Changed SAE reporting bilirubin 
≤2X the upper limit of normal ( ULN ) 
to >2X ULN.  Correction, due to typo.  
Section 10.3.[ADDRESS_936955] show evidence 
within the electronic case report form 
(eCRF ) of review and verification of 
the relationship of each serious 
adverse event (SAE) to 
investigational product (IP)/study 
participation (causality) within 
72 hours of SAE entry into the eCRF.  To align with updated protocol 
template.  
Throughout  Minor editorial and document 
formatting revisions  Minor; therefore have not been 
summarized  
 
 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 7 
 TABLE OF CONTENTS  
PAGE  
1. PROTOCOL SUMMARY  ................................ ................................ ........................  11 
1.1. Synopsis  ................................ ................................ ................................ ..... 11 
1.2. Schema  ................................ ................................ ................................ ...... 17 
1.3. Schedule of Activities (SoA)  ................................ ................................ ........  18 
2. INTRODUCTION  ................................ ................................ ................................ .... 31 
2.1. Study Rationale  ................................ ................................ ..........................  31 
2.2. Background  ................................ ................................ ................................  32 
2.3. Benefit/Risk Assessment  ................................ ................................ ............  34 
2.3.1.  Risk Assessment  ................................ ................................ .........  35 
2.3.2.  Benefit Assessment  ................................ ................................ ..... 40 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ..................  40 
3. OBJECTIVES AND ESTIM ANDS  ................................ ................................ ...........  41 
4. STUDY DESIGN  ................................ ................................ ................................ .... 46 
4.1. Overall Desig n ................................ ................................ ............................  46 
4.2. Scientific Rationale for Study Design  ................................ ..........................  47 
4.2.1.  Participant Input into Design  ................................ ........................  50 
4.3. Justification for Dose  ................................ ................................ ..................  50 
4.4. End of Study Definition  ................................ ................................ ...............  52 
5. STUDY POPULATION  ................................ ................................ ...........................  53 
5.1. Inclusion Criteria  ................................ ................................ .........................  53 
5.2. Exclu sion Criteria  ................................ ................................ ........................  55 
5.3. Inclusion and Exclusion Criteria for PegIFN  ................................ ................  57 
5.4. Lifestyle Considerations  ................................ ................................ ..............  59 
5.4.1.  Alcohol and Tobacco  ................................ ................................ ... 59 
5.4.2.  Activity  ................................ ................................ .........................  59 
5.5. Screen Failures ................................ ................................ ...........................  59 
5.6. Criteria for Temporarily Delaying Administration of Study 
Intervention  ................................ ................................ ................................ . 59 
6. STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY  ..............................  59 
6.1. Study Intervention(s) Administered  ................................ .............................  60 
6.2. Preparation/Handling/Storage/Accountability  ................................ ..............  61 
6.3. Measures to Minimise Bias: Randomisation and Blinding  ...........................  61 
6.4. Study Intervention Compliance  ................................ ................................ ... 62 
6.5. Dose Modification  ................................ ................................ .......................  62 
6.6. Study Intervention after the End of the Study  ................................ ..............  62 
6.7. Treatment of Overdose  ................................ ................................ ...............  62 
6.8. Concomitant Therapy ................................ ................................ ..................  63 
6.8.1.  Nucleos(t)ide Treatment during and after the End of the 
Study  ................................ ................................ ...........................  63 
6.8.2.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  .........................  63 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... 64 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 8 
 7.1. [COMPANY_004]3228836 Dose Modification and Stoppi[INVESTIGATOR_2121]  ...............................  64 
7.1.1.  [COMPANY_004]3228836 Liver Chemistry Stoppi[INVESTIGATOR_2121]  ..........................  64 
7.1.2.  [COMPANY_004]3228836 Haematological Stoppi[INVESTIGATOR_2121] ...........................  67 
7.1.3.  [COMPANY_004]3228836 Drug Induced Kidney Injury (Renal) 
Stoppi[INVESTIGATOR_2121]  ................................ ................................ ..........  68 
7.1.4.  [COMPANY_004]3228836 -Induced Vascular Inflammation and 
Complement Stoppi[INVESTIGATOR_2121]  ................................ .....................  69 
7.2. PegIFN Dose Modification and Stoppi[INVESTIGATOR_2121]  ................................ ........  70 
7.2.1.  PegIFN Haematological Dose Modification and 
Discontinuation Guidelines  ................................ ..........................  71 
7.2.2.  PegIFN ALT Elevation Dose Modification and 
Discontinuation Guidelines  ................................ ..........................  71 
7.2.3.  Psychiatric Disorder Dose Modification and 
Discontinuation Guidelines  ................................ ..........................  71 
7.3. Study Intervention Restart or Rechallenge after stoppi[INVESTIGATOR_31735]  .........  72 
7.4. Participant Discontinuation/Withdrawal from the Study  ...............................  [ADDRESS_936956] to Follow Up  ................................ ................................ ........................  74 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  74 
8.1. Efficacy Assessments  ................................ ................................ .................  75 
8.2. Safety Assessments  ................................ ................................ ...................  75 
8.2.1.  Physical Examinations  ................................ ................................ . 75 
8.2.2.  Ophthalmologic Examination for PegIFN  ................................ ..... 75 
8.2.3.  Vital Signs  ................................ ................................ ....................  76 
8.2.4.  Electrocardiograms  ................................ ................................ ...... 76 
8.2.5.  Clinical Safety Laboratory Assessments  ................................ ...... 76 
8.2.6.  Injection Site Reactions  ................................ ...............................  77 
8.2.7.  Suicidal Ideation and Behaviour Risk Monitoring  .........................  77 
[IP_ADDRESS].  Columbia Suicide -Severity Rating Scale (C -
SSRS)  ................................ ................................ ........  77 
[IP_ADDRESS].  Beck Depression Inventory -II (BDI -II) ...........................  77 
8.3. Adverse Events (AEs), Serious Adverse Events (SAEs) a nd Other 
Safety Reporting  ................................ ................................ .........................  [ADDRESS_936957]  ...........  80 
[IP_ADDRESS].  ALT Increases  ................................ ..............................  80 
[IP_ADDRESS].  Vascular Inflammation and Complement 
Activation  ................................ ................................ .... 80 
[IP_ADDRESS].  Thrombocytopenia  ................................ .......................  80 
[IP_ADDRESS].  Renal Injury  ................................ ................................ .. 80 
[IP_ADDRESS].  Injection Site Reactions  ................................ ................  81 
8.4. Genetics  ................................ ................................ ................................ ..... 81 
8.5. Pharmacokinetics  ................................ ................................ .......................  81 
8.6. Biomark ers ................................ ................................ ................................ . 81 
8.7. Resistance Monitoring  ................................ ................................ ................  82 
8.8. Independent Data Monitoring Committee  ................................ ....................  83 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 9 
 8.9. Internal Safety Review Team (SRT)  ................................ ............................  83 
8.10.  Medical Resource Utilisation and Health Economics  ................................ .. 83 
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  83 
9.1. Statistical Hypotheses ................................ ................................ .................  83 
9.2. Sample Size Determination  ................................ ................................ ........  84 
9.3. Analysis Sets  ................................ ................................ ..............................  86 
9.4. Statistical Analyses  ................................ ................................ .....................  86 
9.4.1.  General Considerations  ................................ ...............................  86 
9.4.2. Primary Objective  ................................ ................................ ........  86 
[IP_ADDRESS].  Main Estimands ................................ ............................  87 
[IP_ADDRESS].  Supplementary Estimands  ................................ ...........  87 
[IP_ADDRESS].  Handling of Withdrawal from Study and Missing 
HBsAg and HBV DNA Data  ................................ ........  89 
[IP_ADDRESS].  Primary Analyses  ................................ .........................  89 
9.4.3.  Secondary Endpoints  ................................ ................................ ... 90 
[IP_ADDRESS].  Secondary Estimands  ................................ ..................  90 
[IP_ADDRESS].  Handling of withdrawal from study and missing 
data for secondary endpoints  ................................ ..... 92 
[IP_ADDRESS].1.  Comparison of efficacy between 
treatment arms  ................................ ....... 92 
[IP_ADDRESS].2.  Other secondary endpoints  .....................  93 
[IP_ADDRESS].  Secondary Efficacy Analyses  ................................ ....... 93 
9.4.4.  Safety Endpoints  ................................ ................................ ..........  93 
9.4.5.  Exploratory Endpoints  ................................ ................................ .. 94 
[IP_ADDRESS].  PK and PK -PD Analyses  ................................ ..............  94 
[IP_ADDRESS].  Safety and Tolerability  ................................ ..................  94 
[IP_ADDRESS].  Efficacy  ................................ ................................ ........  95 
[IP_ADDRESS].  Virology  ................................ ................................ ........  95 
[IP_ADDRESS].  Biomark ers ................................ ................................ ... 95 
9.5. Interim Analysis  ................................ ................................ ..........................  95 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ...............................  97 
10.1.  Appendix 1: Regulatory, Ethical, a nd Study Oversight 
Considerations  ................................ ................................ ............................  97 
10.1.1.  Regulatory and Ethical Considerations  ................................ ........  97 
10.1.2.  Financial Disclosure  ................................ ................................ ..... 97 
10.1.3.  Informed Consent Process  ................................ ..........................  98 
10.1.4.  Data Protection  ................................ ................................ ............  98 
10.1.5.  Committees Structure  ................................ ................................ .. 99 
10.1.6.  Dissemination of Clinical Study Data  ................................ ...........  99 
10.1.7.  Data Quality Assurance  ................................ .............................  100 
10.1.8.  Source Documents  ................................ ................................ .... 101 
10.1.9.  Study and Site Start and Closure  ................................ ...............  101 
10.1.10.  Publication Policy  ................................ ................................ ....... 102 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .......................  103 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ..... 106 
10.3.1 . Definition of AE  ................................ ................................ ..........  106 
10.3.2.  Definition of SAE  ................................ ................................ ........  107 
10.3.3.  Definition of Cardiovascular Events  ................................ ...........  108 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 10 
 10.3.4.  Recording and Follow -Up of AE and SAE  ................................ .. 109 
10.3.5.  Reporting of SAE to [COMPANY_004]  ................................ ...........................  111 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ ..... 112 
10.4.1.  Definitions:  ................................ ................................ .................  112 
10.4.2.  Cont raception Guidance:  ................................ ...........................  113 
10.5.  Appendix 5: Genetics  ................................ ................................ ................  116 
10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart Guidelines  ..........................  117 
10.7.  Appendix 7: Country -specific requirements  ................................ ...............  120 
10.7.1.  China  ................................ ................................ .........................  120 
[IP_ADDRESS].  China Schedule of Activities  ................................ ....... 120 
[IP_ADDRESS].  China Biomarkers and Archived Samples  ..................  120 
10.8.  Appendix 8: Abbreviations and Trademarks  ................................ ..............  121 
11. REFERENCES  ................................ ................................ ................................ ..... 124 
 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 11 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
A Phase IIb Multi -Center, Randomised, Open Label Study to Assess the Efficacy and 
Safety of Sequential  Treatment with [COMPANY_004]3228836 followed by [CONTACT_690618] a 2a in Participants with Chronic Hepatitis B Virus (B -Together)  
Brief Title:  Phase IIb Study of Sequential [COMPANY_004]3228836 and Peginterferon Treatment in 
Participants with Chronic Hepatitis B (B -Together)  
Rationale:  
Study 209348 is intended to evaluate whether up to 24 weeks of treatment with 
[COMPANY_004]3228836 followed by [CONTACT_8622] 24 weeks of pegylated interferon  (PegIFN ) can increase 
the rate of hepatitis B virus surface antigen ( HBsAg ) loss in participants on stable 
nucleos(t)ide analogue ( NA) therapy, and whether virologic response can be sustained 
once PegIFN treatment is discontinued.  Efficacy of sequential therapy with 
[COMPANY_004]3228836 and PegIFN will be compared to treatment with [COMPANY_004]3228836  alone , which 
is being currently being explored in a separate  Phase IIb study, 209668.  Study 209348 
will also evaluate the safety and tolerability of the treatment regimen.  
Key Objectives and Estimands :  
Objectives  Estimands  
Primary  
Efficacy: To investigate the efficacy of two 
different durations of [COMPANY_004]3228836 followed 
by [CONTACT_8622] 24 weeks of PegIFN therapy in 
participants with CHB on stable NA therapy.  The main Estimand supporting the primary objective is 
defined as:  
• Population: Partici pants with CHB on stable NA 
therapy  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks 
followed by [CONTACT_8622] 24 weeks of PegIFN therapy while 
on stable NA therapy  
• Variable (Categorical): Participants achieving 
Sustained Virologic Response (SVR) (HBsAg < lower 
limit of quantification ( LLOQ ) and Hepatitis -B virus 
deoxy -ribonucleic acid ( HBV DNA ) <LLOQ) for 24 
weeks after the planned end of sequential treatment, 
without use of any rescue medication  
• Intercurrent Events : 
o Discontinuation of, interruption in, and non-
adherence to [COMPANY_004]3228836 and PegIFN not 
related to any wide disruptive events (such as 
COVID -19 pandemic) will be ignored (treatment 
policy  strategy ).  
o Ineligibility to receive PegIFN will be ignored 
(treatment policy strategy)  
o Use of rescue medication (com posite strategy ). 
o Wide disruptive events (such as COVID -19 
pandemic) leading to discontinuation of, 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 12 
 Objectives  Estimands  
interruption in, and non -adherence to 
[COMPANY_004]3228836 and PegIFN will be handled 
assuming they had not happened (hypothetical 
strategy).  
• Population Summary: The percentage of 
participants in each treatment group who achieve 
SVR, without use of any rescue medication  
The main primary estimand supporting the primary 
objective in participants with chronic hepatitis B  (CHB ) 
on stable NA therapy in each treatment arm  is the 
percentage of participants that achieve SVR (HBsAg 
<LLOQ and HBV DNA <LLOQ) for 24 weeks after the 
planned end of sequential treatment  in the absence of 
rescue medication, regardless of ineligibility to receive 
PegIFN, discontinuation of, interrupt ion in, and non -
adherence to [COMPANY_004]3228836 and PegIFN,  had they not 
been affected by [CONTACT_165763] . 
 
Three supplementary Estimands are defined to support 
the primary objective:  
• The first supplementary Estimand is defined in the 
same way as the main E stimand, except the 
assessment time frame for patients achieving SVR 
will be 24 weeks after the actual end of treatment. 
Therefore, the strategy for intercurrent events of 
treatment discontinuation will be while -on-treatment. 
This supplementary estimand su pporting the primary 
objective in participants with CHB on stable NA 
therapy in each treatment arm is the percentage of 
participants that achieve SVR (HBsAg <LLOQ and 
HBV DNA <LLOQ) for 24 weeks after the actual end 
of sequential treatment in the absence o f rescue 
medication, regardless of ineligibility to receive 
PegIFN, discontinuation of, interruption in, and non -
adherence to [COMPANY_004]3228836 and PegIFN,  had they 
not been affected by [CONTACT_165763].  
 
• The second supplementary Estimand is to 
understand the relationship between the PegIFN 
duration and achieving SVR for 24 weeks after the 
actual end of treatment, defined as:  
o Population: Participants with CHB on stable NA 
therapy  
o Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 
weeks followed by 24 weeks of PegIFN therapy 
while on stable NA therapy  
o Variable: The relationship between SVR for 24 
weeks after actual end of treatment and the 
duration of PegIFN received by [CONTACT_4317]  
o Intercurrent Events:  
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 13 
 Objectives  Estimands  
▪ Discontinuation and delayed start of, 
PegIFN, wi ll be accounted to reflect the 
actual duration from the first to the last 
dose of PegIFN received (while -on-
treatment strategy).  
▪ Interruption in and other non -adherence 
to PegIFN will be ignored (treatment 
policy strategy)  
▪ Discontinuation of, interruption  in and 
non-adherence to [COMPANY_004]3228836 will be 
ignored (treatment policy strategy)  
▪ Use of rescue medication ( composite  
strategy).  
▪ Wide disruptive events (such as 
COVID -19 pandemic) leading to 
discontinuation and delayed start  of, 
PegIFN will be handled with while -on-
treatment strategy; wide  disruptive 
events leading to interruption in and 
other non -adherence to PegIFN will be 
ignored  (treatment policy strategy) ;  
wide disruptive events leading to 
discontinuation of, interruption in, and 
non-adherence to [COMPANY_004]32 [ZIP_CODE] will be 
ignored ( treatment  policy strategy ). 
o Population Summary: The percentage of 
participants achieving SVR for 24 weeks after 
the actual end of treatment by [CONTACT_690619][INVESTIGATOR_690584] (supporting the 
primary objective in participants with CHB on stable NA 
therapy ) is the percentage of participants achieving SVR 
for 24 weeks after the actual end of treatment by [CONTACT_690620], taking into account discontinuation  and 
delayed start of PegIFN , regardless of interruption in and 
other non -adherenc e to PegIFN, regardless of 
discontinuation of, interruption in  and non-adherence to 
[COMPANY_004]3228836.  
 
• The third supplementary Estimand is defined in the 
same way as the main Estimand, except the 
strategy for intercurrent events of  PegIFN ineligibility 
for more than  12 weeks and/or missing more than 
12 doses of PegIFN  will be principal stratum. This 
supplementary E stimand supporting the primary 
objective is the percentage of participants  in each 
treatment arm  that achieve SVR (HBsAg <LLOQ 
and HBV DNA <LLOQ) for [ADDRESS_936958] 12 doses of PegIFN,  in the absence of rescue 
medication, regardless of discontinuation of , 
interruptions in or non-adherence to [COMPANY_004]3228836  
had they not been affected by [CONTACT_165768].  
 
Secondary  
Efficacy: To assess the efficacy of 
[COMPANY_004]3228836 and PegIFN therapy on 
biomarkers and virus specific antibody 
responses  The Estimand supporting the objective is defined as:  
• Population: Participants with CHB on stable NA 
therapy ; For the time to alanine aminotransferase 
(ALT) normali sation  variable, population will be 
aforementioned participants with baseline ALT 
>upper limit normal ( ULN). 
• Treatment: 300 mg [COMPANY_004]3228836 for 12, or 24 
weeks followed by 24 weeks of P egIFN therapy 
while on stable NA therapy  
• Categorical Variables:  
o Achieving HBsAg <LLOQ and HBV DNA 
<LLOQ at  two time points: (1)  the planned  end 
of treatment and (2) at the end of 24 weeks 
follow -up 
o Categorical changes from baseline in HBsAg 
(e.g., <0.5, ≥0.5, ≥1, ≥1.5, ≥3 log10 IU/mL) at 
each scheduled visit or analysis window . 
o ALT normali sation  (ALT  ≤ULN) over time in 
absence of rescue medication in participants 
with baseline ALT  >ULN  
Population summary is the percentage of 
participants in each category for each treatment 
group.  
o HBe antibody (anti-HBeAg) levels . 
• Continuous Variables:  
o Actual values and change from baseline over 
time for HBsAg, HBV DNA and hepatitis B virus 
e-antigen ( HBeAg ) 
o Actual values and change from baseline over 
time for HBs antibody (anti -HBsAg) levels over 
time 
o Actual values and change from baseline over 
time for ALT  
Population summary is the mean values and 
the mean changes from baseline of each 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 15 
 Objectives  Estimands  
variable for participants in each treatment 
group.  
• Time to Event Variable:  
o Time to ALT normali sation  in absence of rescue 
medication in participants with baseline 
ALT>ULN  
Population summary is the Turnbull’s estimator 
for non -parametric estimation of  Time to ALT 
normali sation  in each treatment arm  
• Intercurrent Events: Discontinuation of, interruption 
in, and non-adherence to [COMPANY_004]3228836 and PegIFN 
will be ignored (treatment policy) ; PegIFN ineligibility 
will be ignored (treatment policy); Rescue 
medication will be ignored (treatment policy ), except 
for ALT normali sation  which can only be achieved in 
the absence of rescue medication ; Wide disruptive 
events (such as COVID -19 pandemic) leading to 
discontinuation of, interruption in, and non -
adherence to [COMPANY_004]3228836 and PegIFN  will be 
handled with Treatment Policy Strategy . 
• The group  of estimands supporting this objective  is 
the population summary for each variable in each  
treatment arm in the population regardless of 
discontinuation of , interruption in or non-adherence 
to [COMPANY_004]3228836 and PegIFN,  and regardless of 
rescue medica tion (except for ALT normali sation  
which can only be achieved in the absence of 
rescue medication) or PegIFN ineligibility.  
 
Efficacy: To investigate the durability of 
virologic response after sequential therapy 
with 12 weeks of [COMPANY_004]3228836 followed by 
24 weeks of PegIFN in participants with CHB 
on stable NA therapy for up to 36 weeks off 
treatment  The same definition as the above secondary estimand, 
focusing on the timepoints following the 24 weeks off -
treatment period  in the treatment arm of 300 mg 
[COMPANY_004]3228836 for 12 weeks followed by [CONTACT_8622]  24 weeks 
of PegIFN therapy while on stable NA therapy.  
Efficacy: To compare efficacy between 
different treatment durations:  
12 or 24 weeks of  [COMPANY_004]3228836 followed by 
24 weeks PegIFN  The same definition as the primary estimand except 
treatments and population summary are defined as:  
• Treatments: Arms 1 and 2. One treatment 
comparison between Arms 1 & 2  up to 24 weeks off -
treatment  
• Population summary: difference in proportion of 
participants who achieve SVR between treatment 
arms  
The group of estimands supporting this objective in 
participants with CHB on stable NA therapy  is the 
difference between treatment arms 1 and 2 in the 
proportion of participants that achieve SVR for 24 we eks 
after the planned end of sequential treatment , in the 
absence of rescue medication , regardless of ineligibility 
to receive PegIFN,  regardless of discontinuation of, 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 16 
 Objectives  Estimands  
interruption in or non-adherence to [COMPANY_004]3228836 and 
PegIFN  had they not been affected by [CONTACT_165768].  
Overall Design:  
This is a Phase  IIb, multi -centre, randomi sed, open -label study to assess the efficacy and 
safety of sequential treatment with [COMPANY_004]3228836 (300  mg/week for 12 or 24 weeks) 
followed by [CONTACT_690621] (180  mcg/week for up to 24 weeks) in participants with CHB on 
stable NA therapy.  During the [COMPANY_004]3228836 treatment period a 300  mg loading dose 
will be administered on Day 4 and Day 11.  Participants will continue their NA therapy 
for the duration of  the study.  
Brief Summary:  
The purpose of this study is to investigate the efficacy of 12 or 24 weeks  of [COMPANY_004]3228836 
followed by [CONTACT_8622] 24 weeks of PegIFN therapy in participants with CHB on stable NA 
therapy.  Study details include:  
Study Duration: 79 weeks  
Treatment Duration: [ADDRESS_936959]-treatment Follow -up: 36 or 24 weeks off treatment follow -up (note NA -therapy will 
continue throughout study)  
Number of Participants:  
This study will enro l approximately [ADDRESS_936960] passed the screening requirements and entered the study. The 
expected screen failure rate for participants is 20%.  
In the case of a disruptive event impacting (e.g., COVID -19, natural disaster), sites and/or 
participants may be unable to conduct/attend dosing visits, conduct/attend follow -up 
visits, participants may be discontinued from study treatment, and/or participants may be 
withdrawn from the study.  
The study tea m may enro l additional participants to within 10% of the planned 100.  
Note: "Enrolled" means a participant's, or their legally acceptable representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process a nd after study personnel have confirmed that all eligibility criteria have been 
met. Potential participants who are screened for the purpose of determining eligibility for 
the study, but do not participate in the study, are not considered enrolled, unless 
otherwise specified by [CONTACT_760].  
TMF- 13966464  CONFIDENTIAL  
  209348 
  Protocol Amd 01 
 17 
 Intervention Arms  and Duration: 
The total duration of the study, including screening, treatment, and post-treatment follow-
up, is not expected to exceed 7 9 weeks for each participant: 
• Arm 1: 24 weeks [COMPANY_004]3228836 + 24 weeks PegIFN + 24 weeks off-treatment 
• Arm 2: 12 weeks [COMPANY_004]3228836 + 24 weeks PegIFN + 36 weeks off-treatment 
A 45-day screening window is included in the total study duration.  Eligible participants 
who fall outside of the 45-day window may be re-screened at the discretion of the Investigator/site. 
There are no plans for group dose adjustments.  Individual dose adjustments for 
[COMPANY_004]3228836 for safety are outlined in the monitoring/stoppi[INVESTIGATOR_3418].  Individual dose 
adjustments for PegIFN for safety are outlined in the monitoring/stoppi[INVESTIGATOR_690585] 90 mc g/mL. 
Participants that leave the study early will not be replaced. 
Data Monitoring / Other Committee: Yes  
1.2. Schema 
 
   

TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 18 
 1.3. Schedule of Activities (SoA)  
Both treatment arms will use the same Screening Table ( Table 1).  Separate tables have 
been produced for the [COMPANY_004]3228836 treatment  period ( Table 2 and Table 3).  Both 
treatment  arms will use the same PegIFN Treatment Table (Table 4), Reassessment of 
PegIFN  Eligibili ty Table s (Table 5 and Table 6; only required if participant is  ineligible 
to start PegIFN  as per Table 4) and Off Treatment Follow -up Table  (Table 7). 
[China specific Schedule of Activities can be found in   Appendix 7: Country -specific 
requirements ] 
Instructions that are applicable to all treatment arms include:  
• In selected countries/sites, participants will have the option to use  a centralised 
home nursing provider. Only selected visits will have the option to be performed 
as a home visit, these will include drug administration, blood draws, participant  
assessments and data collection. The full specifications of the home nursing 
services will be outlined in the Study Reference Manual ( SRM ).  
• Haematology  (platelet count ) will be analy sed at a local laboratory prior to each 
[COMPANY_004]3228836 dose.  The blood draw can be taken the day before [COMPANY_004]3228836 
dosing.  Results must be available prio r to dosing.   Haematology samples will be 
collected for central laboratory assessments in parallel .  After [COMPANY_004]3228836 
treatment is completed, h aematology is only collected centrally on weeks of clinic 
visits.  
• If a participant is not eligible to start PegIFN, eligibility will be reassessed.  If the 
participant does not become eligible after [ADDRESS_936961] 12 weeks of PegIFN treatment .  
Irrespective of the week that a participant starts PegIFN, the final dose will be 
given on Study Week 48  for Arm 1 and Week 36 for Arm 2  (Figure 1). 
• PegIFN dosing maybe self -administered at home, where local regulations allow at 
the visits indicated in the SoA ( Table 4). 
 
TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 19 
 Figure 1 Schematic of Planned [COMPANY_004]3228836 and PegIFN Dosing  Periods  and 
Off Treatment Follow -up Period  
 
 
  

TMF-13966464  CONFIDENTIAL   
  209348  
  Protocol Amd 01  
 20 
 Table 1 Screening ( All Treatment  Arms ) 
ASSESSMENTS   
Informed Consent (obtained any time prior to screening)  X 
Inclusion and exclusion criteria  X 
Demography  X 
Medical history (includes substance usage) and current medical conditions  X 
Medication history and concomitant medication review  X 
Full physical exam including height and weight  X 
Vital signs  X 
Ocular exam (unless completed within 3 months)  X 
12-lead ECG  X 
Neuropsychiatric assessment (C -SSRS and BDI -II) X 
LABORATORY ASSESSMENTS  
Serum hCG pregnancy test (women of childbearing potential [WOCBP])  X 
FSH/Estradiol (to confirm status of women of non -child-bearing potential)1 X 
Haematology/Chemistry/Urinalysis  X 
TSH, T4  X 
Urine ACR  X 
PT, INR, aPTT  X 
HIV, hepatitis D, and hepatitis C screen  X 
Hepatitis B profile (HBsAg, HBV DNA, HBeAg)  X 
Alpha -fetoprotein  X 
APRI/ FibroSure X 
ANCA (with MPO -ANCA, PR3 -ANCA if results are positive or border -line positive)  X 
Complement C3, C4, C5a, hsCRP, MCP -1, complement Bb, Ang -2 X 
1. As appropriate to confirm menopause  
 
 
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
21 
 Table 2 [COMPANY_004]3228836  Treatment Period: Treatment Arm 1 (Week 1 -24) 
Day 1 4 8 11 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 
Week  1 1 2 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window (days)   1 day  2 3 days  
Randomisation  X  
[COMPANY_004]3228836 dosing  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Safety Assessments  
AE/SAE review  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Conmed review  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Symptom directed exam  X      X    X    X    X    X    
Vital signs X X X X X X X X X X X X X X X X X X X X X X X X X X 
[ADDRESS_936962] 
(WOCBP)  X1      X    X    X    X    X    
Haematology [includes 
platelet and WBC with 
differential] X  X  X X X X X X X X X X X X X X X X X X X X X X 
PT, INR, aPTT  X      X    X    X    X    X   X 
TSH, T4                          X 
Chemistry  X  X  X X X X X X X X X X X X X X X X X X X X X X 
Urinalysis  X  X  X X X X X X X X X X X X X X X X X X X X X X 
Urine ACR X    X  X  X  X  X  X  X  X  X  X  X X 
HBsAg and HBV DNA  X  X  X X X X X X X X X X X X X X X X X X X X X X 
Anti- HBsA g and anti -
HBeA g X      X    X    X    X    X    
HBeAg3 X  X  X X X X X X X X X X X X X X X X X X X X X X 
Complement C3, C4, 
C5a, Bb, hs -CRP, MCP -
1 X    X  X  X  X  X  X  X  X  X  X  X  
ANCA, Ang II  X      X    X    X    X    X    
PK [COMPANY_004]3228836  X X X X    X      X      X      X 
HBV RNA, and 
Sequencing (HBV 
genotype/phenotype; 
HBV DNA and/or RNA)  X    X  X  X  X  X  X  X  X  X  X  X  
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
22 
 Day 1 4 8 11 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 
Week  1 1 2 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window (days)   1 day  2 3 days  
HBcrAg  X      X      X      X      X  
PBMC Collection for 
immunophenotypi[INVESTIGATOR_007]2 X      X       X             
Soluble Protein 
(immunology)  X    X  X   X    X    X    X    X 
PAXGene RNA for 
expression analysis in 
whole blood  X      X       X             
OPTIONAL: Genetics  X                          
Archived Samples  
[serum; plasma]  X    X  X  X  X  X  X  X  X  X  X  X  
1. A WOCBP must have both a confirmed menstrual period prior to the first dose of study intervention AND a negative highly sensi tive pregnancy test [urine or serum] within [ADDRESS_936963] dose of study treatment (performed locally)  
2. Only for selected sites able to transport to the analysis lab as specified in the SRM  
3. Only for participants HBeAg positive at screening  
4. ECG to be conducted once at any point from Week 23 and prior to initiation of PegIFN  
  
  
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
23 
 Table 3 [COMPANY_004]3228836 Treatment Period:  Treatment Arm 2 (Week 1 -12) 
Day 1 4 8 11 15 22 29 36 43 50 57 64 71 78 
Week  1 1 2 2 3 4 5 6 7 8 9 10 11 12 
Window (days)  1 day  2 3 days  
Randomi sation  X  
[COMPANY_004]3228836 dosing  X X X X X X X X X X X X X X 
Safety Assessments  
AE/SAE review  X X X X X X X X X X X X X X 
Concomitant med review  X X X X X X X X X X X X X X 
Symptoms directed exam  X      X    X    
Vital signs X X X X X X X X X X X X X X 
[ADDRESS_936964] (WOCBP)  X1      X    X    
Haematology [includes platelet and WBC with differential] X  X  X X X X X X X X X X 
TSH, T4              X 
PT, INR, aPTT  X      X    X   X 
Chemistry  X  X  X X X X X X X X X X 
Urinalysis  X  X  X X X X X X X X X X 
Urine ACR X    X  X  X  X  X X 
HBsAg and HBV DNA  X  X  X X X X X X X X X X 
Anti- HBsA g and anti -HBeA g X      X    X    
HBeAg (for participants HBeAg positive at screening)  X  X  X X X X X X X X X X 
Complement C3, C4, C5a, Bb, hs -CRP, MCP -1 X    X  X  X  X  X  
ANCA, Ang II  X      X    X    
PK [COMPANY_004]3228836  X X X X    X      X 
HBV RNA, and sequencing (HBV genotype/phenotype, HBV DNA, and/or RNA)  X    X  X  X  X  X  
HBcrAg  X      X      X  
PBMC Collection for immunophenotypi[INVESTIGATOR_007]2 X      X       X 
Soluble Protein (immunology)  X    X  X   X    X 
PAXGene RNA for expression analysis in whole blood  X      X       X 
OPTIONAL: Genetics  X              
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
24 
 Day 1 4 8 11 15 22 29 36 43 50 57 64 71 78 
Week  1 1 2 2 3 4 5 6 7 8 9 10 11 12 
Window (days)  1 day  2 3 days  
Archived Samples  [serum; plasma]  X    X  X  X  X  X  
1. A WOCBP must  have both a confirmed menstrual period prior to the first dose of study intervention AND a negative highly sensitive pregnanc y test [urine or serum] within [ADDRESS_936965] dose of study treatment (locally performed)  
2. Only for selected sites able to transport to the analysis lab as specified in the SRM   
3. ECG to be conducted at any point from Week 11 and prior to initiation of PegIFN  
 
 
 
  
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
25 
 Table 4 PegIFN Treatment Period  
Participants will be assessed using Column 1 below to determine eligibility to begin treatment with PegIFN and moved to the “Yes” column 
based on the eligibility criteria outlined in Section 5.3.  If a  participant is determined to be eligible  for PegIFN dosing, they will begin 
PegIFN Dosing on Week 1.   If a participant is determined to be ineligible  for PegIFN, see Table 5.  
PegIFN Dosing Week  1a 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window  3 days  
Confirmed Eligibility for Peg -
IFN Confirm 
PegIFN 
Eligibility1 Yes2                        
Clinic visit3 X X X X  X  X  X   X   X    X    X 
Peg-IFN dosing   X X X X X3 X X3 X X3 X X3 X3 X X3 X3 X X3 X3 X3 X X3 X3 X3 X 
Safety Assessments    
AE/SAE review  X  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant medication review  X  X X X X X X X X X X X X X X X X X X X X X X X 
Symptoms directed  exam  X    X    X     X   X    X     
Vital signs X  X X X  X  X  X   X   X    X    X 
Injection site reactions  X X X X  X  X  X   X   X    X    X 
Neuropsychiatric assessment 
(C-SSRS and BDI -II) X  X X X  X  X  X   X   X    X    X 
Laboratory Assessments    
Pregnancy test (WOCBP)   X   X    X  X   X   X    X    X 
Haematology [includes platelet 
and WBC with differential] 4  X X X X  X  X  X   X   X    X    X 
TSH, T4        X       X           X 
PT, INR, aPTT   X   X         X   X    X    X 
Chemistry   X X X X  X  X  X   X   X    X    X 
Urinalysis   X X  X    X     X   X    X    X 
Urine ACR  X X  X    X     X   X    X    X 
HBsAg and HBV DNA   X X X X  X  X  X   X   X    X    X 
Anti-HBsAg and anti -HBeAg  X   X    X     X   X    X    X 
HBeAg (for participants HBeAg 
positive at screening)   X X X X  X  X  X   X   X    X    X 
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
26 
 PegIFN Dosing Week  1a 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window  3 days  
Complement C3, C4, C5a, Bb, 
hs-CRP, MCP -1   X  X    X 1.     X   X    X     
ANCA, Ang II   X   X    X     X   X    X     
PK – PegIFN   X X  X  X       X   X    X     
PK –[COMPANY_004]3228836   X  X   X    X   X            
HBV RNA, and sequencing 
(HBV genotype/phenotype; 
HBV DNA and/or RNA)   X X  X  X  X  X   X   X    X    X 
HBcrAg  X   X    X     X       X     
PBMC Collection for 
immunophenotypi[INVESTIGATOR_007]5  X   X         X            
Soluble Protein (immunology)   X X  X  X       X   X    X     
PAXGene RNA for expression 
analysis in whole blood   X   X         X            
Archived Samples [serum; 
plasma]   X X X X  X  X  X   X   X    X    X 
a. The first planned PegIFN visit occurs 7 days after the  planned [COMPANY_004]3228836 dosing perio d. 
1. Assessment of PegIFN eligibility should be based upon pre -dose safety assessments and laboratory assessments from previous visit  
2. For specific Peg -IFN eligibility criteria please refer to protocol Section 4.1; If ineligible for PegIFN refer to  Table 5. 
3. If consistent with local regulations, participants are permitted to self -administer PegIFN at home, site staff may call to assess the participant by [CONTACT_1555] t his visit and no clinic visit is required .  If 
local regulations or practices prefer to administer PegIFN within the clinic, this can be a clinic visit.    
4. Participants  in Japan are expected to return for a mid -week haematology  assessment during Week 1 and at Week 5 and 7 in accordance wit h local regulations   
5. Only for selected sites able to transport to the analysis lab as specified in the SRM   
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
27 
 Table 5 Reassessment of PegIFN Eligibility  
If a participant is ineligible for PegIFN dosing immediately  (Week 1 , Table 4), complete the SoA of PegIFN Eligibility Week 1 , Table 5.   
Eligibility for PegIFN will be reassessed following the SoA in Table 5 on PegIFN Elig ibility Week 2, 3, 4, 6, 8, 10 and 1 3.   
If a participant becomes eligible for PegIFN  during any of the reassessment visits , the SoA in  Table 4 should be followed starting at 
the Week 1 “Yes” column  for the remainder of PegIFN dosing visits  and stoppi[INVESTIGATOR_690586] “25” – for example, if a participant becomes eligible for PegIFN on PegIFN Eligibility Week 4, the SoA 
in Table 4 should be followed from Week 1 to Week 21 ( Table 6). 
PegIFN Eligibility Week  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window  3 days  
Eligible for PegIFN ( Section  4.1) No No No No  No  No  No   No            
Clinic visit  X X X X  X  X  X   X   X    X    X 
Safety Assessments   
AE/SAE review   X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant medication review   X X X X X X X X X X X X X X X X X X X X X X X 
Symptoms directed  exam   X X X  X  X  X   X   X    X     
Vital signs  X X X  X  X  X   X   X    X    X 
Neuropsychiatric assessment (C -
SSRS and BDI -II)  X X X  X  X  X   X            
Laboratory Assessments (If not 
Eligible to begin PegIFN 
treatment )  
Pregnancy test (WOCBP)  X   X    X  X   X   X    X    X 
Haematology [includes platelet and 
WBC with differential] X X X X  X  X  X   X   X    X    X 
TSH, T4       X       X           X 
PT, INR, aPTT  X   X         X   X    X    X 
Chemistry  X X X X  X  X  X   X   X    X    X 
Urinalysis  X X  X    X     X   X    X    X 
Urine ACR X X  X    X     X   X    X    X 
HBsAg and HBV DNA  X X X X  X  X  X   X   X    X    X 
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
28 
 PegIFN Eligibility Week  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Window  3 days  
Anti- HBsAg and anti -HBeAg X   X    X     X   X    X    X 
HBeAg (for participants HBeAg 
positive at screening)  X X X X  X  X  X   X   X    X    X 
Complement C3, C4, C5a, Bb, hs -
CRP, MCP -1  X  X    X     X   X    X     
ANCA, Ang II  X   X    X     X   X    X     
PK – [COMPANY_004]3228836  X  X   X    X   X            
HBV RNA and sequencing (HBV 
genotype/phenotype; HBV DNA 
and/or RNA)  X X  X  X  X  X   X   X    X    X 
 HBcrAg X   X    X     X       X     
PBMC Collection for 
immunophenotypi[INVESTIGATOR_007]1             X            
Soluble Protein (immunology)              X            
PAXGene RNA for expression 
analysis in whole blood              X            
Archived Samples [serum; plasma]  X X X X  X  X  X   X   X    X    X 
1. Only for selected sites able to transport to the analysis lab as specified in the SRM  
 
 
 
 
  
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
29 
 Table 6 PegIFN Dosing for Participants becoming Eligible for PegIFN after Week 1  
Become Eligible for PegIFN at PegIFN Eligibility Week ( Table 5) PegIFN Dosing ( Table 4) should continue until PegIFN Dosing Week  
2 23 
3 22 
4 21 
6 19 
8 17 
10 15 
13 12 
 
  
TMF-13966464  CONFIDENTIAL  
  
 209348  
 Protocol Amd 01  
30 
 Table 7 Off-Treatment Week (OTW) Follow -up: Week 1 -24 (Treatment Arm 1) or Week 1 -36 (Treatment Arm 2)  
Assessments  OTW1a OTW2  OTW4  OTW8  OTW12  OTW18  OTW24  OTW301 OTW361 Early 
Termination  
Window  3 days  NA 
Safety Assessments   
AE/SAE review  X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X 
Symptoms directed  exam  X X X X X X X X X X 
Vital signs X X X X X X X X X X 
Neuropsychiatric assessment (C -SSRS and BDI -II)[ADDRESS_936966] (WOCBP)  X  X X X X X X X X 
Haematology [includes platelet and WBC with differential] X  X  X  X   X 
PT, INR, aPTT  X  X  X  X   X 
Chemistry  X X X X X X X X X X 
Urinalysis  X  X  X  X   X 
Urine ACR X  X  X  X   X 
HBsAg and HBV DNA  X X X X X X X X X X 
Anti-HBsAg and anti -HBeAg X  X X X X X X X X 
HBeAg (for participants H BeAg positive at screening)  X X X X X X X X X X 
Complement C3, C4, C5a, Bb, hs -CRP, MCP -1, ANCA, Ang II  X    X  X   X 
PK for PegIFN2 X X X X      X 
HBV RNA and sequencing ( HBV genotype/phenotype; HBV DNA 
and/or RNA)  X X X X X X X X X X 
HBcrAg X  X X X  X   X 
PBMC Collection for immuno phenotypi[INVESTIGATOR_007]3 X      X   X 
PAXGene  RNA for expression analysis in whole blood  X    X  X   X 
Soluble Protein (immunology)  X  X  X  X   X 
Archived Samples  [serum; plasma]  X X X X X X X X X X 
a. The first planned Off treatment  visit occurs [ADDRESS_936967] 1 dose of PegIFN.  
3. Only for selected sites able to transport to the analysis lab as specified in the SRM . 
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 31 
 2. INTRODUCTION  
2.1. Study Rationale  
Chronic hepatitis B (CHB) infection results in progressive liver disease that may lead to 
complications such as cirrhosis, liver failure, and hepatocellular carcinoma. First -line 
therapy for CHB is treatment with a nucleoside or nucleotide (nucleos(t)ide) analogue  
(NA) . While these antiviral agents are effective in suppressing hepatitis B virus (HBV ) 
replication in both hepatitis B virus e -antigen (HBeAg)-positive and H BeAg-negative 
CHB, patients frequently relapse after treatment is discontinued, particularly if hepatitis B 
virus surface antigen (HBsAg) loss was not achieved . The high rate of relapse in these 
patients is hypothesi sed to be due to their inability to raise an effective immune response 
to the virus in the presence of high circulating levels of H BsAg, which continues to be 
produced by [CONTACT_690622], even in the absence of ongoing viral replication.  
Recently, a functional cure of CHB infection has been endorsed as an endpoint for new 
HBV therapi[INVESTIGATOR_014]. Functional cure of CHB infection is defined as sustained loss of HBsAg 
from serum (with or without anti -HBsAg seroconversion) and undetectable HBV DNA in 
serum, after completion of a finite course of treatment [Lok, 2017 ; Cornberg , 2019 ].  
Functio nal cure occurs in only a very small percentage of patients on NA therapy alone 
(approx . 3% per annum) [Lok, 2017 ]. 
Interferons (IFNs) are a group of immunomodulatory drugs approved as a monotherapy for 
the treatment of certain patients with CHB.  Peginterferons (PegIFN)  are indicated for the 
treatment o f adult patients with H BeAg positive and H BeAg negative CHB who have 
compensated liver disease and evidence of viral replication and liver inflammation.  
Weekly injections of PegIFN for 48 weeks has been demonstrated to achieve functional 
cure in a small p roportion (up to 9%) of CHB patients as monotherapy, or in combination 
with nucleosides (off -label)  [Marcellin , 2016] .  Patients that have lower level s of serum 
HBsAg before starting treatment with PegIFN  have been shown to respond better than 
those with higher levels in clinical trials [Ren, 2019; Lee, 2018 ]. 
[COMPANY_004]3228836 is being developed for the treatment of CHB and is a 2’ -O-(2-methoxyethyl) -
modified chimeric phosphorothioate antisense oligonucleotide (2’ -MOE chimeric ASO) 
drug targeted to HBV ribonucleic acid (RNA ).  [COMPANY_004]3228836 is complementary to 
sequences present in all HBV -derived RNA transcripts and its hybridi sation  to the cognate 
RNA r esults in ribonuclease H -mediated degradation.  It is highly specific for HBV RNA 
transcripts and is not homologous to any regions of the human transcriptome, including 
either a single nucleotide mismatch or with 17 or more consecutive nucleotide matches.  
[COMPANY_004]3228836 is an antisense oligonucleotide that is designed to inhibit the synthesis of 
viral proteins (e.g., H BsAg, H BeAg) by [CONTACT_690623] a direct effect 
on HBV covalently closed circular DNA (HBV cccDNA) or integrated HBV DNA. 
Treat ment of patients with CHB with [COMPANY_004]3228836 will permit examination of whether 
reduction of viral proteins allows resumption of a host immune response against HBV virus 
and infected cells and if longer treatment with [COMPANY_004]3228836 will result in H BsAg loss 
leading to sustained suppression of HBV replication after cessation of all treatments for 
CHB.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 32 
 Efficacy of 4 weeks treatment with [COMPANY_004]3228836 has been investigated in Phase I Ia study, 
ISIS 505358 -CS3, in both treatment naïve participants and participants on stable NA 
therapy.  Both groups of study participants experienced declines in H BsAg, including some 
achieving H BsAg levels <  lower limit of quantification (LLOQ ), followed b y acute ALT 
elevations (refer to Investigator’s Brochure [[COMPANY_004] Document Number 2019N425040_00 ]). 
The efficacy and safety of [COMPANY_004]3228836 trea tment for up to 24 weeks duration is currently 
being evaluated in a Phase I Ib study (Study 209668, [STUDY_ID_REMOVED]).   It is hypothesi sed 
that additional immunomodulatory therapy (such as PegIFN) may be needed to achieve 
optimal durable H BsAg loss.  Study 209348  is intended to evaluate whether up to 24 weeks 
of treatment with [COMPANY_004]3228836 followed by 24 weeks of PegIFN can increase the rate of 
HBsAg loss in participants on stable NA therapy, and whether virologic response can be 
sustained once PegIFN treatment is discontinued.  Efficacy of sequential therapy with 
[COMPANY_004]3228836 and PegIFN will be compared to the response observed with [COMPANY_004]3228836  
in the absence of PegIFN  in the Ph ase IIb study, 209668.  Study 209348 will also evaluate 
the safety and tolerability of the treatment regimen.  
2.2. Background  
HBV infection, especially chronic infection, is a significant worldwide medical problem.  
Globally, in 2015, an estimated 257 million people we re living with chronic Hepatitis B, 
with only 9% of patients with Hepatitis B being treated. Viral hepatitis led to 1.34 million 
deaths and of these deaths, 66% were the results of complications of CHB infection 
[WHO , 2015].  
The goal of therapy for CHB is to improve quality of life and survival by [CONTACT_103044], decompensated liver disease, end -stage liver 
disease, hepatocellular carcinoma (HCC ), or death. This goal can be achieved if HBV 
replication is suppressed in a sustained manner thereby [CONTACT_103045] [ Liaw , 2004;  Feld, 2009]. In both 
HBeAg-positive and H BeAg-negative CHB, the ultimate treatment endpoint is loss of 
detectable serum hepatitis B surface antigen (H BsAg) and serum HBV DNA [ Lok, 2009;  
EASL , 2012]. Loss of H BsAg is preceded by a robust immunological response to HBV 
infection resulting in sustained s uppression of serum HBV deoxyribonucleic acid (DNA) 
and disease resolution.  
First-line therapy for CHB is treatment with a NA  therapy . While these antiviral agents are 
effective in suppressing HBV replication in both H BeAg-positive and H BeAg-negative 
CHB, patients frequently relapse after treatment is discontinued, particularly if H BsAg loss 
was not achieved. PegIFN s are also approved for treatment of CHB [ Lok, 2009;  EASL , 
2012] and are  dosed for  a finite  treatment duration (usually up to 48 weeks). Because of 
the frequent and  sometimes severe side effects associated with PegIFN and high cost versus 
a small gain in treatment response, P egIFNs  are less frequently used than N As. 
Unfortunately, with both the N As and PegIFN , HBsAg loss and the subsequent 
development of antibodies t o HBsAg are rarely achieved . Rates of H BsAg loss following 
12 months of treatment with either a NA and/or PegIFN  generally range from 0 to 3% in 
most studies [ Lok, 2009;  EASL , 2012] , with occasional studies reporting  higher  rates for 
example ~10% functional cure after TDF+Peg IFN for 48 weeks (off-label) [ Marcellin , 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 33 
 2016] . Thus, most patients on treatment fail to achieve a sustained off -treatmen t virological 
response and require extended and often life -long therapy to suppress HBV DNA.  
It has been proposed that the continued production of viral antigens by [CONTACT_690624] 
[Vanlandschoot , 2003]. In vitro studies with human peripheral blood mononuclear cells 
(PBMCs) have shown H BsAg impairs t he functioning of dendritic cells and inhibits the 
activation of monocytes [ Vanlandschoot , 2002;  Op den Brouw , 2009]. Further, data 
suggest the production of vast excess of H BsAg (so called non -infectious “sub -viral 
particles”) likely functions as a decoy for host antibody responses. Most chronically 
infected patients produce antibody to H BsAg, but these can only be detected as immune 
complexes due to the vast excess of circulating antigen [ Maruyama , 1993]. H BeAg is also 
thought to have a role in immune response evasion through down regulation of the innate 
immune system [ Milich , 1998; Wu, 2009; Walsh , 2012]. As noted above, since loss of 
HBsAg expression is rarely achieved while loss of H BeAg expression occurs in a higher 
proportion of the patient population, H BsAg appears to be the main antagonist of immune 
clearance.  
Should the viral antigens be instrumental in preventing clearance of persistent infection by 
[CONTACT_27639], reducing the expression of these antigens, especially H BsAg, would 
be expected to permit reconstitution of an immune response against HBV [ Boni , 2007; 
Boni , 2012; Bertoletti , 2013]. Support for this  hypothesis is the observation that 
spontaneous seroconversion and resolution of chronic infection is most likely in patients 
that have lower serum H BsAg levels [ Chen , 2012;  Höner Zu Siederdissen , 2014].  
Similarly, during treatment with N As, patients with low H BsAg levels are more likely to 
lose H BsAg and seroconvert to anti -HBs antibody positive  than patients with high H BsAg 
levels [ Wursthorn , 2010; Jaroszewicz , 2011 ; Boni , 2012;  Höner Zu Siederdissen , 2014].  
A study to examine whether inhibition of H BsAg production for a finite duration would 
lead to sustained suppression of HBV has not been possible up to the present due to the 
lack of spec ific inhibitors of H BsAg. 
[COMPANY_004]3228836, an antisense oligonucleotide, was designed to inhibit the synthesis of 
HBsAg without having a direct effect on cccDNA or integrated HBV DNA. [COMPANY_004]3228836 
directly targets all HBV messenger RNA ( mRNAs ) via Ribonuclease H (RNAse H) 
mediated degradation, resulting in the reduction of viral proteins including H BsAg. 
[COMPANY_004]3228836 treatment permits examination of whether reduction of H BsAg allows 
resumption of a host immune response against HBV and infected cells and can suppress  
serum H BsAg to <LLOQ.  [COMPANY_004]3228836 has been designed and selected to minimi se risk 
of proinflammatory response associated as a class effect by [CONTACT_690625] ( ASO ) sequence as well as avoiding the presence of Cp G 
motifs that can be recogni sed by [CONTACT_690626] [ Henry , 2008].  However, it 
is expected that [COMPANY_004]3228836 may trigger marginal immune activation in the local 
environment of the liver, which may not be readily detectable in periphery.  In turn, the 
intrinsic immunostimulatory activity of [COMPANY_004]3228836 may contribute to the efficacy in 
addition to direct pharmacodynamic response of H BsAg reduction [ Yuen , 2019].  
Recently, a functional cure of CHB infection has been endorsed as the endpoint for new 
HBV therapi[INVESTIGATOR_014] [ Kim, 2018]. Functional cure of CHB infection is defined as sustained 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 34 
 suppress ion of serum H BsAg to <LLOQ (with or without anti -HBsAg seroconversion,) 
and undetectable HBV DNA in serum, after completion of a finite course of treatment 
[Lok, 2017].  
Function al cure occurs in only a very small percentage of patients on NA therapy alone 
(approx . 3% per annum), meaning  that patients frequently relapse once they are taken off 
treatment [ Lok, 2017].  The high rate of relapse in these patients is hypothesised to be due 
to their inability to raise an effective immune response to the virus in the presence of high 
circulating levels of H BsAg, which continues to be produced by [CONTACT_690622], even 
in the absence of ongoing viral replication.  
2.3. Benefit/Risk Asses sment  
More detailed information about the identified and potential benefits and risks and 
expected adverse events  (AEs)  of [COMPANY_004]3 228836 may be found in the Investigator’s 
Brochure.  Pegylated interferon  (Pegasys) was approved by [CONTACT_33438] ( FDA ) for treatment of  HBV  in 2005 . The safety profile of PegIFN is well 
characterised.  M ore detailed information about the  benefit risk profile of PegIFN can be 
found in the prescribing information  [Pegasys  PI, 2017 ]. 
In addition to the study related risks listed in the table, it should be noted that Corona Virus 
Disease-19 (COVID -19) is a risk for everyone. The magnitude of the risk depends on th e 
prevalence in the population, frequency, duration and closeness of contact [CONTACT_690627], use of protective measures, age, ethnicity, sex and co -morbidities including 
medications.  
Currently, there is no evidence that patients with chronic HBV have in creased 
susceptibility to severe acute respi[INVESTIGATOR_6507] -2 infection.  Patients with 
uncomplicated viral hepatitis (i.e., without cirrhosis, or history of transplantation or current 
immunosuppressant use) don’t appear to be over -represented in hospi[INVESTIGATOR_690587] -19, and therefore viral hepatitis isn’t considered a risk factor for 
a more severe course of COVID -19 [Fix, 2020; Boettler , 2020] . 
The actual risk of COVID -19 will vary by [CONTACT_103049], so study participants should 
follow any national or local hospi[INVESTIGATOR_102999], as well as specific recommendations from 
their healthcare providers.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
35 
 2.3.1.  Risk Assessment  
Risks are summari sed in the table below.  Additional withdrawal/stopp ing criteria for liver chemistry, drug induced vascular inflammation 
(DIVI), haematology , renal function, and PK are discussed in Section 7.1. 
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Investigational Product (IP) [[COMPANY_004]3228836]  
Nonclinical Risks :  
Drug Induced Vascular Inflammation and Complement 
Activation  Inflammatory and immune changes are recogni sed as a 
class effect of antisense oligonucleotides (ASOs). 
Vasculitis and/or perivascular inflammation has been 
described in monkey studies with many if not most ASOs . 
 
This effect has not been observed in clinical studies with 
[COMPANY_004]3228836 to date . Laboratory  Evaluations : Inclusion of biomarker panels 
to look for inflammatory and immune activation that would 
be expected to accompany vascular inflammation  
 
Stoppi[INVESTIGATOR_2121]:  Proposed Monitoring Schedule and 
Stoppi[INVESTIGATOR_102995] (see Section 7.1.4 ) 
 
Clinical Risks : 
Drug induced liver injury / ALT Flares  The liver is a site of accumulation of antisense 
oligonucleotides. Liver findings in nonclinical studies of 
[COMPANY_004]3228836 were generally limited to mild hepatic 
enzyme elevations associated with hepatic vacuolation 
without concomitant histologic evidence of degeneration 
in mice, consistent with findings noted with other 2 ’-
methoxyethyl (MOE) ASOs. Review of the available 
clinical data indicates liver enzymes are increased on 
treatment with ASOs in a low percentage of pat ients 
compared to placebo.  
 
Alanine aminotransferase   (ALT) elevations (defined as 
ALT ≥2X upper limit normal ( ULN)) were observed in the 
ISIS [ADDRESS_936968] 
concomitantly with ALT flares . There were no changes in 
bilirubin.  Laboratory Evaluations: hepatic enzyme monitoring as 
presented in  Table 9 
 
Stoppi[INVESTIGATOR_2121]: ALT flares are expected in the study 
population. Monitoring and stoppi[INVESTIGATOR_165736] 7.1.1  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
36 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Thrombocytopenia leading to clinically significant bleeding 
events  Two types of thrombocytopenia have been described for 
the 2 ’-MOE ASOs [ Chi, 2017; Crooke , 2017].  One type is 
a rapid onset, unpredictable thrombocytopenia.  The other 
more common type is characterised by a gradual decline 
in platelets leading to mild to severe thrombocytopenia 
and can be asymptomatic or associated with mild to 
severe bleeding.   In monkeys given [COMPANY_004]3228836, there 
were incidences of both types in a 39 -week study.  
Thrombocytopenia was not reported in the clinical studies 
with [COMPANY_004]3228836 (ISIS 505358 -CS1 and ISIS 505358 -
CS3)  Laboratory Evaluations: platelet count  
 
Stoppi[INVESTIGATOR_2121]: monitoring and stoppi[INVESTIGATOR_165737] 7.1.[ADDRESS_936969] of 
ASOs.  
No adverse events related to renal function were reported 
in Study ISIS 505358 -CS3 Laboratory Evaluations: Serum creatinine, estimated 
glomerular filtration rate (eGFR ), urinalysis with 
microscopy and albumin to creatinine ratio  (ACR ) 
assessed per the SoA tables  
 
Stoppi[INVESTIGATOR_2121]: Monitoring Schedule and Stoppi[INVESTIGATOR_102997] 7.1.[ADDRESS_936970] been reported with ASOs and 
reported in clinical studies with [COMPANY_004]3228836 (ISIS 
505358 -CS1 and ISIS 505358 -CS3).  
Injection site reactions were the most common study 
treatment -related adverse events ( AEs) reported and 
were Grade 1 (mild) and Grade 2 (moderate) in severity.  Evaluations: Participant s are assessed for injection site 
reactions at all visits during the on -treatment period.  
 
In order to minimi se the risk of injection site reaction 
(ISR), injections should be rotated within each anatomical 
site or site(s) of injection should be changed 
administration -to-administration. Injection into areas with 
ongoing injection site reactions should be avoided.  
Investigational Product (IP) [ PegIFN]  
Clinical Risks1:  
ALT Flares  Chronic hepatitis B participants  experienced transient 
acute exacerbations (flares) of hepatitis B (ALT elevation 
greater than 10 -fold higher than the upper limit of normal) 
during PegIFN  treatment (12% and 18%) and post -
treatment (7% and 12%) in H BeAg negative and H BeAg 
positive particip ants, respectively.  Laboratory Evaluations: hepatic enzyme monitoring as 
presented in the S oA 
 
Stoppi[INVESTIGATOR_2121]: ALT flares are expected in the study 
population. Monitoring , dose adjustment  and stoppi[INVESTIGATOR_690588] 7.2 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
37 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Severe CNS effects, particularly depression, suicidal 
ideation and attempted suicide  Severe CNS effects, particularly depression, suicidal 
ideation and attempted suicide have been observed in 
some patients during PegIFN therapy, and even after 
treatment discontinuation mainly during the 6 -month 
follow -up period. Other central nervous syste m (CNS ) 
effects including aggressive behaviour (sometimes 
directed against others such as homicidal ideation), 
bipolar disorders, mania, confusion and alterations of 
mental status have been observed with alfa interferons.  The Columbia Suicide Severity Rating  Scale  and Beck 
Depression Inventory -II will be completed by [CONTACT_690628].  
 
Participants displaying evidence of depression will be 
managed as per Table 12. 
 
If partic ipants develop new or worsening psychiatric 
symptoms or if suicidal ideation is identified, treatment 
should be discontinued,  and the patient followed  up with 
psychiatric intervention as appropriate.  
Refer to Section 8.2.7  Suicidal  Ideation and Behaviour 
Risk Monitoring  
 
Decrease in haem oglobin, platelet count, total white blood 
cell ( WBC ) count and ANC  PegIFN treatment has been associated with decreases in 
haemoglobin, platelet count, total WBC count and ANC.  Eligibility for PegIFN treatment will be assessed prior to 
starting treatment  as per Section 5.3 
 
Laboratory Evaluations: Haematology monitoring as per 
the SOA.  
Stoppi[INVESTIGATOR_690589]  7.2 
Endocrine disorders:  
Thyroid function abnormalities or worsening of pre -
existing thyroid disorders  
 
 
Hypoglycaemia/Hyperglycaemia/Diabetes Mellitus   
 
Thyroid function abnormalities or worsening of pre -
existing thyroid disorders have been reported with the use 
of alfa interferons, including PegIFN .  
 
 
 
 
 
Hypoglycaemia, hyperglycaemia and diabetes mellitus 
have been observed with PegIFN .   
 
Participants with uncontrolled thyroid function are 
excluded from this study.  
Thyroid function tests will be monitored as per the SOA . 
Abnormalities of thyroid function should be managed 
according to local guidance.  If thyroid function cannot be 
adequately managed PegI FN treatment should be 
discontinued.  
 
Participants with uncontrolled diabetes are excluded from 
this study.  
Blood glucose will be monitored throughout the study.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
38 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Abnormalities of blood glucose should be managed 
according to local guidance.  If blood glucose  cannot be 
adequately managed PegIFN treatment should be 
discontinued.  
 
Cardiovascular disorders: Hypertension, supraventricular 
arrhythmias, congestive heart failure, chest pain and 
myocardial infarction  These have been associated with alfa interferon 
therapi[INVESTIGATOR_014], including PegIFN .  Patients with significant/unstable cardiac disease are 
excluded from the study.  
 
Participants will undergo an electrocardiogram ( ECG ) at 
screening  and prior to PegIFN treatment . 
 
If there is any deterioration of cardiovascular status, 
therapy should be suspended or discontinued.  
Retinopathy including retinal haemorrhages, cotton wool 
spots, papi[INVESTIGATOR_59411], optic neuropathy and retinal artery 
or vein obstruction which may result in loss of vision  These have been reported in rare instances with PegIFN .  All participants will have a baseline eye examination.  
 
Any participant complaining of a change in vision or a 
new visual disturbance will have an urgent eye 
examination  and PegIFN sh ould be discontinued.  
Fever/Infections  Serious infections (bacterial, viral, fungal) and sepsis 
have been reported during treatment with alfa interferons 
including PegIFN .  Appropriate anti -infective therapy should be started 
immediately, and discontinuation of PegIFN should be 
considered  
Pulmonary symptoms, including dyspnoea, pulmonary 
infiltrates, pneumonia, and pneumonitis  These have been reported during therapy with PegIFN .  Participants with clinically significant pulmonary disease 
are excluded from the study.  
 
Any participant developi[INVESTIGATOR_553346], cough, and dyspn oea or 
other respi[INVESTIGATOR_690590] a chest X ray 
taken. If there is evidence of persistent or unexplained 
pulmonary infiltrates or pulmonary function impairment, 
treatment  should be discontinued.  
Exacerbation or provocation of psoriasis . Use of PegIFN has been associated with exacerbation or 
provocation of psoriasis . In cases of onset or worsening of psoriatic lesions, 
discontinuation of therapy will be considered.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
39 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Development of autoantibodies  and autoimmune 
disorders  These have been reported during treatment with alfa 
interferons.  Patients with signs or symptoms compatible with 
autoimmune disorders will be evaluated carefully, and the 
benefit -risk of continued inte rferon therapy should be re -
assessed   
1. The full benefit risk profile can be found in the Pegasys label  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
40 
 2.3.2.  Benefit Assessment  
Treatment of CHB with NAs has been effective in reducing the long -term complications 
of CHB, but evidence is emerging that H BsAg loss is associated with lower rates of 
hepatocellular carcinoma [ Kim, 2014; Yip, 2016]: Even patients who achieve complete 
viral suppression experience significantly lower r ates of hepatocellular carcinoma if they 
are able to achieve H BsAg loss.  Thus, there is a need in patients with CHB for a finite 
treatment that allows them to achieve immune control of their infection (functional cure, 
defined as H BsAg loss with HBV DNA s uppression), removing the need for lifelong 
therapy and to improve long term disease outcomes, particularly development of 
hepatocellular carcinoma.  
[COMPANY_004]3228836 demonstrated target engagement in CHB patients who were not on treatment 
and in CHB patients on stable NA therapy. Overall, continued clinical development of 
[COMPANY_004]3228836 is supported by [CONTACT_103050] [ADDRESS_936971] response rates (RR) to PegIFN  [Ren, 
2019 ].  In study ISIS 505358 -CS3 it was demonstrated that 4 weeks treatment with 
[COMPANY_004]3228836 weekly resulted in marked declines in serum H BsAg in the majority of 
participants , including four participants  that achieved HBsAg seroclearance 
(<0.05 IU/mL) , but subseq uently relapsed .  A [COMPANY_004]3228836 mediated reduction of serum 
HBsAg l evel prior to starting a short course of PegIFN therapy is expected to result  in 
higher rates of HBsAg seroclearance and durability of response  than if either agent was 
used alone  and provide additional benefit over [COMPANY_004]3228836 treatment alone . 
2.3.3.  Overall Benefit:  Risk Conclusion  
Considering  the measures taken to minimi se risk to participants in this study, the 
potential risks identified in association with [COMPANY_004]3228836 , PegIFN  and from COVID -19 
are balanced by [CONTACT_103051] . 
  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
41 
 3. OBJECTIVES AND ESTIMANDS   
Objectives  Estimands and Endpoints  
Primary  
Efficacy: To investigate the efficacy of two 
different durations of [COMPANY_004]3228836 followed 
by [CONTACT_8622] 24 weeks of PegIFN therapy in 
participants with CHB on stable NA therapy.  The main Estimand supporting the primary objective is 
defined as:  
• Population: Participants with CHB on stable NA 
therapy  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks 
followed by [CONTACT_8622] 24 weeks of PegIFN therapy while 
on stable NA therapy  
• Variable (Categorical): Participants achieving 
Sustained Virologic Response (SVR) (H BsAg 
<LLOQ and HBV DNA <LLOQ) for 24 weeks after 
the planned end of sequential treatment, without use 
of any rescue medication  
• Intercurrent Events:  
o Discontinuation of, interruption in, and non -
adherence to [COMPANY_004]3228836 and PegIFN not 
related to any wide disruptive events (such as 
COVID -19 pandemic) will be ig nored (treatment 
policy strategy).  
o Ineligibility to receive PegIFN will be ignored 
(treatment policy strategy)  
o Use of rescue medication (composite strategy).  
o Wide disruptive events (such as COVID -19 
pandemic) leading to discontinuation of, 
interruption in , and non -adherence to 
[COMPANY_004]3228836 and PegIFN will be handled 
assuming they had not happened (hypothetical 
strategy).  
• Population Summary: The percentage of 
participants in each treatment group who achieve 
SVR, without use of any rescue medication  
The main p rimary estimand supporting the primary 
objective in participants with CHB on stable NA therapy 
in each treatment arm is the percentage of participants 
that achieve SVR (H BsAg <LLOQ and HBV DNA 
<LLOQ) for 24 weeks after the planned end of sequential 
treatme nt in the absence of rescue medication, 
regardless of ineligibility to receive PegIFN, 
discontinuation of, interruption in, and non -adherence to 
[COMPANY_004]3228836 and PegIFN, had they not been affected 
by [CONTACT_165763].  
 
Three supplementary Estimands are  defined to support 
the primary objective:  
• The first supplementary Estimand is defined in the 
same way as the main Estimand, except the 
assessment time frame for patients achieving SVR 
will be 24 weeks after the actual end of treatment. 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
42 
 Objectives  Estimands and Endpoints  
Therefore, the stra tegy for intercurrent events of 
treatment discontinuation will be while -on-treatment. 
This supplementary estimand supporting the primary 
objective in participants with CHB on stable NA 
therapy in each treatment arm is the percentage of 
participants that ac hieve SVR (H BsAg <LLOQ and 
HBV DNA <LLOQ) for 24 weeks after the actual end 
of sequential treatment in the absence of rescue 
medication, regardless of ineligibility to receive 
PegIFN, discontinuation of, interruption in, and non -
adherence to [COMPANY_004]3228836 and  PegIFN, had they 
not been affected by [CONTACT_165763].  
 
• The second supplementary Estimand is to 
understand the relationship between the PegIFN 
duration and achieving SVR for 24 weeks after the 
actual end of treatment, defined as:  
o Population: Participants with CHB on stable NA 
therapy  
o Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 
weeks followed by 24 weeks of PegIFN therapy 
while on stable NA therapy  
o Variable: The relationship between SVR for 24 
weeks after actual end of treatment and the 
duration of PegIFN received by [CONTACT_4317]  
o Intercurrent Events:  
▪ Discontinuation and delayed start of, 
PegIFN, will be accounted to reflect the 
actual duration from the first to the last 
dose of PegIFN received (while -on-
treatment strategy).  
▪ Interru ption in and other non -adherence 
to PegIFN will be ignored (treatment 
policy strategy)  
▪ Discontinuation of, interruption in and 
non-adherence to [COMPANY_004]3228836 will be 
ignored (treatment policy strategy)  
▪ Use of rescue medication ( composite  
strategy).  
▪ Wide disru ptive events (such as 
COVID -19 pandemic) leading to 
discontinuation and delayed start of, 
PegIFN will be handled with while -on-
treatment strategy; wide disruptive 
events leading to interruption in and 
other non -adherence to PegIFN will be 
ignored (treatmen t policy strategy);  
wide disruptive events leading to 
discontinuation of, interruption in, and 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
43 
 Objectives  Estimands and Endpoints  
non-adherence to [COMPANY_004]3228836 will be 
ignored ( treatment policy strategy ). 
o Population Summary: The percentage of 
participants achieving SVR for 24 weeks after 
the actual end of treatment by [CONTACT_690619][INVESTIGATOR_690591]  
• The second supplementary Estimand (supporting 
the primary objective in participants with CHB on 
stable NA therapy ) is the percentage of participants 
achieving SVR for 24 weeks after the actual end of 
treatment by [CONTACT_690629][INVESTIGATOR_690592], taking into account  
discontinuation and delayed start of PegIFN, 
regardless of interruption in and other non -
adherence to PegIFN, regardless of discontinuation 
of, interruption in and non -adherence to 
[COMPANY_004]3228836.  
 
• The third supplementary Estimand is defined in the 
same way as the main Estimand, except the 
strategy for intercurrent events of PegIFN ineligibility 
for more than  12 weeks and/or missing more than 
12 doses of PegIFN will be principal stratum. This 
supplementary Estimand supporting the primary 
objective is the percentage of participants in each 
treatment arm that achieve SVR (H BsAg <LLOQ 
and HBV DNA <LLOQ) for [ADDRESS_936972] 12 doses of PegIFN, in the absence of rescue 
medication, regardless of discontinuation of, 
interruptions in o r non -adherence to [COMPANY_004]3228836 
had they not been affected by [CONTACT_165768].  
Secondary  
Efficacy: To assess the efficacy of 
[COMPANY_004]3228836 and PegIFN sequential therapy 
on biomarkers and virus specific antibody 
responses  The Estimand supporting the objective is defined as:  
• Population: Participants with CHB on stable NA 
therapy; For the time to ALT normali sation  variable, 
population will be aforementioned participants with 
baseline ALT >ULN.  
• Treatment: 300 mg [COMPANY_004]3228836 for 12, or 24 
weeks followed by  24 weeks of PegIFN therapy 
while on stable NA therapy  
• Categorical Variables:  
o Achieving H BsAg <LLOQ and HBV DNA 
<LLOQ at two time points: (1) the planned end 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
44 
 of treatment and (2) at the end of 24 weeks 
follow -up 
o Categorical changes from baseline in H BsAg 
(e.g., <0.5, ≥0.5, ≥1, ≥1.5, ≥3 log10 IU/mL) at 
each scheduled visit or analysis window.  
o ALT normali sation  (ALT ≤ULN) over time in 
absence of rescue medication in participants 
with baseline ALT >ULN  
Population summary is the percentage of 
participants in each category for each treatment 
group.  
o HBe antibody (anti -HBeAg) levels . 
 
• Continuous Variables:  
o Actual values and change from baseline over 
time for H BsAg, HBV DNA and H BeAg 
o Actual values and change from baseline over 
time for HBs antibody (anti -HBsAg) levels over 
time 
o Actual values and change from baseline over 
time for ALT  
Population summary is the mean values and 
the mean changes from baseline of each 
variable for participants in each treatment 
group.  
• Time to Event Variable:  
o Time to ALT normali sation  in absence of rescue 
medication in participants with baseline 
ALT>ULN  
Population summary is the Turnbull’s estimator 
for non -parametric estimation of Time to ALT 
normali sation  in each treatment arm  
• Intercurrent Events: Discontinuation of, interruption 
in, and non -adherence to [COMPANY_004]3228836 and PegIFN 
will be ignored (treatment policy); PegIFN ineligibility 
will be ignored (treatment policy); Rescue 
medication will be ignored (treatment policy), except 
for ALT normali sation  which can only be achieved in 
the ab sence of rescue medication ; Wide disruptive 
events (such as COVID -19 pandemic) leading to 
discontinuation of, interruption in, and non -
adherence to [COMPANY_004]3228836 and PegIFN will be 
handled with Treatment Policy Strategy.  
• The group of estimands supporting this  objective is 
the population summary for each variable in each 
treatment arm in the population regardless of 
discontinuation of, interruption in  or non -adherence 
to [COMPANY_004]3228836 and PegIFN, and regardless of 
rescue medication (except for ALT normali sation  
which can only be achieved in the absence of 
rescue medication) or PegIFN ineligibility.  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
45 
 Objectives  Estimands and Endpoints  
Efficacy: To investigate the durability of 
virological response after sequential therapy 
with 12 weeks of [COMPANY_004]3228836 followed by 
24 weeks of PegIFN in participants with CHB 
on stable NA therapy for up to 36 weeks off 
treatment.  The same definition as the above secondary estimand, 
focusing on the timepoints following the 24 weeks off -
treatment period in  the treatment arm of 300 mg 
[COMPANY_004]3228836 for 12 weeks followed by [CONTACT_8622] 24 weeks 
of PegIFN therapy while on stable NA therapy.  
Efficacy: To compare efficacy between 
different treatment durations:  
12 or 24 weeks of  [COMPANY_004]3228836 followed by 
24 weeks PegIFN  The same definition as the primary estimand except 
treatments and population summary are defined as:  
• Treatments: Arms 1 and 2. One treatment 
comparison between Arms 1 & 2  up to 24 weeks off -
treatment  
• Population summary: difference in proportion of 
particip ants who achieve SVR between treatment 
arms  
The group of estimands supporting this objective in 
participants with CHB on stable NA therapy is the 
difference between treatment arms 1 and 2 in the 
proportion of participants that achieve SVR for 24 weeks 
after the planned end of sequential treatment, in the 
absence of rescue medication, regardless of ineligibility 
to receive PegIFN, regardless of discontinuation of, 
interruption in or non -adherence to [COMPANY_004]3228836 and 
PegIFN had they not been affected by [CONTACT_690630] e disruptive 
events.  
Exploratory  
Pharmacokinetics (PK) and PK -
pharmacody namic  (PD) relationships of 
[COMPANY_004]3228836 and PegIFN : To evaluate PK, 
PK-efficacy relationship and PK -safety 
relationship  Efficacy assessments  for PK/PD relationship  include but 
not limited to  
• Categorical: virologic response, H BsAg level 
<LLOQ, HBV DNA level <LLOQ, and 
seroconversion (anti -HBsAg and anti -HBeAg);  
• Change from baseline: H BsAg, HBV DNA, anti -
HBsAg and anti -HBeAg levels;  
• Time to event: virologic response (HBsAg and HBV 
DNA levels <LLOQ), nadir of H BsAg and HBV DNA, 
HBsAg level <LLOQ, HBV DNA level <LLOQ, 
seroconversion (anti -HBsAg and anti -HBeAg), and 
peak of ALT flares  
Safety assessments  for PK/PD relationship  include but 
not limited to vital signs, labor atory measurements and 
adverse events  
PK assessments include but not limited to C  and 
terminal half -life (t½).  
Safety and Tolerability : To investigate the 
safety profile of sequential therapy with 
[COMPANY_004]3228836 (up to 24 weeks) followed by 
[CONTACT_690621] ( up to 24 weeks) in participants with 
CHB on stable NA therapy.  Clinical assessments including l aboratory measurements 
and adverse events  at timepoints specified in the SoA 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
46 
 Objectives  Estimands and Endpoints  
Biomarkers:  To assess the effect of 
[COMPANY_004]3228836 and  PegIFN sequential therapy 
on immunological biomarkers.  
 
To describe the relationship(s) between  
virology biomarkers including H BsAg and 
immunological biomarkers.  
 
 Laboratory measurements of and correlation between 
the following : 
o Virological biomarkers, including specific viral 
parameters ( HBsAg, HBeAg , HBV DNA, HBV 
RNA, H BcrAg)  
o Soluble biomarkers, including levels of circulating 
cytokines and chemokines  
o Markers of immune cell function, including relative 
frequencies of immune cell subsets among 
PBMCs, activation status as determined by 
[CONTACT_165769][INVESTIGATOR_165740], and 
functional assays including HBV -specific cytokine 
and/or antibody production  
Timepoints are specified in the SoA 
 
4. STUDY DESIGN  
4.1. Overall Design  
This is a Phase  IIb, multi -centre, randomi sed, open -label study to assess the efficacy and 
safety of sequential treatment with [COMPANY_004]3228836 (300  mg/week for 12 or 24 weeks) 
followed by [CONTACT_690621] (180  mcg/week for up to 24 weeks) in participants with CHB on 
stable NA therapy.  During the [COMPANY_004]3228836 treatment period , a 300  mg loading dose 
will be administered on Day 4 and Day 11.  Participants will continue their NA therapy 
for the duration of the study.  
Participants will be randomi sed (1:1) into one of two parallel treatment arms.  
1. 300 mg [COMPANY_004]3228836 once/week for 24 weeks (p lus loading dose on Day 4 and 
11) followed by [CONTACT_690621] (180  mcg/week for up to 24 weeks). Participants will be 
followed up for an additional 24 weeks (off -treatment phase) once PegIFN 
treatment is complete.  
CCI
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
47 
 2. 300 mg [COMPANY_004]3228836 once/week for 12 weeks (plus load ing dose on Day 4 and 
11) followed by [CONTACT_690621] (180  mcg/week for up to 24 weeks).  Participants will be 
followed up for an additional 36 weeks (off -treatment phase) once PegIFN 
treatment is complete.  
The planned duration of [COMPANY_004] 3228 836 is 24 weeks and 12 week s in Treatment Arm 1 and 
2 respectively.  If a participant prematurely discontinues [COMPANY_004]3228836 treatment the 
participant is encouraged to complete the SoA as per the planned [COMPANY_004]3228836 dosing 
period.  At the e nd of the planned [COMPANY_004]3228836  dosing period , participants will be re -
assessed for eligibility to start PegIFN treatment based on the label.  
1. Participants immediately eligible for PegIFN will begin treatment  
2. Participants who are not considered eligible will be re -assessed for eligibility and 
may delay sta rt of PegIFN treatment for up to 12 weeks.  
3. Participants who fail to meet PegIFN eligibility criteria by [CONTACT_690631] 13 (i.e. can no longer receive at least 12 weeks of PegIFN treatment) will 
not receive treatment with PegIFN.  
Note: all particip ants are expected to end PegIFN treatment at the same time, regardless 
of when they start therapy (Treatment Group 1: all participants should complete treatment 
by [CONTACT_10585] 48; Treatment Group 2: Week 36) . 
As such, the planned treatment duration with PegIFN fo r participants on study 209348 
may vary from a minimum of 12 weeks to a maximum of 24 weeks.  
Participants will be randomised 1:1 . Populations will be stratified based on H BsAg level 
(HBsAg ≤3 log IU/mL and >3 log IU/mL) and whether participants are H BeAg positive 
or negative.  Lower H BsAg has been associated with increased likelihood of H BsAg loss 
in patients treated with PegIFN -containing regimens [Ren, 2019; Lee, 2018 ; Yeo, 2019 ].  
With existing therapi[INVESTIGATOR_690593] H BeAg positive 
and negative patient populations [Ren, 2019 ]. 
4.2. Scientific Rationale for Study Design  
The rationale for the proposed study is to evaluate the potential of up to 48 weeks of 
sequential therapy with [COMPANY_004]3228836 and PegIFN to achieve sustained loss of HBsAg and 
HBV DNA in participants on stable NA therapy.  Sustained virologic response  is defined 
as undetectable levels of H BsAg and HBV DNA on treatment and maintaining this for a 
minimum of 24 weeks off -treatment  ([COMPANY_004]3228836 and PegIFN) .   
This Ph ase IIb study has been designed to answer two questions which are considered 
critical to the overall development of [COMPANY_004]3228836 to achieve functional cure in patients 
with CHB:  
1. Does sequential therapy with [COMPANY_004]3228836 (12 or 24 weeks) followed by [CONTACT_8622] 
24 weeks of Pe gIFN result in improved rates of efficacy in NA -controlled CHB 
patients compared to [COMPANY_004] 3228 836 monotherapy?   
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
48 
 2. Is the efficacy rate affected by [CONTACT_690632]3228836 prior to 
starting PegIFN?  
Addressing these questions is critical to our understanding of the potential for sequential 
therapy with immunomodulators to achieve functional cure in patients with CHB, and to 
optimise the duration of treatment with [COMPANY_004]3228836 prior to starting PegIFN (or other 
immunomodulators in future studies).  
The proposed study will investigate efficacy of two different sequential treatment regimens 
with [COMPANY_004]3228836 and PegIFN (Pegasys; Hoffman La -[COMPANY_002]) in participants with CHB 
that are controlled with stable NA therapy.  
Rationale for Patient Population  
Participants will continue their NA therapy for the duration of the study.  Liver flares 
(elevated ALT and related biomarkers) are common occurrences during treatment of CHB 
patients with interferon -containing therapi[INVESTIGATOR_014], and flares were also observed after [ADDRESS_936973] evaluating  
proof of concep t (POC ) in participants whose infection is already under control with stable 
NA therapy.  Patients whose infection is controlled by [CONTACT_690633] H BsAg detectable in 
serum due to the presence of HBV cccDNA and integrated DNA in infected hepatocytes.  
As such, this patient population has the best benefit:risk profile for early POC studies with 
experimental therapi[INVESTIGATOR_014].  
Rationale for Selection of PegIFN  
PegIFN is an immunomodulatory therapy approved for use in CHB patients.  Rates of 
sustained loss of HBsAg following up to 48 weeks of treatment typi[INVESTIGATOR_690594] 1 - 9% 
at 24 weeks off -treatment follow -up when used in combination with NAs [Ren, 2019 ]. 
Rationale for Sequential Therapy ([COMPANY_004]3228836 followed by [CONTACT_690621] ) 
Numerous studies have looked at predictors of response to PegIFN use in CHB.  Lower 
levels of baseline H BsAg consistently predict the highest response rate to PegIFN  in terms 
of HBsAg loss [Ren, 2019 ].  In study ISIS 505358 -CS3, it was demonstrated that 4 weeks 
treatment with 150  mg or 300  mg [COMPANY_004]3228836 weekly (including loading doses) resulted 
in marked declines in serum H BsAg in the majority of participant s, including 4 who 
experienced transient HBsAg seroclearance.  The proposed design of study 209348 tests 
the hypothesis that using [COMPANY_004]3228836 to reduce  serum H BsAg load prior to starting a 
CCI
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
49 
 short course of PegIFN  therapy wi ll result in higher rates of sustained seroclearance than 
if either agent was used alone.  
Rationale for Duration of [COMPANY_004]3228836 Treatment (12 or 24 weeks)  
The current hypothesis of functional cure is based on the ability of a patient to raise an 
effective immune response to HBV in infected hepatocytes once immunosuppressive 
HBsAg has been lost from the blood.  The duration of suppression of H BsAg required to 
enable reconstitution of anti -HBV immunity is still unknown.  In the majority of 
participants that responded to [COMPANY_004]3228836 in study ISIS 505358 -CS3, serum H BsAg 
levels were still declining when treatment was stopped after 4 weeks.  Of note, in 
participants that did not become H BsAg <LLOQ, reductions of H BsAg had not yet reached 
a plateau during treatment, suggesting that continued dosing has the potential to further 
reduce H BsAg levels.  Taken together, the data suggest that a longer duration of treatment 
with [COMPANY_004]3228836 may be required to increase the rate of partici pants achieving H BsAg 
levels <LLOQ.  In the proposed study , we will investigate 2 different durations of treatment 
with [COMPANY_004]3228836 (12 and 24 weeks at 300  mg/week) prior to starting Peg IFN in order to 
optimise rates of sustained seroclearance.  
Rationale fo r Duration of PegIFN (up  to 24 weeks)  
Current PegIFN treatment guidelines recommend 48 weeks treatment.  In this study 
PegIFN will be administered for a maximum of 24 weeks duration.  The rationale for 
administering a shorter duration of PegIFN is:  
1. PegIFN administration is associated with numerous adverse effects and can be 
difficult to tolerate. This may in part explain the low use of PegIFN despi[INVESTIGATOR_690595] H BeAg and H BsAg loss compared to nucleos(t)ide therapy.  
2. Shorter duration of PegIFN may be m ore attractive to providers and patients. 
When [COMPANY_004] has sought advice from external experts on the role of PegIFN 
therapy in the context of our development program, the experts considered up to 
[ADDRESS_936974] been associated 
with better treatment outcomes.  In this study, the preceding [COMPANY_004]3228836 
treatment is anticipated to reduce H BsAg to lower or even undetectable levels  
prior to administration of PegIFN .  In this context it is unclear whether longer 
duration of PegIFN would be beneficial.  
4. A systematic review of treatment of CHB  infection by [CONTACT_690634] N showed that 
PegIFN  induced sustained biochemical and virological responses (ALT 
normali sation , HBeAg seroconversion, HBV DNA suppression) in about one -
thirds of patients after 6 or 12 months of therapy. Importantly, the studies with 
longer duration of PegIFN treatment didn’t show greater efficacy for the primary 
endpoints (virological responses), although the rate of H BsAg loss appeared 
slightly better with 12 months of treatment.   
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
50 
 4.2.1.  Participant Input into Design  
A small group of patients  with CHB were asked to review an example informed consent 
form in related study 209668. The patients provided feedback for more clarity in the 
informed consent form regarding the purpose of the study and optional assessments (e.g. , 
biomarkers), mode of ad ministration of [COMPANY_004]3228836, the study burden in both terms of 
visit schedule and duration of visit.  Efforts to reduce the burden of visits were encouraged.  
Input from these patients will be incorporated into the Informed Consent Form.  The study 
team rev iewed the blood collection timepoints and made changes to balance participant 
burden with the data/timepoints needed for safety and efficacy analyses.  
Due to the feedback from patients that the number of visits may be challenging (weekly 
visits to the clin ic/hospi[INVESTIGATOR_307]), the study team are working with countries/sites to provide an 
option where participants may use a centralised home nursing provider.  The home nursing 
providers will go to the participant, decreasing the number of times the participant must 
travel to/from the clinic/hospi[INVESTIGATOR_307].  Only selected visits will have the option to be performed 
as a home visit, these will include drug administration, blood draws, participant 
assessments and data collection. The full specifications of the home nursing ser vices will 
be outlined in the SRM.  
4.3. Justification for Dose  
[COMPANY_004]3228836  Dose Levels, Frequency and Duration  
[COMPANY_004]3228836 has been evaluated over a 4-week dosing duration in both healthy volunteers 
(ISIS 505358 -CS1 study) and in participant s with CHB (ISIS [ZIP_CODE] 8-CS3 study). In both 
studies, [COMPANY_004]3228836 was administered subcutaneously on Study Day 1, 4, 8, 11, 15, and 
22. The loading schedule (i.e. loading doses ) on Day [ADDRESS_936975] dose of [COMPANY_004]3228836 evaluated was 2700 mg over 4 weeks (450 mg 
per injection including loading schedule; n=3) in healthy volunteers, and 1800 mg over 
4 weeks (300 mg per injection including loading schedule; n=17) in participants with CHB. 
In participants with CHB dosed with 300 mg per injection in ISIS 505358 -CS3 study, 
continuous H BsAg declines were observed in many participants during [COMPANY_004]3228836 
treatment, with 2 participants achieving H BsAg seroclearance b y study Week 4. In both 
participants who achieved seroclearance by [CONTACT_10585] 4, H BsAg subsequently became 
detectable after discontinuation of [COMPANY_004]3228836 d osing. Moreover, many participants had 
declining H BsAg levels that hadn’t plateaued by [CONTACT_57627] . Taken together , the 
data suggest that a longer duration of [COMPANY_004]3228836 therapy may be required to both 
increase the rate of seroclearance and to achieve sustained seroclearance.  
In study 209 348, two different treatment durations  with [COMPANY_004]3228836  (12 weeks and up to 
24 weeks) will be studied  prior to initiating treatment with PegIFN  to assess differences in 
the efficacy endpoints (e.g., proportion of participant s achieving seroclearance, durability 
of response ): 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
51 
 1. 300 mg [COMPANY_004]3228836 for 24 weeks followed by [CONTACT_8622] 24 weeks of PegIFN ; 
2. 300 mg [COMPANY_004]3228836 for 12 weeks followed by [CONTACT_8622] 24 weeks of PegIFN ; 
PegIFN  
PegIFN will be dosed according to the SoA (Section 1.3) for CH B patients for up to 
[ADDRESS_936976] evaluated the safety and tolerability of PegIFN 
when dosed with NAs (Ren, 2019) .  Except for telbivudine, which is c ontraindicated in the 
PegIFN label, no worsening of the safety and tolerability profile of PegIFN and/or 
commonly prescribed NAs has been reported when dosed concurrently in CHB patients.  
Co-administration of [COMPANY_004]3228836 and Nucleos(t)ide Analogues  
[COMPANY_004]3228836 is unlikely to be a victim or perpetrator of drug -drug interactions when 
administered with NAs due to their divergent absorption, distribution, metabolism, and 
excretion pathways.  
Drug -drug interactions with [COMPANY_004]3228836 as victim:  
Upon entry into  the system circulation, [COMPANY_004]3228836 rapi[INVESTIGATOR_103007] 
(approximately 95%) to serum proteins and is then rapi[INVESTIGATOR_103008]. 
[COMPANY_004]3228836 enters hepatic cells through target -mediated endocytosis and enters renal 
cells through micropi[INVESTIGATOR_690596] [ Geary , 2008; Bennett , 2010]. [COMPANY_004]3228836 is eliminated 
primarily via nucleolytic de gradation by [CONTACT_103055] [ Geary , 2008]. None 
of these processes is inhibited or induced by [CONTACT_34677] -molecule drugs including NAs (e.g., 
tenofovir, e ntecavir, lamivudine , adefovir and telbivudine).  
In Cohorts 1 -3 of the ISIS 505358 -CS3 study , treatment naïve participant s were started on 
tenofovir after treatment ended; in Cohort 4, where participant s were NA-experienced, the 
majority of participant s entered the study  on entecavir.   Clinical data from this study 
suggest that co -administration of entecavir  is unlikely to impact plasma PK of 
[COMPANY_004]3228836.  [COMPANY_004]3228836 was co -administered with entecavir  throughout the treatment 
period in 4 participant s in Co hort 4 while administered alone in 18 participant s in Cohorts 
1 to 3.   [COMPANY_004]3228836 plasma concentration was comparable with entecavir  (n=4) and 
without entecavir  (n=18).  Dose normali sation  was applied to Cohort 1 as 150 mg of 
[COMPANY_004]3228836 was administered in  Cohort 1 as compared to 300 mg in Cohorts 2 to 4.   
Drug -drug interactions with [COMPANY_004]3228836 as perpetrator:  
Tenofovir, entecavir, and other NAs circulated in the blood stream with little binding to 
serum proteins [ Bristol -Myers Squibb , 2018; [COMPANY_009]  2018]. Tenofovir, entecavir, 
lamivudine, adefovir and telbivudine are predominantly renally eliminated from systemic 
circulation [ Epi[INVESTIGATOR_54736] , 2002; Kearney , 2004 ; Hepsera , 2012; Tyzeka , 2013; Entecavir , 2015; 
Bristol -Myers Squibb , 2018; [COMPANY_009] , 2018]. These [ADDRESS_936977] been reported to be mediated by 
[CONTACT_103056]: the organic anion transporter (OAT) 1, OAT3, 
the organic cation tra nsporter (O CT) 1, and OCT2 [ Cihlar , 2001; Cihlar , 2004; Servais , 
2006; Uwai , 2007;  Minuesa , 2009; Yanxiao , 2011; Xu, 2013].  It has been shown that 
2’-MOE ASO is neither a substrate nor an inhibitor of OAT1, OAT3, OCT1 and OCT2 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
52 
 [Yu, 2016; Shemesh , 2017]. Therefore, alth ough [COMPANY_004]3228836 was shown to be 
extensively distributed into the kidney in non -clinical studies, it is unlikely to interact with 
tenofovir, entecavir, lamivudine, adefovir, telbivudine, or other NAs. 
In Cohorts 1 -3 of the ISIS 505358 -CS3 study , treatment n aïve participant s were started on 
tenofovir after treatment ended; in Cohort 4, where participant s were NA-experienced, the 
majority of participant s were on entecavir.   Clinical data from this study suggest that 
co-administration of [COMPANY_004]3228836 is unlikely to impact efficacy and safety profiles.  In 
Cohorts 1 to 3 in ISIS 505358 -CS3 study, [COMPANY_004]3228836 was administered alone for 
4 weeks, and then tenofovir dosing was started on Study Day 29  ([ADDRESS_936978] dosing  
of [COMPANY_004]3228836 ). Given the long plasma and tissue half -life of [COMPANY_004]3228836 
(approximately 3 weeks), there is a period of at least several weeks during which there was 
a substantial presence of both drugs in the plasma, liver and other tissues.  Potent reduc tion 
of HBV DNA was observed following initiation of tenofovir in all participant s.  There were 
no obvious differences in tenofovir potency and efficacy in participant s who received 
150 mg of [COMPANY_004]3228836 (Cohort 1), 300 mg of [COMPANY_004]3228836 (Cohorts 2 and 3), a nd 
placebo (no [COMPANY_004]3228836).   There were no adverse event or clinical laboratory results that 
may indicate a change in tenofovir safety profile due to drug -drug interaction with 
[COMPANY_004]3228836.  
Clinical data suggest that co -administration of [COMPANY_004]3228836 is also unlikely to impact 
tenofovir PK.  In Cohorts 1 to 3  (n=18)  in the ISIS 505358 -CS3 study, a daily dose of 
300 mg tenofovir was initiated on Day 29 ([ADDRESS_936979] dose of [COMPANY_004]3228836), and 
the tenofovir pre -dose plasma concentration was measured on Da y 36, after tenofovir has 
been dosed for one week.  Hepatic [COMPANY_004]3228836 concentration is at steady state after 
4 weeks of dosing with the loading schedule, and there should be a substantial amount of 
[COMPANY_004]3228836 in the liver on Day 36 ([ADDRESS_936980]  dose of [COMPANY_004]3228836 ) due to 
the hepatic  half-life of [ADDRESS_936981] entecavir 
PK. In Cohor t 4 in ISIS 505358 -CS3 study, entecavir was co -administered  with 
[COMPANY_004]3228836 throughout the treatment period in 4 participant s and administered alone in 
2 participant s (participant s on placebo).  Entecavir concentration was comparable in 
participant s with G SK3228836 (n= 4) and without [COMPANY_004]3228836 (n=2) , and comparable to 
that in public domain, suggesting that co -administration of [COMPANY_004]3228836 is unlikely to 
impact entecavir  PK 
4.4. End of Study Definition  
The end of the study is defined as the date of the last visit of the last participant in the 
study.  
A participant is considered to have completed the study if they completed all phases of 
the study for which they were eligible, including the last visit.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
53 
 5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment  criteria, also 
known as protocol waivers or exemptions, is not permitted.  Participants are eligible to be 
included in the study only if all of the following criteria apply:  
5.1. Inclusion Criteria  
AGE  
1. At least 18 to 75 years of age at the time of signing the informed consent [if 
country/site age requirements for consent differ, the more stringent (e.g.,  higher 
age) restriction will be required for that country/site].  
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS   
2. Participants who  are eligible to be treated with PegIFN ( Table 8) 
3. Documented chronic HBV infection ≥[ADDRESS_936982] 6 months prior to screening and with no planned changes to 
the stable regimen over the duration of the study  
4. Plasma or serum H BsAg concentration >100 IU/mL  
5. Plasma or serum HBV DNA  <90 IU/mL  
6. Alanine Transaminase (ALT) ≤[ADDRESS_936983]  
 
SEX  
7. Male and/or Female  
a. A male participant is eligible to participate if they agree to the following 
during the intervention period and for at least [ADDRESS_936984] dose 
of study treatment  
i. Refrain from donating sperm  
ii. AND be abstinent from heterosexual intercourse as their 
preferred and usual lifestyle (abstinent on a long term and 
persistent basis) and agree to remain abstinent OR Must agree to 
use contraception/barrier as detailed below  
1. Agree to us e a male condom [and should also be advised 
of the benefit for a female partner to use a highly 
effective method of contraception as a condom may 
break or leak] when having sexual intercourse with a 
woman of childbearing potential who is not currently 
pregnant 
b. A female participant is eligible to participate:  
TMF-[ADDRESS_936985] one of the following conditions applies:  
1. Is not a woman of childbearing potential (WOCBP) as 
defined in Section 10.4 Contraception and Barrier 
Guidance  
2. Is a WOCBP and using a contraceptive method that is  
highly effective (with a failure rate of <1% per year),  
preferably with low user dependency during the  
intervention period and for at least [ADDRESS_936986]  
dose of study treatment     
• A WOCBP must have a negative highly sensitive pregnancy test (urine or 
serum as required by [CONTACT_427]) within [ADDRESS_936987] cannot be confirmed as negative (e.g., an ambiguous 
result), a serum pregnancy test is required. In such cases, the participant 
must be excluded from participation if the serum pregnancy result is 
positive.  
Additional requirements for pregnancy testing during and after study 
intervention are located in Section  10.2. 
Contraceptive use by [CONTACT_103057].  
The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy  
 
INFORMED CONSENT  
8. Capable of giving signed informed consent as described in Section 10.1, which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.  
 
 
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 55 
 5.2. Exclusion  Criteria  
Participants are excluded from the study if any of the following criteria apply:  
MEDICAL CONDITIONS  
1. Clinically significant abnormalities, aside from chronic HBV infection in medical 
history (e.g., moderate -severe liver disease other than chronic HBV, acute coronary 
syndrome within 6 months of screening, major surgery within 3 months of 
screening, signifi cant/unstable cardiac disease, uncontrolled diabetes, bleeding 
diathesis , autoimmune disease , or coagulopathy) or physical examination  
2. Co-infection with:  
a. Current or past history of Hepatitis C virus (HCV)  
b. Human immunodeficiency virus (HIV)  
c. Hepatitis D vir us (HDV)  
3. History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by  
a. Both Aspartate aminotransferase (AST) -Platelet Index (APRI) >2 and 
FibroSure/FibroTest result >0.7  
i. If only one parameter (APRI or FibroSure/FibroTest) result is 
positive, a discussion with the Medical Monitor is required before 
inclusion in study is permitted  
b. Regardless of APRI or Fibrosure/ FibroTest  score , if the participant meets 
one of the following historical criteria, they will be excluded from the study  
i. Liver biopsy ( i.e., Metavir Score F4)  
ii. Liver stiffness >12 kPa   
4. Diagnosed or suspected hepatocellular carcinoma as evidenced by [CONTACT_716]  
a. Alpha -fetoprotein concentration ≥200 ng/mL  
b. If the screening alpha fetoprotein concentration is ≥50 ng/mL and 
<200  ng/mL, the absence of liver mass must be documented by [CONTACT_47441] [ADDRESS_936988] 5 years with the exception of specific 
cancers that are cured by [CONTACT_78043] (e.g., skin cancer), participants  under 
evaluation for possible malignancy are not eligible.  
6. History of vasculitis or presence of symptoms and signs of potential vasculitis [e .g., 
vasculitic rash, skin ulceration, repeated blood detected in urine without identified 
cause]or history/presence of other diseases that may be associated with vasculitis 
condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing 
polycho ndritis, mononeuritis multiplex)]  
7. History of extrahepatic disorders possibly related to HBV immune conditions (e.g., 
nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa , 
cryoglobulinaemia, uncontrolled hypertension ) 
8. Poorly controlled t hyroid dysfunction or abnormal thyroid stimulating hormone 
(TSH ) levels  
9. Positive (or borderline positive) Anti-neutrophil cytoplasmic antibody (ANCA ) at 
screening : 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 56 
 a. Participants that meet these  criteria may be considered for inclusion in the 
study following : 
i. Analysis of MPO -ANCA [ perinuclear anti -neutrophil cytoplasmic 
antibodies  (pANCA )] and PR3 -ANCA [ classical anti -neutrophil 
cytoplasmic antibodies (cANCA )] AND  
ii. A discussion with the Medical Monitor to review participant’s 
complete medical history to ensure  no past history or current 
manifestations of a vasculitic/inflammatory/auto -immune condition  
10. Low C3 at screening AND evidence of past history or current manifestations of 
vasculitic/inflammatory/auto -immune conditions  
a. All participants with low C3 at scree ning should have their medical history 
discussed with the Medical Monitor prior to enrolment  
11. History of alcohol or drug abuse/dependence  
a. Current alcohol use as judged by [CONTACT_103059]  
b. History of or curren t drug abuse/dependence as judged by [CONTACT_103060]  
i. Refers to illicit drugs and substances with abuse potential. 
Medications that are used by [CONTACT_103061], whether 
over-the-counter or th rough prescription, are acceptable and would 
not meet the exclusion criteria  
12. Pre-existing severe psychiatric condition or a history of severe psychiatric 
disorders, including severe depression , suicidal ideation and attempted suicide.  
 
PRIOR/CONCOMITANT THERAPY  
13. Currently taking, or took within 3 months of screening, any immunosuppressing 
drugs (e.g., prednisone), other than a short course of therapy (≤2 weeks) or 
topi[INVESTIGATOR_2855]/inhaled steroid use.  
14. Participants for whom immunosuppressive treatment is not advise d, including 
therapeutic doses of steroids.  
15. Patients with prior treatment with Pegylated interferon or interferon are excluded.  
16. Participants requiring anti -coagulation therapi[INVESTIGATOR_014] (for example warfarin, Factor Xa  
inhibitors or anti -platelet agents like clopi [INVESTIGATOR_7745])  
17. Participants currently taking, or took within 6 months of screening, telbivudine  
 
PRIOR/CONCURRENT CLI NICAL STUDY EXPERIEN CE 
18. The participant has participated in a clinical trial and has received an 
investigational product within the following time period prior to the first dosing 
day in the current study: 5 half -lives (if known) or twice the duration (if known) of 
the biological effect of the study treatment (whichever is longer) or 90 days (if half -
life or duration is unknown).  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 57 
 19. Prior treatment  with any oligonucleotide or small interfering RNA (siRNA) within 
[ADDRESS_936989] dosing day  
 
DIAGNOSTIC ASSESSMEN TS 
20. Fridericia’s QT correction formula (QTcF) ≥450  msec (if single ECG  at screening 
shows QTcF ≥450  msec, a mean of triplicate measurements should be used to 
confirm that participant meets exclusion criterion).  
21. Laboratory results as follows  
a. Serum albumin <3.5 g/dL  
b. Glomerular filtration rate (GFR) <60 mL/min /1.73  m2 as calculated by [CONTACT_285088][INVESTIGATOR_690597] (for Japan, 
Japanese Society of Nephrology  - Chronic Kidney Disease Initiative 
equation).  
c. International normali sed ratio (INR) >1.25  
d. Platelet count <140 X 109/L 
e. Absolute neutrophil count (ANC) <1.5 x 109 cells/L 
f. Baseline haemoglobin <10 g/ dL 
g. Total bilirubin >1.[ADDRESS_936990] .  For participants with benign unconjugated 
hyperbilirubinemia with total bilirubin >1.[ADDRESS_936991],  discussion for 
inclusion to the study is required with the Medical Monitor  
h. Urine albumin to creatinine ratio (ACR) 0.03 m g/mg (or 30 mg/g). In the 
event of an ACR above this threshold, eligibility may be confirmed by a 
second measurement .  In cases where participants have low urine albumin 
and low urine creatinine levels resulting in a urine ACR calculation 0.03 
mg/mg (or 30 mg/g), the investigator should confirm that participant does 
not have a history of diabetes, hypertension or other risk factors that may 
affect renal function and discuss with the medical monitor, or designee  
 
OTHER EXCLUSIONS  
22. History of/sensitivity to [COMPANY_004]3228836 or interferon -containing therapi[INVESTIGATOR_014], or 
components thereof, or a history of drug or other allergy that, in the opi[INVESTIGATOR_20953], contraindicates their participation  
 
5.3. Inclusion and Exclusion Criteria for PegIFN  
Participants who permanently discontinue [COMPANY_004]3228836 due to a liver stoppi[INVESTIGATOR_249209] 
(Section 7.1.1 ) are not eligible for treatment with PegIFN.  
Participants who had [COMPANY_004]3 228836 dosing held or who se dose was reduced due to 
Protocol defined liver monitoring criteria (Section 7.1.1 ) are eligible for PegIFN 
treatment only if:  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 58 
 a. ALT is <5xUL N and bilirubin/INR are ≤baseline or ULN (whichever is 
higher)  at PegIFN eligibility assessment  
AND  
b. Additional lab assessments performed do not suggest drug-induced liver 
injury ( DILI ) or other condition contraindicated for treatment in the 
PegIFN label.  
For participants who do not meet both of these criteria, eligibility for PegIFN should be 
determined by [CONTACT_690635] a risk/benefit assessment and the following 
PegIFN eligibility criteria ( Table 8). 
Note:   If local prescribing PegIFN  guidelines are more stringent  than the criteria below , 
follow the most stringent criteria . 
• ALT <[ADDRESS_936992]   
• Platelets >90 x 109/L  
• Absolute Neutrophil Count  (ANC)  >1.5 x 109/L  
• Haemoglobin 10 g/dL    
In addition : 
• TSH + T4 should be confirmed to be normal and/or adequately controlled  
• The absence of severe psychiatric condition  
• An ophthalmologic examination should have been conducted at screening (or 
results from a prior ophthalmolo gical examination within [ADDRESS_936993] been available) .   
Table 8 Eligibility Criteria to start PegIFN  
Baseline Laboratory Assessment  Inclusion Criteria  
i) Platelets  >90 x 109 cells/L  
ii) ANC  >1.5 x 109 cells/L  
iii) Haemoglobin  >10 g/ dL 
iv) ALT <[ADDRESS_936994]  
v) TSH/T4  Within normal range or adequately controlled  
vi) Neuropsychiatric Assessment  No severe psychiatric condition  
vii) Ocular Exam  No condition contraindicated for PegIFN, however 
periodic examinations maybe required based upon 
screening assessment (refer to Section 8.2.2 ) 
 
TMF-[ADDRESS_936995] the clinic.  
Participants who use tobacco products will be instructed that use of nicotine -containing 
products (including nicotine patches and other delivery devices such as vapori sers) will not 
be permitted while they are in the clinical unit.  
5.4.2.  Activity 
Participants will abstain from strenuous exercise for 48 hours before each blood 
collection for clinical laboratory tests.  For the duration of the study, until final follow -up, 
participants are encouraged to refrain from changing their activity beyo nd that which they 
normally perform.  Additionally, participants will abstain from taking creatine -containing 
exercise supplements for all parts of the study.  
5.5. Screen Failures  
Screen failures are defined as participants who consent to participate in the cli nical study 
but are not subsequently randomi sed. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen 
failure details, eligibility criteria , any protocol deviations  and any serious adverse events 
(SAE s). 
Individuals who do not meet the criteria for participation  in this study (screen failure) may 
not be rescreened unless discussed and agreed with the Medical Monitor. Individuals who 
fall out of the screening window, may be rescreened at the discretion of the investigator 
and site.   
5.6. Criteria for Temporarily Delayi ng Administration of Study 
Intervention  
See Section 7.1 for guidance on treatment hold and criteria for temporarily delaying 
[COMPANY_004]3228836  and/or PegIFN . 
6. STUDY INTERVENT ION(S) AND CONCOMITANT 
THERAPY  
Study intervention  is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to a study participant according 
to the study protocol.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 60 
 6.1. Study Intervention( s) Administered  
Study Treatment  
Study Treatment  
Product Name:  [CONTACT_23983]3228836  PegIFN  
Formulation Description:  Clear colourless  to slightly yellow 
solution  Injection for subcutaneous use .  
The commercia l product is used 
unmodified , except a l abel is applied to 
indicate clinical investigational  use. 
Dosage Form:  Solution for injection  Solution for injection  
Unit Dose Strength(s)/Dosage 
Level(s):  150 mg/mL; 1.0  mL nominal volume 
per vial (minimal overfill per vial)  180 mcg/0.5 mL; pre -filled syringe  
Route/Administration/Duration:  SC, multiple (once weekly  up to 24 
weeks , plus loading doses)  180 mcg/week, S C, up to 24 weeks  
Dosing Instructions:  Administer two SC injections for 300 
mg dose . Administer SC injection; r efer to label  
Manufacturer/Source of 
Procurement:  [COMPANY_004] GlaxoSmithKline Manufacturing 
SpA, Parma (Italy)  F Hoffmann -La [COMPANY_002] AG, Wurmisweg, 
[ADDRESS_936996], Switzerland . 
 
Method for Individuali sing 
Dosage  Dispensing into syringes  Pre-filled syringe that contains 
graduation marks corresponding to 180 
micrograms (mcg), 135 mcg and 90 mcg  
SC=subcutaneous ;  
[COMPANY_004]3228836  injection instruction s 
The site of [COMPANY_004]3228836 injection will be recorded for each participant and dose(s).  
Sites of [COMPANY_004]3228836 injection are listed in order of prefere nce and are a guide for the 
clinical staff.  
1. Abdominal quadrants  
2. Thighs  
3. Outer area of the upper arms  
4. Buttocks  
[COMPANY_004]322 8836 injections should be rotated within each anatomical site or site(s) of 
injection should be changed administration -to-adminis tration. Injection into areas with 
ongoing injection site reactions should be avoided.  
PegIFN injection instructions  
PegIFN  is administered by [CONTACT_690636].  PegIFN should 
be inspected visually for particulate matter and discoloration before administration, and 
not used if particulate matter is visible or product is discoloured . 
A participant may  self-inject PegIFN  only if the physician determines that it is appropriate,  
and the patient agrees to medical follow -up as necessary and has been trained in proper 
injection technique.  
Discard the unused portion in excess of the labelled  volume. Use only one vial or prefilled 
syringe or disposable auto -injector per dose . 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 61 
 6.2. Preparation/Handling/Storage/Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of  the study intervention.  
Only participants enrolled in the study may receive study intervention and only authori sed 
site staff may supply or administer study intervention.  All study interventions must be 
stored in a secure, environmentally controlled, and  monitored (manual or automated) area 
in accordance with the labelled storage conditions with access limited to the investigator 
and authori sed site staff.  
The investigator, institution, or the head of the medical institution (where applicable) is 
responsi ble for study intervention accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study intervention are 
provided in the St udy Reference Manual  (SRM) .  
Under normal conditions of handling and administration, study intervention is not expected 
to pose significant safety risks to site staff .  Take adequate precautions to avoid direct eye 
or skin contact [CONTACT_690637].  In the case of unintentional 
occupational exposure notify the monitor, Medical Monitor and/or [COMPANY_004] study contact.  
A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions e ither will be provided to the 
investigator, where this is required by [CONTACT_1207], or is available upon request from [COMPANY_004].  
6.3. Measures to Minimi se Bias: Randomi sation and Blinding  
All participants will be centrally randomi sed using an Interactive Voice/Web Response 
System (IVRS/IWRS).  Before the study is initiated, the telephone number and call -in 
directions for the IVRS and/or the log in information and directions for the IWRS will be 
provided to each site.  
Study intervention will be dispensed at the study  visits summari sed in the SoA.  Returned 
study intervention should not be re -dispensed to the participants.  
Participants will be randomi sed in a 1:[ADDRESS_936997] foreknowledge 
of allocation pre -randomi sation.  
[COMPANY_004] is unblinded however the r isk of p otential bias will be mitigated  by [CONTACT_690638]:  
• Dummy randomi sation  schedule will be used by [CONTACT_690639], although  this will not  completely mask treatment 
assignment due to the different visit/regimen schedules for each arm.  
• Where feasible, limit the central te ams exposure to virological biomarkers 
including H bsAg, HbsAb  and HBV DNA.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 62 
 • Details will be included in separate blinding plans.  
Unblinded monitors and, in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to unblinded study int ervention records at the site(s) to verify that 
randomi sation/dispensing has been done accurately.  
[COMPANY_004]’s Clinical Safety Department staff may reveal the treatment allocation for any 
participant with an SAE.  If the SAE requires that an expedited regulatory  report be sent to 
one or more regulatory agencies, a copy of the report, identifying the participant’s 
intervention assignment, may be sent to investigators in accordance with local regulations 
and/or [COMPANY_004] policy.  
6.4. Study Intervention  Compliance  
When participants are  dosed at the site, they will receive study intervention  directly from 
the investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose o f study 
intervention  and study participant  identification will be confirmed at the time of dosing by 
a member of the study site staff other than the person administering the study intervention . 
Participants may self -inject PegIFN during specified visits in  the PegIFN treatment phase 
(see Table 4) as allowed per country requirements.  Site staff will telephone to confirm 
the dose as described above.  
6.5. Dose Modification  
Dose  modifications of [COMPANY_004]3228836 are not planned for this study.   Dose modifications 
of PegIFN are allowed per S ection 7.2. 
6.6. Study Intervention after the End of the Study  
No intervention is planned at the end of the study, although participants may be asked to 
enrol in a long -term roll -over study based on their res ponse.  
6.7. Treatment  of Overdose  
For this study, any dose of [COMPANY_004]3228836  greater than 300 mg within a 24 -hour time period 
will be considered an overdose.  
[COMPANY_004] does not recommend specific treatment for an overdose.  
In the event of an overdose, the investigator sh ould:  
• Contact [CONTACT_27465].  
• Closely monitor the participant for AE/SAE and laboratory abnormalities until 
[COMPANY_004]3228836 can no longer be detected systemically (at least 105 days).  
• Obtain a plasma sample for PK analysis within [ADDRESS_936998] 
dose of study intervention if requested by [CONTACT_1689] (determined on a 
case-by-case basis).  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 63 
 • Document the quantity of the excess dose as well as the duration of the 
overdosing in the case report form ( CRF ). 
Decisions regarding dos e interruptions or dose modifications of PegIFN will be made by 
[CONTACT_690640].  
6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or pres cription medicines, 
vitamins, and/or herbal supplements or other specific categories of interest)  that the 
participant is receiving at the time of enrollment or receives during the study must be 
recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
The Medical Monitor should be contact[CONTACT_26237].  
Concomitant medications, including NA therapy , should be recorded.  
Traditional Chinese medicine (TCM) and/or acupuncture as it relates to CHB therapy 
should be avoided during the duration of the study.  If participants report use of TCM 
and/or acupuncture, then details must be recorded in the concomitant medication CRF.  
6.8.1.  Nucleos(t)ide Treatment during and after the End of the Study  
The investigator is responsible for ensuring that consideration has been given to the care 
of the participant’s medical condition, and that participants are able to continue their 
therapy over t he duration of the study.  
The investigator is responsible for ensuring that consideration has been given to the post -
study care of the participant’s medical condition, whether or not [COMPANY_004] is providing specific 
post-study treatment.  
6.8.2.  Prohibited Medications an d Non -Drug Therapi[INVESTIGATOR_690598]3228836 are not permitted during the 
study:  
• Immunosuppressing drug (e.g., prednisone) use >2  weeks duration from 3  months 
prior to Screening through the final Follow -up visit (see Section  5.2), unless 
required for safety  
• Prior treatment with any oligonucleotide or small interfering RNA (siRNA) 
within [ADDRESS_936999] dosing  
• Creatine -containin g gym supplements  
• Anticoagulation therapy  
• Anti-platelet therapy  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 64 
 Refer to the local  label for prohibited concomitant medications  for PegIFN  [Pegasys , 
2017 ]. Telbivudine is contraindicated in the PegIFN label;  the combination of telbivudine 
with interferon products (such as peginterferon) to treat hepatitis may increase the risk of 
periphera l neuropathy  [Tyzeka , 2013 ]. 
7. DISCONTINUATION OF STUDY INTERVENTIO N AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
A participant may withdraw from the study treatment at any time at his/her own request or 
may be withdraw n at any time at the discretion of the Investigator for safety, behavioural 
or administrative reasons.  In rare instances, it may be necessary for a participant to 
permanently discontinue (definitive discontinuation)  study intervention .  Participants that 
withdraw from treatment for any reason should be encouraged to complete all their on -
treatment and follow -up visits and assessments.   Every effort should be made to  complete 
the early termination (ET) study procedures and observations if the participant do es not 
enter post -treatment follow -up. 
Any laboratory parameter that meets the stoppi[INVESTIGATOR_690599] . 
For participants meeting the stoppi[INVESTIGATOR_3418] ( Section  7.1- Section 7.2), participants should 
be monitored until laboratory abnormalities resolve, stabili se, or return to within baseline 
values as indicated.  The participant must then attend the visits specified i n the SoA.  See 
the SoA for data to be collected at the time of discontinuation of study intervention and 
follow -up and for any further evaluations that need to be completed.  
7.1. [COMPANY_004]3228836 Dose Modification and Stoppi[INVESTIGATOR_2121]  
7.1.1.  [COMPANY_004]3228836 Liver Chemistry Stoppi[INVESTIGATOR_97175], and increased monitoring criteria have been designed to assure 
participant safety and to evaluate liver event etiology.  Study intervention will be 
discontinued for a participant if the liver stoppi[INVESTIGATOR_539093] e met. Restart/re -challenge 
guidelines are presented in Section 10.6 (Appendix 6 ). 
Discontinuation of study intervention for abnormal liver tests is required when:  
• a participant meets one of the conditions outlined in Table 9. 
• when in the presence of a bnormal liver chemistries not meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes study intervention discontinuation is in 
the best interest of the participant.  
Table 9 lists the criteria for withholding or discontinuing the study medication in a study 
participant with elevation of ALT.  Additional testing will be performed (see safety 
follow -up procedures for participants who meet increased monitoring o r stoppi[INVESTIGATOR_3418]), 
and the participant monitored until liver chemistry abnormalities resolve, stabili se, or 
return to within baseline values.  The participant must then attend the follow -up visits 
specified in the SoA.  
TMF-[ADDRESS_937000]  the participant evaluated (within 24 hours) for repeat 
assessment of liver chemistries and additional testing and close monitoring (a specialist or 
hepatology consultation is recommended).  Participants must be monitored weekly until 
liver chemistry abnor malities (ALT, AST, alkaline phosphatase, bilirubin) resolve, 
stabili se, or return to within baseline values.  Upon completion of the safety follow -up 
procedures (see below), the participant must attend the follow -up visits specified in the 
SoA.  
Table [ADDRESS_937001] ≤ALT <[ADDRESS_937002]  
and 
Bilirubin ≤1.[ADDRESS_937003]  
and 
INR ≤1.5 (if available)  Monitor twice weekly  
Additional lab assessments  Permanently discontinue IMP if  
ALT >[ADDRESS_937004] >4  weeks  
 
 
ALT [ADDRESS_937005]  
and 
Bilirubin  ≤1.[ADDRESS_937006]  
and 
INR ≤1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold: [COMPANY_004]3228836 150 
mg SC weekly when ALT <[ADDRESS_937007]; increasing dose to 300 mg 
(if applicable) should be agreed 
with Medical Monitor  Permanently discontinue IMP if 
any of the following apply:  
• ALT [ADDRESS_937008] >4  weeks  
• ALT [ADDRESS_937009] recurs after 
IMP taken off hold  
ALT [ADDRESS_937010] <bilirubin ≤[ADDRESS_937011] 
(>35%  direct)  
and 
INR 1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold: [COMPANY_004]3228836 150 
mg SC weekly when bilirubin 
returns to <1.[ADDRESS_937012]; increasing 
dose to 300  mg (if  applicable) 
should be agreed with Medical 
Monitor  Permanently discontinue IMP if 
the following recurs after IMP 
taken off hold:  
1.[ADDRESS_937013] <bilirubin ≤[ADDRESS_937014] 
(>35%  direct)  
And 
INR 1.5 (if available)  
ALT [ADDRESS_937015] and any of the 
following apply:  
• bilirubin >[ADDRESS_937016] 
(>35%  direct)  
• associated with the 
appearance  
or worsening of 
hepatitis symptoms  
• INR >1.5  (if available)   Permanently discontinue IMP  
 
Monitor twice weekly until stable 
ALT 
 
Additional lab assessments if not 
already done  
ALT = alanine aminotransferase; IMP = investigational medicinal product; ULN = upper limit of normal  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 66 
 *Notes:  
• Any abnormal laboratory parameters that meet the criteria for individual treatment 
discontinuation must be confirmed by [CONTACT_103065] a new collection of blood samp les 
as soon as possible.  
• Deterioration considered clinically significant from the baseline in the liver 
parameters must be confirmed by [CONTACT_103043], total bilirubin, direct bilirubin 
and INR (if available).  
• If one criterion in the list above is met and confirmed by [CONTACT_103066], further 
treatment may be discontinued for this participant after discussion with the 
Medical Monitor.  Results of retesting must be evaluated before the next dose is 
administered.  
• Monitor participant until liver chemistry abnormalit ies resolve, stabili se, or return 
to within baseline values . 
• Cases such as Gilbert syndrome, where baseline bilirubin values are high, should  
be discussed with the Medical Monitor, to assess if it is a case of DILI or the  
participant may continue with dosing.  
The procedures listed below are to be followed if a participant meets any of the liver 
chemistry stoppi[INVESTIGATOR_103013] 9: 
Notify th e Medical Monitor within 24  hours of learning of the abnormality to confirm the 
participant’s study treatment cessation and follow -up. 
Complete the Liver Event CRF.  
Complete the “Safety Follow -up Procedures” listed below.  
Safety Follow -up Procedures for Pa rticipants Who Meet Any of The Liver 
Monitoring and Stoppi[INVESTIGATOR_2121]:  
Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibo dy or monospot testing);  
o Hepatitis E IgM antibody.  
o Hepatitis B virus DNA load  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• Obtain a blood sample for pharmacokinetic (PK) analysis as soon as possible 
following the occurrence of an event. Record the date/time of the PK blood 
sample collection and the date/time of the last dose of study treatment prior to 
blood sample collection on the CRF. If the date or time of the last dose is unclear, 
provide the participant’s best approximation. Instructions f or sample handling and 
shippi[INVESTIGATOR_278796].  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 67 
 • Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH).  
• Review fractionated bilirubin  
• Assess eosinophilia  
• Record the appearance or worsening of clinical symptoms of hepatitis (fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or 
eosinophilia) as relevant on the Adverse Event (AE) CRF.  
• Record use of concomitant medications, acetaminophen, herbal remedies, other 
over the counter medications, or putative hepatoto xins on the Concomitant 
Medications CRF.  
• Record alcohol use on the Liver Events CRF.  
The following are required for participants who meet the ALT and bilirubin stoppi[INVESTIGATOR_690600] . 
• Anti-nuclear antibody, anti-smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies and quantitative total immunoglobulin G (IgG or gamma 
globulins).  
• Serum acetaminophen adduct high performance liquid chromatography (HPLC) 
assay (quantifies potential acetaminophen  contribution to liver injury in 
participants with definite or likely acetaminophen use in the preceding week 
[James , 2009]) , if available . 
• Liver imaging (ult rasound, magnetic resonance, or computeri sed tomography) or 
Liver biopsy to evaluate liver disease.  
• The Liver Imaging and/or Liver Biopsy CRFs are also to be completed if these 
tests are performed.  
7.1.2.  [COMPANY_004]3228836 Haematological Stoppi[INVESTIGATOR_42224] a particip ant develops signs or symptoms of thrombocytopenia, obtain a platelet count 
(local lab) as soon as possible and hold dosing until the platelet count is confirmed.  
If the platelet count is uninterpretable or a decreasing trend is noted below the lower limit  
of normal ( LLN ) reference  range, re -check the platelet counts as soon as possible (the 
investigator may, at their  discretion, opt to have the participant come to their next 
scheduled visit OR ask the  participant to come earlier than their scheduled visit,  as they 
feel appropriate based on  review of the participants clinical presentation and laboratory 
results). Samples  showing  platelet clumpi[INVESTIGATOR_103017].  
Participants with platelet values below 75 x 109/L will undergo further assessment 
inclu ding, but not necessarily limited to, anti -platelet antibodies.  If the participant has a 
positive anti -platelet antibody, study treatment should be discontinued permanently.  
Monitor until platelet abnormalities resolve, stabili se, or return to within basel ine values.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 68 
 Table 10 [COMPANY_004]3228836 Haematological Stoppi[INVESTIGATOR_103018]  
75 X 109/L 
≤Platelets <100 X 
109/L Monitor weekly, results of local platelet 
count must be available prior to dosing  Hold treatment until platelets return to  100 
x109/L 
[if positive for anti -platelet antibodies, study 
treatment should be discontinued immediately]  50 X 109/L ≤ 
Platelets <75 X 
109/L Monitor every 2 -3 days until three 
successive measurements 75 x109/L, 
then weekly  
Assess anti -platelet antibodies  
<50 x 109/L Monitor daily until 25 x109/L, monitor 
every 2 -3 days until three successive 
measurements 75 x109/L, then weekly 
until platelets ≥100 x109/L 
Assess anti -platelet antibodies  Discontinue treatment permanently  
Glucocorticoids recommended (unless the 
participant has a medical contraindication to 
receiving glucocorticoids), and discontinuation of 
any antiplatelet medicinal products/ non-steroidal 
anti-inflammatory drugs /anticoagulants  
7.1.3.  [COMPANY_004]3228836  Drug Induced Kidney Injury (Renal) Stoppi[INVESTIGATOR_103016], results should be confirmed, and if confirmed, 
further evaluation for alternative causes should be pursued in consultation with the 
Medical Monitor:  
• Persistent ACR ≥0.03 mg/mg (≥30 mg/g)  
• Blood in urinalysis ≥5 red blood cells ( RBC ) per high power field (HPF) 
confirmed by [CONTACT_690641]  
• Persistent elevation of serum creatinine (>26.52 µmol/L or 0.3 mg/dL change  
from baseline)  
Following confirmation of the criteria above, further evaluation may include but not be  
limited to a [ADDRESS_937017], renal  
ultrasound, urine microscopy, serum urea and creatinine, platelet count, urgent serum  
vasculitis screen (including ANCA, antinuc lear antibody [ ANA ], double stranded 
deoxyribonucleic acid [ dsDNA ], cryoglobulins ), serum protein  electrophoresis 
(SPEP)/urine protein electrophoresis (UPEP), and complement panel (C3,  C4, C5a , and 
Bb). Further evaluation and actions should be determined by [CONTACT_690642].  
Treatment Hold/Treatment Discontinuation  
• Hold study treatment in participants who develop ACR ≥0.5 mg/mg (500 mg/g),  
or eGFR >25% re duction from pre -dose range, pending consultation with the  
Medical Monitor and further evaluation of the cause.  
o If a dose is held, once eGFR increases to within baseline, ACR decreases  
to <0.5 mg/mg (500 mg/g), or the underlying cause of the decline in ren al 
TMF-[ADDRESS_937018] be monitored weekly until ACR or eGFR resolve,  
stabilize, or return to within pre -dose range  
• Hold study treatment in participants with ACR ≥2 mg/mg (2000 mg/g), perform  
further evaluation for acute glomerulonephritis, as clinically indicated. If acute  
glomerulonephritis is confirmed or probable (i.e., meets clinical definition of  
rapi[INVESTIGATOR_103020] [RPGN] if biopsy not  feasible),  
[COMPANY_004]3228836 should be permanently discontinued  
o Participants must be monitored weekly until ACR resolves, stabilizes, or  
returns to within baseline values  
• Delay in treatment of suspected RPGN should be avoided.  
7.1.4.  [COMPANY_004]3228836 -Induced Vascular Inflamm ation and Complement 
Stoppi[INVESTIGATOR_165747], results should be confirmed with a repeat sample 
collection and analysis , and if confirmed, further evaluation for alternative causes should 
be pursued in consultation with the Medical Monitor.  
Repeat sample collection of C3, C4, Bb, C5a would be triggered by [CONTACT_690643] ( 2 + haematuria; increasing urine ACR; 
vasculitic or purpuric rash; peripheral neuropathy; jaundice). Additional complement 
analyses for example CH50, Factor B level, Factor H level, sC5b -9 should also be 
considered in discussion with the Medical Monitor a nd Safety Panels.  
• Persisting & deteriorating longitudinal trends in change from baseline for C3 
and/or C4 defined as:  
o If participant’s baseline C3 and/or C4 is within  the lab’s normal range at 
baseline: there is a sequential decline in C3 and/or C4 once le vels have 
fallen below LLN for 4 weeks OR  
o If participant’s baseline C3 and/or C4 is below  the lab’s LLN at baseline: 
there is further sequential decline in C3 and/or C4 for 4 weeks OR  
o Regardless of baseline C3 and/or C4 level: there is a 80% reduction  in the 
participant’s C3 and/or C4 level at any point  AND  
o There is an associated 3-fold increase  in Bb and/or C5a from  participant’s  
baseline OR  
o There are associated biochemical sequelae for example, a rising high 
sensitivity C -reactive protein (hs -CRP); ri sing monocyte chemoattractant 
protein (MCP -1); new thrombocytopenia, new renal impairment with no 
other explanation such as intercurrent infection OR  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 70 
 o There are associated clinical sequelae, for example, 2 + haematuria; 
increasing urine ACR; vasculitic or purpuric rash; peripheral neuropathy; 
jaundice OR  
o There is new cANCA or pANCA positivity  
• Persisting & deteriorating longitudinal trends in change from baseline for Bb 
and/or C5a where  
o There is a 3-fold increase in Bb and/or C5a over baseline  AND  
o This is persisting or increasing week on week in sequential data plots OR  
o There are associated biochemical sequelae for example, a rising hs -CRP; 
rising MCP -1, new thrombocytopenia, new renal impairment with no other 
explanation such as intercurrent infection OR  
o There are associated clinical sequelae, for example, 2 + haematuria; 
increasing urine ACR, vasculitic or purpuric rash; peripheral neuropathy; 
jaundice or any combination of these OR  
o There is new cANCA or pANCA positivity  
Treatment Hold/Treatment Discontinuation  
• Hold study treatment during evaluation of alternative causes for decreased C3 
and/or C4 associated with increased inflammatory markers including one or more 
of hs -CRP, MCP -1, Bb and C5a  
• Discontinue study treatment permanently if persistent change fro m baseline 
(4 weeks) in biomarker pattern (decreased C3/C4 associated with increased 
inflammatory markers including one or more of hs -CRP, MCP -1, Bb, C5a) 
without clear alternative explanation.  
• Discontinue study treatment permanently if suspect clinical sequelae of 
complement activation, DIVI , vasculitis or autoimmunity  regardless of 
biomarkers changes or persistence.  
7.2. PegIFN Dose Modification and Stoppi[INVESTIGATOR_690601]  (see 
Section 2.3.1 ). 
When dose modification is required for moderate to severe adverse reactions, both clinical 
and laboratory, initial dose reduction to 135 mcg is generally adequate  (Pegasys  PI, 2017) . 
However, in some cases a reduction to 90  mcg is necessary . Dose increase to, or towards 
the original dose may be considered if the adverse reaction abates.  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 71 
 7.2.1.  PegIF N Haematological Dose Modification and Discontinuation 
Guidelines  
Table 11 PegIFN Haematological Dose Modification Guidelines1 
Laboratory Values  Reduce PegIFN dose if:  Discontinue PegIFN if:  
Absolute Neutrophil Count 
(ANC)  <750 cells/mm3 reduce to 135  mcg 
(in some cases reduction to 90 mcg 
may be necessary)  <500 cells/mm3 treatment should be 
suspended until ANC values return to 
more than 1000 cell/mm3 
Initially reinstitute at 90  mcg and monitor 
ANC  
Platelet Count  <50 x 109 cells/ L reduce to 90  mcg <25 X 109 cells/ L 
Haemoglobin   Hb <8.5 g/dL 
1.  Not applicable to sites in Japan  
After dose reduction or discontinuation, the patient should be monitored weekly until lab 
values return to within baseline  values.  
7.2.2.  PegIFN ALT Elevation Dose Modification and Discontinuation 
Guidelines  
In participants  with elevations in ALT (greater than [ADDRESS_937019]), more frequent monitoring 
of liver function should be performed and consideration should be given to either 
reducing the dose to 135 mcg or temporarily discontinuing treatment. After reduction or 
withholding, therapy can be resumed  after ALT flares subside.  
In participants  with persistent, severe hepatitis B flares (ALT greater than [ADDRESS_937020]), 
consideration should be given to discontinua tion of treatment.  If ALT increases are 
progressive despi[INVESTIGATOR_690602], therapy should be immediately discontinued.  When practicable, 
abnormal laboratory results should be co nfirmed as soon as possible following 
notification of the investigator . 
7.2.3.  Psychiatric Disorder Dose Modification and Discontinuation 
Guidelines  
Participants will be monitored  for evidence of depression and other psychiatric symptoms  
by [CONTACT_690644] -Severity Rating Scale ( C-SSRS ) and Beck Depression 
Inventory -II (BDI-II). Participants displaying new or worsening symptoms of depression 
will be managed as per Table 12. 
If new or worsening psychiatric symptoms (other than depression) are identified or if 
suicidal ideation is identified, PegIFN should be discontinued and the participant 
followed up with psychiatric intervention as appropriate.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 72 
 Table 12 PegIFN Dose Modification and Stoppi[INVESTIGATOR_690603] (4 -8 weeks)  Depression Status  
Dose Modification  Visit Schedule  Remains stable  Improves  Worsens  
Mild No change  Evaluate once 
weekly by [CONTACT_189115]/or phone  Continue weekly 
visit schedule  Resume normal visit 
schedule  
 (See 
moderate or 
severe 
depression)  
Moderate  Decrease PegIFN 
dose to 135  mcg 
(in some cases 
reduction to 90  
mcg may be 
needed ) Evaluate once 
weekly (office 
visit at least 
every other 
week)  
 Consider 
psychiatric 
consultation. 
Continue 
reduced dosing  
 If symptoms improve 
and are stable for 4 
weeks, may resume 
normal visit 
schedule. Continue 
reduced dosing or 
return to normal 
dose  (See severe 
depression)  
 
Severe  Discontinue 
PegIFN 
permanently  Obtain  
immediate 
psychiatric 
consultation  Psychiatric therapy necessary  
7.3. Study Intervention Restart or Rechallenge after stoppi[INVESTIGATOR_690604]3228836 rechallenge after stoppi[INVESTIGATOR_23893] (i.e., study trea tment 
discontinued) by [CONTACT_103070].  
[COMPANY_004]3228836 restart may be considered only for liver events as follows:   
Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_690605]32288 36 
Restart refers to resuming study intervention following liver stoppi[INVESTIGATOR_90570] a clear underlying cause (other than DILI) of the liver event (e.g. , biliary obstruction, 
pancreatic events, hypotension, acute viral hepatitis). Furthermore, restart is not permitted 
following liver stoppi[INVESTIGATOR_42257] -related hepatitis.  
• Approval by [CONTACT_103071]:  
o Investigator requests consideration for study intervention restart if liver 
chemistries have a clea r underlying cause (e.g., biliary obstruction, 
hypotension and liver chemistries have improved to normal or are within 
1.5 x baseline and ALT  <[ADDRESS_937021]).  
o Possible study intervention -induced liver injury has been excluded by [CONTACT_690645]. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eosinophilia). Where a 
study intervention has a confirmed genetic marker associated with liver 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 73 
 injury, the presence of the marker should be excluded. If study intervention -
related liver injury cannot be excluded, the guidance on rechallenge will 
apply.  
o There is no evidence of alcohol -related hepatitis.  
o Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) 
approval , if required,  of study intervention restart has been obtained.  
If restart of study intervention is approved by [CONTACT_90652]:  
• The participant must be provided with a clear description of the possible benefits 
and risks of study intervention administ ration including the possibility of recurrent, 
more severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the 
restart of study intervention. Documentation of informed consent must be recorded 
in the study  file.  
• Study intervention must be administered at the dose specified by [CONTACT_23983]  
• Participants approved by [CONTACT_165779] a week for liver function tests until stable liver function tests have been 
demonstr ated and then standard laboratory monitoring may resume as per protocol.  
• If the participant meets protocol -defined liver chemistry stoppi[INVESTIGATOR_165755], study intervention should be permanently discontinued.  
• The Medical Monito r and the IRB/IEC must be informed of the outcome for the 
participant following study intervention restart.  
• [COMPANY_004] must be notified of any adverse events.  
For treatment that has been placed on hold, please follow the guidelines above (Section 
7.1.1  to Section 7.2.3 ). 
7.4. Participant Discontinuation /Withdrawal  from the Study  
• A participant may withdraw f rom the study at any time at his/her own request or  
may be withdrawn at any time at the discretion of the investigator for safety, 
behavioural , or compliance reasons.  This is expected to be uncommon.  
• The investigator may ask participants to withdraw from s tudy treatment, but 
continue with post -treatment follow up visits instead of withdrawing completely 
from the study.  
• At the time of discontinuing from the study, if possible, an early discontinuation 
visit should be conducted, as shown in the SoA. See SoA for data to be collected 
at the time of study discontinuation and follow -up and for any further evaluations 
that need to be completed.  
• The participant will be permanently discontinued both from the study intervention 
and from the study at that time.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 74 
 • If the  participant withdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any data collected before such a 
withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destruction of any 
samples  taken and not tested, and the investigator must document this in the site 
study records.  
7.5. Lost to Follow Up  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_690646].  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_690647]/or should continue in the study.  
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3  
telephone calls and, if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medi cal record.  
• Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of Section 
10.1 (Appendix 1 ). 
8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summari sed in the SoA (see Section 1.3). 
• In selected sites/countries, participants will have the option to use a centralised  
home nursing provider. Only selected visits wil l have the option to be performed 
as a home visit, these will include drug administration, blood draws, participant 
assessments and data collection. The full specifications of the home nursing 
services will be outlined in the SRM  
• Protocol waivers or exemp tions are not allowed  
• Immediate safety concerns should be discussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.  
• Adherence to the study design requirements, in cluding those specified in the SoA, 
is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will maintain a 
TMF-[ADDRESS_937022] reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of ICF may be utili sed for 
screening or baseline purposes provided the procedure met the protocol -specified 
criteria and was performed within the time frame defined in the SoA.  
• Repeat or unscheduled samples may be taken for safety reasons or for technical 
issues with the samples.  
8.1. Efficacy Assessments  
The primary objective measurement for efficacy in this study is the assessment of 
[COMPANY_004]3228836 treatment followed by [CONTACT_690648] H BsAg levels  in participants with 
CHB.  The primary efficacy endpoint is achiev ing serum H BsAg level <LLOQ.  
Any H BsAg greater than LLOQ after achieving H BsAg seroclearance needs to be 
confirmed by [INVESTIGATOR_1312] -test within [ADDRESS_937023] is not confirmed.  
HBsAg and HBV DNA  are collected for primary and secondary efficacy endpoints as per 
the SoA ( see Section 1.3).  Details of sample collection can be found in the SRM.  
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  Additional time 
points for safety tests (such as vital signs, physical exams and laboratory safety tests) 
may be added during the course of the study based on newly availab le data to ensure 
appropriate safety monitoring.  
8.2.1.  Physical Examinations  
A complete physical exam will be conducted at the Screening visit.  Symptoms directed 
exam  will be conducted at all other time points.  
• A complete physical exam will include, at a minim um, assessment of the 
dermatologic, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurological 
systems. Height and weight will also be measured and recorded (with participant 
wearing daytime clothing with no shoes).  
• Investigators should pay special a ttention to clinical signs related to previous 
serious illnesses.  
8.2.2.  Ophthalmologic Examination  for PegIFN  
• All patients should receive an eye examination prior to initiation of PegIFN  (SoA, 
Table 1). Patients with pre -existing ophthalmologic disorders (e.g., diabetic or 
hypertensive retinopathy) should receive periodic ophthalmologic exams during 
PegIFN therapy.  Any patient who develops  ocular symptoms must have a prompt 
and complete eye examination.  
TMF-[ADDRESS_937024] 
for the participant in a quiet setting without distractions (e.g., television, cell phones).  
Vital signs will be measured after [ADDRESS_937025] nominal time.  
8.2.4.  Electrocardiograms  
Single 12 -lead ECG will be obtained locally as outlined in the SoA (see Section 1.3) using 
an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, 
and QTc intervals. Manual calculation, if an automatic calculation is not available, is 
acceptable.  
8.2.5.  Clinical Safety Laboratory Assessments  
Refer to  Section 10.2 (Appendix 2) for the list of clinical laboratory tests to be performed 
and to the SoA for the timing and frequency (see Section 1.3).  
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448] ’s condition.  
All laboratory tests with values consider ed clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline 
or are no longer considered significantly abnormal by [CONTACT_97264].  
If such values do not return  to normal/baseline within a period of time judged reasonable 
by [CONTACT_093], the etiology should be identified, and the sponsor notified.  
If such values do not return to normal/baseline or are still considered significantly 
abnormal by [CONTACT_690649]’s last visit, additional follow -up should be 
discussed with the sponsor.  
All protocol -required laboratory assessments, as defined in  Section 10.2 (Appendix 2), 
must be conducted in accordance with the laboratory manual and the SoA.  
If laboratory values from non -protocol specified laboratory tests per formed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by [CONTACT_093] (e.g., SAE or AE or dose modification), then the 
results must be recorded.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 77 
 8.2.6.  Injection Site Reactions  
Injection Site Reactions  (ISRs)  are any experiences which occur at the site of injection of 
the study treatment. Participants will be monitored closely  for ISRs  and ISRs should be 
recorded as AEs . Injection site reactions will be graded according to the cr iteria provided 
in the Division of AIDS (DAIDS)  grading tabl e (see Section 10.3 (Appendix 3 )). 
8.2.7.  Suicidal Ideation and Behaviour Risk Monitoring  
PegIFN  is related to products with an increased risk of suicidal ideation or behaviour .  
Participants  being treated with PegIFN should be monitored appropriately and observed 
closely for suicidal ideation and behaviour  or any other unusual changes in behaviour.  
Participants who experience signs of suicidal ideation or behaviour , should undergo a risk 
assessment. All factors contributing t o Suicidal Ideation and Behaviour should be 
evaluated and consideration should be given to discontinuation of the study intervention.   
When informed consent or assent has been given, families and  caregivers of participants  
being treated with PegIFN should be alerted about the need to monitor participants  for the 
emergence of unusual changes in behaviour , as well as the emergence of suicidal ideation 
and behaviour  and to report such symptoms immediately to the study investigator.  
Baseline assessment of suici dal ideation and behaviour  will be monitored during this study  
using the C -SSRS  and BDI -II. 
[IP_ADDRESS].  Columbia Suicide -Severity Rating Scale (C -SSRS)  
Assessment of treatment -emergent suicidality will be monitored during this study using the 
C-SSRS. The definitions of behavioural suicidal events used in this scale are based on those 
used in the Columbia Suicide History Form [Posner , 2007]. Questions are asked on suicidal 
behaviour , suicidal ideation, and intensity of ideation. Screening visit questions will be in 
relation to lifetime experiences and current experiences , and all subsequent questioning in 
relation to the last assessment. The C -SSRS is to be administered as a patient completed 
questionnaire specified in the SoA (Section 1.3).   
[IP_ADDRESS].  Beck Depression Inventory -II (BDI -II) 
The BDI -II is a 21 -item questionnaire used to assess the intensity of depression in clinical 
and normal patients. The questionnaire will be administered by [CONTACT_690650] (S ection 1.3).  
8.3. Adverse  Events  (AEs), Serious Adverse Events  (SAEs) and 
Other Safety Reporting  
The definitions of an AE or SAE can be found in  Section 10.3 (Appendix 3 ). 
AEs will be reported by [CONTACT_2299] (or, when  appropriate, by a caregiver, surrogate, or 
the participant ’s legally authori sed representative).  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 78 
 The investigator and any qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study interventio n or the study, 
or that caused the participant to discontinue the study intervention (see Section 7).  
8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
All AEs and SAEs will be collected from the signing of the informed consent form until 
the final follow -up visit at the time points specified in the SoA (Section 1.3).  However, 
AEs and SAEs that occur prior to the first administration of investigational medicinal 
product should be recorded only if assessed as related to study participation (e.g., 
protocol -mandated procedures or invasive tests).  
Medical occurrences that begin before the start of study intervention but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the CRF not the AE section.  
All SAEs will be recorded and reported to the sponsor or design ee immediately and under 
no circumstance should this exceed 24 hours, as indicated in  Section 10.3 (Appendix 3 ). 
The investigator will submit any updated SAE data to the sponsor within 24  hours of it 
being available.  
Investigators are not obligated to actively seek AEs or SAEs after the conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from  the study, and he/she considers the 
event to be reasonably related to the study intervention or study participation, the 
investigator must promptly notify the sponsor.  
8.3.2.  Method of Detecting A Es and SAEs  
The method of recording, evaluating, and assessing cau sality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in  Section 10.3  
(Appendix 3 ). 
Care will be taken not to introduce bias when detecting AE and/or SAE.  Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence.  
8.3.3.  Follow -up of A Es and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  will be followed until the event is 
resolved, stabili sed, otherwise explained, or the pa rticipant is lost to follow -up (as defined 
in Section  7.[ADDRESS_937026] to Follow Up ). Further information on follow -up procedures is given 
in Section 10.3  (Appendix 3 ). 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 79 
 8.3.4.  Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety  of participants and the safety of 
a study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under  clinical investigation. 
The sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/IEC, and investigators.  
Investigator safety reports must be prepared for suspected unexpected serio us adverse 
reactions according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor will review 
and then file it along with the Investigator’s Brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.  
8.3.5.  Pregnancy  
• Details of all pregnancies in female participants will be collected after the start of 
study intervention  and until no longer than 6 to 8 weeks following the estimated 
delivery date . 
• If a pregnancy is reported, the investigator should inform [COMPANY_004] within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in  Section 
10.4 (Appendix  4). 
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, foetal  death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE s and will be 
reported as such . 
8.3.6.  Cardiovascular and Death Events  
For any cardiovascular events detailed in  Section 10.3 (Appendix 3 ) and all deaths, whether 
or not they are considered SAEs, specific Cardiovascular (CV) and Death sections of the 
CRF will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non -cardiovascular death.  
The CV CRFs are presente d as queries in response to reporting of certain CV medical 
dictionary for regulatory activities terms.  The CV information should be recorded in the 
specific cardiovascular section of the CRF within one week of receipt of a CV Event data 
query prompting i ts completion.  
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one week 
of when the death is reported.  
TMF-[ADDRESS_937027]  
[IP_ADDRESS].  ALT Increases  
The liver is a site of accumulation of antisense oligonucleotides and this has been exploited 
in the treatment of liver related diseases.  
Outside the setting of disease reactivation or rebound viremia, the etiology of ALT in crease 
(flares) in CHB patients is currently uncertain. It has been postulated that ALT flares are 
evidence of reactivation of the immune system in the liver with accompanying clearance 
of infected hepatocytes, particularly when observed during immunothera py or spontaneous 
loss of H BsAg. Therapeutic ALT flares have been shown to correlate with antiviral effect 
in blood (i.e. declines in HBV DNA, and/or H BsAg).  
A monitoring strategy of ALT is presented in Section 7.1.1  
[IP_ADDRESS].  Vascular Inflammation and Complement Activation  
Inflammatory and immune changes are recogni sed as a class effect of ASOs.  Despi[INVESTIGATOR_103024] -related vascular adverse events in patients, the nature of the toxicity 
demands a conservative approach to care and monitoring to ensure the safety of 
participants.  Because the complement -mediated mechanism of vascular inflammation in 
monkeys has been well established, a monitoring strategy has been pro posed in patients 
that encompasses a multi -pronged approach for monitoring of this toxicity, from separate 
mechanistic, phenotypic and organ -specific perspectives.  
Vascular inflammation will be monitored through various inflammatory markers (e.g., 
compleme nt factors, hs -CRP, ANCA, MCP -1) and presence of clinical signs and 
symptoms.  
A monitoring strategy of vasculitis and complement activation is presented in Section 
7.1.4  
[IP_ADDRESS].  Thrombocytopenia  
Thrombocytopenia, decreased platelets, is a well -recogni sed toxicity associated with ASOs 
and is monitorable in the clinic. Two types of thrombocytopenia have been described by 
[CONTACT_103078] 2 -MOE ASOs.  One type is a rapid onset , unpredictable 
thrombocytopenia that may present with mild or moderate bleeding, however, catastrophic, 
fatal bleeding can occur.  The other more common type is characteri sed by a gradual 
decline in platelets leading to mild to severe thrombocytopenia and  can be asymptomatic 
or associated with mild to severe bleeding.  
A monitoring strategy of platelet count is presented in Section 7.1.2  
[IP_ADDRESS].  Renal Injury  
Glomerulonephriti s, including rapi[INVESTIGATOR_103025], has been reported 
with ASOs and is thought to be a result of the proinflammatory effect of ASOs.  
Accumulation of antisense oligonucleotides in proximal tubule cells of the kidney, is 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 81 
 thought to sometime s lead to increased tubular proteinuria (as described in preclinical 
studies).  Increases in urine protein have been described in the clinic.  
A monitoring strategy of renal function (e.g., serum creatinine , ACR) is presented in 
Section 7.1.3  
[IP_ADDRESS].  Injection Site Reactions  
Injection site reactions were the most commonly reported treatment -related adverse event 
in previous studies with [COMPANY_004]3228836. Injection  site reactions included, but were not 
limited to, pain, erythema and pruritus. Injection site reactions will be assessed at all dosing 
visits and, if present, should be reported as AEs.  
8.4. Genetics  
A blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the study. Participation is 
optional. Participants who do not wish to participate in the genetic research may still 
participate in the study.  
In the event of DNA extractio n failure, a replacement genetic blood sample may be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
See Section 10.5 for Information regarding genetic research. Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM . 
8.5. Pharmacokinetics  
Blood samples will be collected pre-dose for measurement of [COMPANY_004]3228836 and PegIFN  
trough plasma concentrations and plasma concentrations during the terminal elimination 
phase as specified in the SoA (see Section 1.3).  PK samples collected during the off 
treatment period at visits specified in the SoA can be collected at any time.  
• Instructions for the collection and handling of biological samples will be provided 
by [CONTACT_456]. The actual date an d time (24  hour clock time) of each sample will 
be recorded.  
• PK samples will be used to evaluate the PK of [COMPANY_004]3228836 and PegIFN , and to 
explore PK -PD relationships.  
• Samples collected for PK analyses may also be used to evaluate safety or efficacy 
aspects  related to concerns arising during or after the study.  
8.6. Biomarkers  
Collection of blood samples for exploratory biomarker research is also part of this study. 
These exploratory biomarker samples will be collected to evaluate the patho biology  of 
CHB , the participants’ response to [COMPANY_004]3228836 , or the participants’ response to the virus 
following treatment . In addition, continuing research may identify other proteins, 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 82 
 transcripts or biomarkers related to [COMPANY_004]3228836 treatment, the response to [COMPANY_004]3228836 
or the pathogenesis of CHB, which will be evaluated in these samples.  
• Blood samples, including serum, plasma, PBMCs and PAXgene tubes will be 
collected to evaluate virologic and immune biomarkers related to the pathogenesis 
of CHB  and the participants’ resp onse to [COMPANY_004]3228836 , PegIFN or both .  Samples 
will be collected according to the schedule described in the SoA and as detailed in 
the study reference manual provided separately to sites.  
• [COMPANY_004] may store samples for up to 15 years after the end of the study to  achieve 
study objectives and for follow -up exploration of the laboratory findings and/or 
AEs (e.g., measurement of cytokine or chemokine levels, measurement of 
antibodies, etc.).  The archive samples may also be used for studying biomarkers 
that may be af fected by [CONTACT_3148], such as H BcrAg, indoleamine 2,  3 dioxygenase 
(IDO), or other immune -related responses.  Additionally, samples may be used for 
further research by [CONTACT_690651] B or other diseases, the 
development of related or new treatments or research methods.  
For China, see Appendix 7: Country -specific requirements  on biomarkers . 
8.7. Resistance Monitoring  
The barrier to development of [COMPANY_004]3228836 resistance is unknown.  Population sequencing 
of isolates from Study ISIS [ADDRESS_937028] in participants receiving 
concomitant NA therapy due to the suppression of HBV viral replication.  Ongoing viral 
replication during [COMPANY_004]3228836 treatment (e.g., due to  virological breakthrough) may 
increase the risk of the development of resistance.  Investigators should therefore consider 
resistance monitoring for participants who experience virological breakthrough whilst still 
receiving [COMPANY_004]3228836 (i.e., haven’t comp leted treatment).  
Samples collected for viral genotypi[INVESTIGATOR_165751]. Viral DNA and/or viral RNA will be extracted from participant samples 
and the viral genome will be DNA sequenced to determine whether mutations have 
occurred in the [COMPANY_004]3228836 binding region or elsewhere in the genome (and if applicable, 
whether any known nucleos(t)ide resistance mutations are present in the polymerase coding 
region).  
Resistance monitoring will be conducted on all baseline isolates to i dentify pre -existing 
substitutions.  Sequencing of the viral RNA will be attempted in participants receiving 
stable NA therapy and having low DNA levels (e.g. , <LLOQ).  Additional resistance 
monitoring will be conducted and will include, but not limited to , the analysis of isolates 
from participants experiencing virological failure during or post treatment as defined 
below.  Confirmation of resistance should be done within 1 week after results are received.   
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 83 
 Virological breakthrough is defined as one of the  following confirmed (2 sequential 
visits) lab results:  
• ≥1 log increase from nadir of HBV DNA  
• HBV DNA becoming quantifiable after being below the LLOQ  
HBsAg levels for each participant will be measured throughout the study. In addition to 
the standard HBV  DNA virological failure criteria defined above, HBV resistance 
monitoring will also include analysis of isolates from participants with sub -optimal H BsAg 
levels in the absence of detectable HBV DNA.  
8.8. Independent Data Monitoring Committee  
An independent dat a monitoring committee (IDMC) will review ongoing unblinded safety 
data in this study and the planned interim analysis is described in Section 9.5. The IDMC 
will meet on a regular basis as outlined in the charter. The IDMC/Review Board charter 
will describe the procedures related to IDMC operations in greater detail. For details on 
the IDMC , refer to Section 10.1.5 . 
8.9. Internal Safety Review Team (SRT)  
A separate internal safety review team will meet to review all participants safety data on a 
regular basis  to ensure any new or emerging safety issues are  identified and managed in a 
timely manner.  
8.10.  Medical Resource Utilisation  and Health Economics  
Health Economics/Medical Resource Utilisation  and Health Economics  parameters are 
not evaluated in this study.  
9. STATISTICAL CONSIDER ATIONS  
9.1. Statistical Hypotheses  
The primary objective of the study is to investigate the effectiveness of [COMPANY_004]3228836 and 
PegIFN sequential therapy in CHB patients on stable NA therapy. The primary endpoint is 
achieving a sustained virologic response ( SVR, HBsAg <LLOQ and HBV DNA <LLOQ) 
for [ADDRESS_937029] is the  SVR rate of each treatment group. The point estimates for 
SVR and 95% credible intervals will be calculated using a Bayesian probability  approach; 
in addition, posterior  probabilities that the true SVR in each  treatment arm is greater than 
a range of clin ically  meaningful response rates will be  provided.  
Comparisons between treatment arms as defined in the key  secondary objectives will be 
assessed using probability inference approaches.  
9.2. Sample Size Determination  
For the entire study, a pproximately  100 participants  will be enrolled  and randomi sed to 
achieve approximately 50  participants in each treatment group:  
• 24 weeks treatment of [COMPANY_004]3228836 followed by [CONTACT_8622] 24 weeks treatment of 
PegIFN  
• 12 weeks treatment of [COMPANY_004]3228836 followed by [CONTACT_8622] 24 weeks tre atment of 
PegIFN  
It is assumed that the number of responders follows a Binomial distribution, with a  
weakly informative prior (Beta (0.5, 0.5)) for the true RR. The precision for a  range of 
RRs with 95% credible intervals are shown in  Table 13. 
Table 13 95% Credible Interval of Response Rate  
Number of Responders  Response Rate  95% Credible Interval*  
9 18% 9% - 30% 
10 20% 11% - 33% 
11 22% 12% - 35% 
12 24% 14% - 37% 
13 26% 15% - 39% 
14 28% 17% - 41% 
15 30% 19% - 44% 
16 32% 20% - 46% 
17 34% 22%-48% 
18 36% 24% - 50% 
19 38% 26% - 52% 
20 40% 27% - 54% 
*95% equal -tailed interval  
The historical RR of a combination therapy of NA and PegIFN was 10% [Ren, 2019; Lee, 
2018 ]. The lower bounds of 95% credible intervals will exclude the RR of 10% if observed 
RR is greater than or equal to 20% (10 responders out of 50 participants) in an arm . 
TMF-[ADDRESS_937030] 65% posterior confidence that the  true rate  
exceeds a threshold of interest, are shown in Table 14, for various sample sizes, and true  
cure rates. The operating characteristics shown are based on a Bay esian inference  without  
consideration of baseline stratification factors . 
Table 14 End of Study Operating Characteristics by [CONTACT_690652] (%) of 
responders required to 
meet Criterion  Probability of meeting criterion under 
various assumptions  
True 
SVR rate 
= 20%  True 
SVR rate 
= 30%  True 
SVR rate 
= 35%  True SVR 
rate = 
40% 
Probability (true 
response rate > 
20%) > 65%  30 7 (23%)  39% 84% 94% 98% 
40 9 (23%)  41% 89% 97% 99% 
50 12 (24%)  29% 86% 97% 99% 
60 14 (23%)  31% 90% 98% 100%  
Probability (true 
response rate > 
30%) > 65%  30 10 (33%)  6% 41% 64% 82% 
40 14 (35%)  2% 30% 56% 79% 
50 17 (34%)  1% 32% 61% 84% 
60 20 (33%)  1% 33% 65% 88% 
Probability (true 
response rate > 
40%) > 65% 30 14 (47%)  0% 4% 13% 29% 
40 18 (45%)  0% 3% 12% 31% 
50 22 (44%)  0% 3% 12% 33% 
60 26 (43%)  0% 2% 11% 34% 
Based on these operating characteristics, for a true RR of 30%, the proposed  sample  size 
of n= 50 for each arm  has ~ 86% probability of confirming a true response of  at least 20%, 
and if the true rate is 40%, there is an 8 4% chance of confirming a true  response of at least 
30%.  There are no plans for sample size re -estimation.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 86 
 9.3. Analysis Sets  
For the purpose of analyses, t he following popul ations are defined:  
Population  Description  
Screened  All participants who were screened for eligibility  
Enrolled  o All participants who passed screening and entered the study  
o Note screening failures (who never passed screening even if rescreened) 
and participants screened but never enrolled into the study are excluded 
from the Enrolled population as they did not enter the study  
Intent -to-treat (ITT)  • All randomi sed participants.  
• This population will be based on the treatment the participant was 
randomi sed to  
• Any participant who receives a treatment randomi sation number will be 
considered to have been randomi sed 
Safety  • All participants who were randomi sed and received at least one dose of 
study treatment  
• This population will be based on the treatment th e participant received.  
Pharmacokinetics (PK)  • All participants in the Safety population who received an active study 
treatment and had at least 1 non -missing PK assessment (Non -quantifiable 
[NQ] values will be considered as non -missing values)  
• Note: PK samples that may be affected by [CONTACT_690653] (PD)  All participants in the Safety population for whom a Pharmacodynamic sample was 
obtained a nd analysed.  
9.4. Statistical Analyses  
The statistical analysis plan critical component will be finali sed prior to the first patient 
first visit . The full statistical analysis plan  will include a more technical and detailed 
description of the statistical analy ses described in this section. This section is a summary 
of the planned statistical analyses of the most important endpoints including primary and 
key secondary endpoints. No adjustments will be made for multiplicity.  
9.4.1.  General Considerations  
Unless otherwis e specified, baseline will be the last value/assessment before the first dose 
of study treatment ( Day 1 pre-dose). If there are multiple assessments collected at the same 
scheduled time, the average of these assessments will be used as the baseline.  
9.4.2.  Primar y Objective  
The primary analysis for the primary objective  will be conducted once the last participant 
has completed the Week 72 visit and database lock has achieved.  
The primary efficacy endpoint is achieving a sustained virologic response for 24 weeks 
after the planned  end of [COMPANY_004]3228836 and PegIFN sequential treatment in the absence of 
rescue medication. Sustained virologic response is defined as observing H BsAg <LLOQ 
and HBV DNA <LLOQ at each analysis window in the [ADDRESS_937031] sequential treatment assessments will be defined 
in the analysis plan.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 87 
 HBsAg and HBV DNA from the week of end -of-treatment to Off -Treatment Week 24 
will be used to assess the primary endpoint for each arm.  
[IP_ADDRESS].  Main  Estimands  
Main  Estimands supporting the primary objective are defined as:  
• Population: Participants with CHB on stable NA therapy  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks followed by [CONTACT_8622] 24 weeks 
of PegIFN therapy while on stable NA therapy  
• Variable (Categorical): Participants achieving Sustained Virologic Response 
(HBsAg <LLOQ and HBV DNA <LLOQ) for 24 weeks after the planned end of 
sequential treatment, without use of any rescue medication  
• Intercurrent Events:  
o Discontinuation of, interrupt ion in, and non-adherence to [COMPANY_004]3228836 and 
PegIFN not related to any wide disruptive events (such as COVID -19 
pandemic) will be ignored (treatment policy strategy).  
o Ineligibility to receive PegIFN will be ignored (treatment policy strategy)  
o Use of rescue  medication (composite strategy).  
o Wide disruptive events (such as COVID -19 pandemic) leading to 
discontinuation of, interruption in, and non -adherence to [COMPANY_004]3228836 and 
PegIFN  will be handled assuming they had not happened (hypothetical 
strategy).  
• Populat ion-level Summary: The percentage of participants in each treatment 
group who achieve Sustained Virologic Response (H BsAg <LLOQ and HBV 
DNA <LLOQ) for 24 weeks after the planned end of sequential treatment, 
without use of any rescue medication  
[IP_ADDRESS].  Supplementa ry Estimands  
Three supplementary Estimands are defined to support the primary objective . 
The first supplementary Estimand is defined in the same way as the main Estimand, except 
the assessment time frame for patients achieving SVR will be 24 weeks after th e actual end 
of treatment. Therefore, the strategy for intercurrent events of treatment discontinuation 
will be while -on-treatment. Th is supplementary estimand supporting the primary objective 
in participants with CHB on stable NA therapy in each treatment  arm is the percentage of 
participants that achieve SVR (H BsAg <LLOQ and HBV DNA <LLOQ) for 24 weeks 
after the actual  end of sequential treatment in the absence of rescue medication, regardless 
of ineligibility to receive PegIFN, discontinuation of , interruption  in or non-adherence to 
[COMPANY_004]3228836  and PegIFN , had they not been affected by [CONTACT_165763].  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 88 
 The second supplementary Estimand is to understand the relationship  between the PegIFN  
duration and achi eving SVR for 24 weeks after the actual  end of treatment, defined as:  
• Population: Participants with CHB on stable NA therapy  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks followed by [CONTACT_8622] 24 weeks 
of PegIFN therapy while on stable NA therapy  
• Variable: The relationship between SVR for 24 wee ks after actual end of 
treatment and of PegIFN received by [CONTACT_690654]  
• Intercurrent Events:  
o Discontinuation and delayed start of PegIFN will be accounted to reflect the 
actual duration from the first to the last dose of PegIFN received (while -on-
treatment strategy).  
o Interruption in  and other non -adherence to  PegIFN will be ignored 
(treatment policy strategy).  
o Discontinuation of, interruption in and non -adherence to [COMPANY_004]3228836 will 
be ignored (treatment policy strategy).  
o Use of rescue medication ( composite  strategy).  
o Wide disruptive events (such as COVID -19 pandemic)  leading to 
discontinuation and delayed start of PegIFN  will be handled with while -on-
treatment strategy; wide disruptive events leading to  interruption in  and 
other non-adherence to  PegIFN will be ignored (treatment policy strategy); 
wide disruptive events leading to discontinuation of, interruption in, and 
non-adherence to [COMPANY_004]3228836 will be ignored (treatment policy strate gy). 
• Population Summary: The  percentage o f participants achieving SVR for 24 weeks 
after the actual end of treatment by [CONTACT_690629][INVESTIGATOR_007] (groupi[INVESTIGATOR_690606]) in each treatment arm.  
The second supplementary Esti mand (supporting the primary objective in participants with 
CHB on stable NA therapy ) is percentage of participants achieving SVR for [ADDRESS_937032] as the main Estimand, except 
the strategy for intercurrent events of PegIFN ineligibility for  more than  12 weeks  (i.e. can 
no longer receive at least 12 weeks of PegIFN treatment)  and/or missing at least 12 doses 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 89 
 of PegIFN will be prin cipal stratum. This supplementary Estimand supporting the primary 
objective is the percentage of participants in each treatment arm that achieve SVR (H BsAg 
<LLOQ and HBV DNA <LLOQ) for [ADDRESS_937033] 12 doses of 
PegIFN, in the absence of rescue medication, regardless of discontinuation of , interruptions 
in or non-adherence to [COMPANY_004]3228836  had they not been affected by [CONTACT_165763].  
[IP_ADDRESS].  Handling o f Withdrawal from Study and Missing H BsAg and HBV DNA 
Data  
Two approaches will be used to determine a participant ’s response when H BsAg and HBV 
DNA data are missing from visits required to derive the primary Estimand .  
1) For participants where wide disrup tive events (such as COV ID-19 pandemic) prevent 
assessment of the primary outcome, SVR will be imputed using all available data for 
participants for whom SVR can be assessed. For other participants where SVR in the 
absence of rescue medication cannot be as certained due to missing data (withdrawal from 
the study or missing due to other reasons, but not due to a wide disruptive event), the 
participant will be assumed not to have achieved SVR (non -responder imputation).  
2) For the main estiman d supporting the primary objective , a sensitivity analysis will be 
performed using the Bayesian model described in Section [IP_ADDRESS]  assuming missing at 
random whereby a participant ’s response will be imputed using all available data (on and 
off treatment values) for participants who completed the study.  
[IP_ADDRESS].  Primary Analyses  
The primary assessments of interest are the point estimate of sustained virologic RR and 
95% credible intervals; i n addition, posterior probabilities that the true virologic RR in each 
treatment arm is greater than a range of values will be provided.  
A Bayesian hierarchical model will be used to estimate the posterior probability of 
sustained virologic RR incorporatin g the baseline stratification factors [ Jones , 2011 ]. 
Main effects for each of the 2 strata will be included as independent parameters in the 
model denoted γ k (k = 1, 2); Inte ractions between the 2 levels of stratification factors are 
anticipated to be small, and so will be modelled as exchangeable random effects (ψ g) 
centred on zero to enable borrowing of information about the RR across strata.  
𝜃𝑔=𝜏+𝛾1𝐼{𝐵1+}+𝛾2𝐼{𝐵2+}+𝜓𝑔 
𝜏~𝑁𝑜𝑟𝑚𝑎𝑙  (0,106)  
𝛾𝑘~𝑁𝑜𝑟𝑚𝑎𝑙  (0,106),𝑘=1,2  
𝜓𝑔~𝑁𝑜𝑟𝑚𝑎𝑙  (0,𝜔2),𝑔=1,2,3,4 
𝜔~𝐻𝑎𝑙𝑓 −𝑁𝑜𝑟𝑚𝑎𝑙  (1) 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 90 
 Where θg is defined as the log odds of treatment response, index g =1,  2, 3, and [ADDRESS_937034] ψ refers to each of the  4 possible combinations of strata levels . The 
parameter τ + ψ [ADDRESS_937035] in reference stratum (H BsAg ≤3 log IU/mL 
and Negative H BeAg), while g denotes a random stratum effect in group g.  
The four stratum and representation of the two baseline stratification factors B 1 and B 2 in 
the model are shown in Table 15. 
Table 15 Baseline Stratification Factors for Four Stratum  
Stratum  B1: HBsAg B2: HBeAg 
1: HBsAg <3 log IU/mL and Negative H BeAg B1- (≤3 log IU/mL)  B2- (Negative)  
2: HBsAg ≥3 log IU/mL and Negative H BeAg B1+ (>3 log IU/mL)  B2- (Negative)  
3: HBsAg <3 log IU/mL and Positive H BeAg B1- (≤3 log IU/mL)  B2+ (Positive)  
4: HBsAg ≥3 log IU/mL and Positive H BeAg B1+ (>3 log IU/mL)  B2+ (Positive)  
 
The point estimates of sustained virologic RR in each treatment arms with 95% credible 
intervals will be calculated.  Handling of withdrawal from study and missing H BsAg and 
HBV DNA data is described in Section [IP_ADDRESS] . 
Posterior probability of sustained virologic RR exceeding a range of clinically 
meaningful RRs will be generate d using the model specified.  
9.4.3.  Secondary Endpoints  
[IP_ADDRESS].  Secondary Estimands  
Three groups of estimands are defined for the secondary efficacy objectives. Categorical 
definitions for secondary analyses will be provided in the RAP.  
1. Estimands supporting secondary objective of assessing the efficacy of [COMPANY_004]3228836 
and PegIFN sequential therapy on biomarkers and virus specific antibody responses 
are defined as follows:  
• Population: Participants with CHB on stable NA therapy ; For the time to ALT 
normali sation variable, population will be aforementioned participants with 
baseline ALT >ULN.  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks followed by [CONTACT_8622] 24 weeks 
of PegIFN therapy while on stable NA therapy  
• Intercurrent Events: Discontinuation of, interruption in, and non-adherence to 
[COMPANY_004]3228836 and PegIFN will be ignored (treatment policy).  PegIFN ineligibility 
will be ignored (treatment policy); Rescue medication will be ignored (treatment 
policy) , except for ALT normali sation which can only be achieved in the absence  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 91 
 of rescue medication ; Wide disruptive events (such as COVID -19 pandemic) 
leading to discontinuation of, interruption in, and non -adherence to [COMPANY_004]3228836 
and PegIFN will be ignored (treatment policy  strategy ). 
• Categorical Variables:  
o Achieving H BsAg <LLOQ a nd HBV DNA <LLOQ at two time points: (1) 
the planned end of treatment  and (2) at the end of 24 weeks follow -up 
o Categorical changes from baseline in H BsAg (e.g. , <0.5, ≥0.5, ≥1, ≥1.5, ≥3 
log10 IU/mL) .  
o ALT normali sation (ALT≤ULN) over time in absence of rescue medication 
in participants with baseline ALT>ULN  
o HBe antibody (anti -HBeAg) levels  
• Population summary of Categorical Variables: p ercentage  of participants in each 
category for each treatment arm  
• Continuous Variables:  
o Actual values and change from ba seline over time of H BsAg, HBV DNA , 
and HBeAg levels  
o Actual values and change from baseline over time for  HBs antibody (anti -
HBsAg) levels  over time  
o Actual values and change from baseline over time for ALT . 
• Population summary of Continuous Variables: mea n values and  mean changes 
from baseline of each variable for participants in each treatment arm  
• Time to Event Variable:  
o Time to ALT normali sation in absence of rescue medication in participants 
with baseline ALT>ULN  
• Population summary of Time to Event Var iable: Turnbull’s estimator for non -
parametric estimation  of Time to ALT normali sation in each treatment arm  
The estimands supporting this objective are the population summary for each variable in 
each treatment arm in the population regardless of discontinuation of , interruption in, or 
non-adherence to planned treatment, and regardless of rescue medication  (except for ALT 
normali sation  which can only be achieved in the absence of rescue medication) or PegIFN 
ineligibility.    
Missing data for variab les defined above will be ignored, only available data will be 
summari sed. Further details will be provided in the report and analysis plan ( RAP ). 
2. Estimands supporting secondary objective of investigating the durability of virological 
response after sequential therapy with  12 weeks of [COMPANY_004]3228836 followed by [CONTACT_8622] 
24 weeks of PegIFN in participants with CHB on stable NA therapy  for up to 36  weeks  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 92 
 off treatment  are defined the same as the above secondary estimand, focusing on the 
timepoints following the 24 weeks off -treatment period.  
3. Estimands supporting secondary objective of comparing efficacy between treatment  
arms  of 12 and 24 weeks of [COMPANY_004]3228836 followed by [CONTACT_8622] 24 weeks of PegIFN are 
defined as follows:  
• Population: Participants with CHB on stab le NA therapy  
• Treatment: 300 mg [COMPANY_004]3228836 for 12 or 24 weeks followed by  [CONTACT_8622] 24 weeks 
of PegIFN therapy while on stable NA therapy . One treatment comparison between 
Arms 1 and 2 up to 24 weeks off -treatment  
• Categorical Variables:  
o Achieving SVR ( HBsAg < LLOQ and HBV DNA <LLOQ ) at the planned end 
of sequential treatment and over the 24 weeks follow -up. 
o Population Summary of Categorical Variables: difference in percentage of 
participants who achieve SVR  between treatment arms . 
• Intercurrent Events: Discontin uation of, interruption in, and non-adherence to 
[COMPANY_004]3228836 and PegIFN will be ignored (treatment policy).  PegIFN ineligibility 
will be ignored (treatment policy); Participants who have used rescue medication 
will be counted as non -responders (composite st rategy); Wide disruptive events 
(such as COVID -19 pandemic) leading to discontinuation of, interruption in, and 
non-adherence to [COMPANY_004]3228836 and PegIFN will be handled assuming they had 
not happened (hypothetical strategy).  
The estimands supporting this objective in participants with CHB on stable NA therapy for 
the treatment comparison is the difference between treatment arms 1 and 2 in the proportion 
of participants that achieve SVR for 24 weeks after the planned end of sequential treatment , 
in the  absence of rescue medication , regardless of ineligibility to receive PegIFN, 
regardless of discontinuation of,  interruptions in or non-adherence to [COMPANY_004]3228836 and 
PegIFN , had they not been affected by [CONTACT_165763].    
[IP_ADDRESS].  Handling of withdrawal from study and missing data for secondary 
endpoints  
[IP_ADDRESS].1.  Comparison  of efficacy between treatment arms  
Two approaches will be used to determine a participant’s response when H BsAg and HBV 
DNA data are missing from visits required to derive the secondary estimand of  comparing 
efficacy between treatment of 12 and 24 weeks of [COMPANY_004]3228836 followed by [CONTACT_8622] 
24 weeks of PegIFN   
1) For participants where wide disruptive events (such as COVID -19 pandemic) prevent 
assessment of the  HBsAg and HBV DNA required to derive SVR , SVR will be imputed 
using all available data for participants for whom SVR can be assessed. For other 
participants where SVR in the absence of rescue medication cannot be ascertained due to 
missing data (withdrawal from the study or missing due to other reas ons, but not due to a 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 93 
 wide disruptive event), the participant will be assumed not to have achieved SVR (non -
responder imputation).  
2) For the estimand supporting the objective of comparing efficacy between treatment 
arms , a sensitivity analysis will be performed using the Bayesian model described in 
Section [IP_ADDRESS]  assuming missing at random whereby a participant’s response will be 
imputed using all available data (on and off treatment values) for participants who 
completed the study.  
[IP_ADDRESS].2.  Other secondary endpoints  
Other than the H BsAg and HBV DNA data supporting the se condary objective of 
comparing efficacy between treatment arms, missing data for variables defined in any other 
secondary or exploratory estimand will be ignored, assuming missing completely at 
random.  
[IP_ADDRESS].  Secondary Efficacy Analyses  
The s econdary efficacy co mparison of interest is the  difference in sustained virologic RR 
for 24 weeks after the planned end of sequential treatment between treatment arms:  
• Arm 1 vs. Arm 2  in percentage of participants achieving SVR for 24 weeks after 
the planned end of sequential  treatment, without use of any rescue medication.  
The model in Section [IP_ADDRESS]  will be used to separately estimate the log odds of response 
for each treatment arm.  Comparisons between the treatment arms will be conducted by 
[CONTACT_690655].  The point estimates of differences in sustained virologic RR 
with 95% credible intervals will be calculated for the treatment comparisons described in 
the estimands .  Handling of withdrawal from study and missing H BsAg and HBV DNA 
data is described in Section [IP_ADDRESS] .  Details of the model will be  included in the RAP.  
9.4.4.  Safety Endpoints  
All safety analyses will be based on the Safety Population.  
Exposure to study medication, measured by [CONTACT_690656], will be summari sed by [CONTACT_2939].  
The proportion of pa rticipants reporting A Es will be tabulated for each treatment arm. The 
following summaries of A Es will be provided:  
• Incidence and severity of All A Es; 
• Incidence and severity of treatment related A Es; 
• Incidence and severity of A Es leading to withdrawal from  study;  
• Incidence of serious A Es (SAEs).  
 
Laboratory data, vital signs and ECG data (absolute values and change from Baseline) will 
be summari sed by [CONTACT_78488].  In addition, the maximum postbaseline toxicity 
grade (based on DAIDS categories) will be tabulated by [CONTACT_2939].  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 94 
 9.4.5.  Exploratory Endpoints  
[IP_ADDRESS].  PK and PK -PD Analyses  
Pharmacokinetics (PK) of [COMPANY_004]3228836 and PegIFN will be characteri sed. In all 
participants, C  and terminal half -life (t½) will be estimated , as data permit . 
PK-PD relationships including PK -efficacy relationships and PK -safety relationships will 
be evaluated , as data permit : 
• Efficacy assessments  for PK/PD relationship  include but not limited to : 
o Categorical: virologic response, seroclearance (H BsAg <LLOQ, HBV DNA 
<LLOQ), and seroconversion (anti-HBsAg and anti -HBeAg);  
o Change from baseline: H BsAg, HBV DNA, anti -HBsAg and anti -HBeAg 
levels;  
o Time to event: virologic response  (HBsAg and HBV DNA levels < LLOQ) , 
nadir of H BsAg and HBV DNA, H BsAg<LLOQ, HBV DNA <LLOQ, 
seroconversion (anti -HBsAg and anti-HBeAg), peak of ALT flares  
• Safety assessments for PK/PD relationship include but not limited to vital signs, 
laboratory measurements and adverse events  
• PK assessments include but not limited to C and terminal half -life (t½).  
[IP_ADDRESS].  Safety and Tolerability  
The safety profile of sequential therapy with [COMPANY_004]3228836 (up to 24 weeks) followed by 
[CONTACT_690621] (up to 24 weeks) in participants with CHB on stable NA therapy  will be 
investigated.  
• Clinical assessments include laboratory measurements and adverse events at 
timepoints specified in the SoA.  
CCI
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 95 
 [IP_ADDRESS].  Biomarkers  
The effect  of [COMPANY_004]32 [ZIP_CODE] and PegIFN sequential therapy on immunological biomarkers  
will be assessed. The relationship(s) between virology biomar kers including H BsAg and 
immunological bi omarkers will be described.  
• Biomarker assessments include Laboratory measurements of and correlation 
between the following:  
o Virological biomarkers, including specific viral parameters (H BeAg, HBV 
DNA, HBV RNA, H BcrAg)  
o Soluble biomarkers, including levels of circulating cytokines and chemokines  
o Markers of immune cell function, including relative frequencies of immune cell 
subsets among PBMCs, activation status as determined by [CONTACT_165769][INVESTIGATOR_690607], and functional assays including HBV -specific 
cytokine and/or antibody production  
Timepoints are specified in the SoA . 
Deta ils of exploratory analyses for exploratory efficacy, virology, and biomarker will be 
provided in the RAP. The results of H BcrAg, HBV RNA, virology and biomarker 
investigations may be reported separately from the main clinical study report. All endpoints 
of interest from all comparisons will be descriptively and/or graphically summari sed as 
appropriate to the data.  
9.5. Interim Analys is 
One interim analys is is planned for the study in addition to regular IDMC safety reviews 
(see Section  10.1.5 ). The interim analysis will be based on the ITT population.  
CCI
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 96 
 The approximate timing, endpoint and criteria for the interim analysis is summari sed in 
Table 16.   
Table 16 Interim Analysis Timing, Endpoint and Decision Rule 
Interim  Timing  Endpoint  Decision Rule  
1 All participants 
complete end-of-
treatment visit  Sustained virologic 
response rate 
(primary endpoint)  The predicted end -of-study sustained virologic response  
rate will be modelled to  support development plan  decision 
making. No option  to stop the trial at this point  as all 
particip ants will have  completed treatment.  
The RAP  will describe the planned interim analys is in greater detail.  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 97 
 10. SUPPORTING DOCUMENTA TION AND O PERATIONAL 
CONSIDERATIONS  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences ( CIOMS) International Ethical Guidelines  
o Applicable International Conference on Harmonisation ( ICH) Good Clinical 
Practice (GCP) Guidelines  
o Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other relevant documents ( e.g., 
adver tisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated.  
• Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate  hazard to study participants.  
• The investigator will be responsible for the following:  
o Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/ IEC 
o Notifying the IRB/IEC of SAE or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC,  European regulation 
536/2014 for clinical studies (if applicable), ), European Medical Device 
Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulations  
10.1.2.  Financial Disclosure  
Investigators and sub -investiga tors will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are re sponsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 98 
 10.1.3.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to 
the particip ant or their legally authori sed representative and answer all questions 
regarding the study.  
• Participants must be informed that their participation is voluntary. Participants or 
their legally authori sed representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_937036] 
requirements, where applicable, and the IRB/IEC or study centre .  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authori sed person obtaining the informed consent must 
also sign the ICF.  
• Participants must be re -consen ted to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or their legally 
authori sed representative .  
A participant who is rescreened is not required to sign another IC F if the rescreening 
occurs within 45 days from the previous ICF signature [CONTACT_568].  
[COMPANY_004] (alone or working with others) may use participant’s coded study data and samples 
and other information to carry out this study; understand the results of this study; lear n 
more about [COMPANY_004]3228836  or about the study disease; publish the results of these research 
efforts; work with government agencies or insurers to have [COMPANY_004]32 [ZIP_CODE]  approved for 
medical use or approved for payment coverage.  
The ICF contains a separate section that addresses the use of participant data and 
remaining samples for optional further research. Where approved by [CONTACT_1201]/IEC, t he 
investigator or authorised designee will inform each partic ipant of the possibility of 
further research. Participants will be told that they are free to refuse to participate and 
may withdraw their consent at any time and for any reason during the storage period. A 
separate signature  [CONTACT_22862] a participant ’s agreement to al low any 
participant data and/or remaining leftover samples to be used for further research not 
related to the study/disease. Participants who decline further research will tick the 
corresponding “No” box . 
10.1.4.  Data Protection  
• Participants will be assigned a uni que identifier by [CONTACT_456]. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.  
• The partic ipant must be informed that his/her personal study -related data will be 
used by [CONTACT_10999]. The level of 
TMF-[ADDRESS_937037] also be explained to the participant  who will be required to give 
consent for their data to be used as described in the informed consent .  
• The participant must be informed that his/her medical records may be examined 
by [CONTACT_690657], by [CONTACT_6667]/IEC members, a nd by [CONTACT_9326].  
10.1.5.  Committees Structure  
Independent Data Monitoring Committee : The overall responsibility of the IDMC, which 
consists of at least [ADDRESS_937038] the ethical and safety 
interests of participants recruited into clinical studies while ensuring the scientific 
validity of the studies. The IDMC will meet at predefined times for each study, as well as 
ad hoc (as deemed appropriate), to evaluate the risk versus benefit of [COMPANY_004]3228836.  
Specifi c responsibilities of the IDMC include:   
• Reviewing the IDMC Charter supplied by [CONTACT_690658]; all IDMC members must approve and sign 
the Charter prior to enrolling the first patient into the study.  
• Determining the type of information needed for review of efficacy/safety data, as 
required, in the context of benefit/risk.  
• Recommending the format for the presentation of this information.  
• Reviewing data collection methods, safety/efficacy monitoring procedures and 
makin g recommendations for additions or adjustments to the trial design 
following interim analys is. 
[COMPANY_004] is responsible for the selectio n of IDMC memb ers.  The IDMC Chairperson may 
assist in selecting IDMC members.  The skills and experiences necessary to proper ly 
fulfil the role of the IDMC ( e.g., relevant medical specialties) require careful 
consideration and have been pre -specified by [CONTACT_23983].  In the event that a member is unable 
to continue participation on the IDMC, [COMPANY_004], in conjunction with the IDMC Chairperson , 
will recommend a replacement.  [COMPANY_004] has the final decision on the replacement.  No 
substitution of members is permissible for individual meetings.  
10.1.6.  Dissemination of Clinical Study Data  
• Where required by [CONTACT_25435], an investigator s ignatory 
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results at a 
[COMPANY_004]  site or other mutually agreeable location.  
• [COMPANY_004] will also provide all investigator s who participated  in the study  with a 
summary of the study results  and will tell the investigators what treatment their 
patients  received.  The investigator (s) is/are encour aged to share the summary 
results with the study participants , as appropriate.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 100 
 • The procedures and timing for public disclosure of the protocol and results 
summary and for development of a manuscript for publication for this study will 
be in accordance with  [COMPANY_004] Policy.  
• [COMPANY_004] intends to make anonymi sed patient -level data from this trial available to 
external researchers for scientific analyses or to conduct further research that can 
help advance medical science or improve patient care. This helps ensure the dat a 
provided by [CONTACT_165793]  
10.1.7.  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically ( e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate 
and correct by [CONTACT_1189].  
• The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.  
• Quality tolerance limits (QTLs) will be pre -defined in the trial master file  to 
identify systematic issues that can impact participant safety and/or reliability of 
study results. These pre -defined parameter s will be monitored during and at the 
end of the study and all deviations from the QTLs and remedial actions taken will 
be summari sed in the clinical study report.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulator y agency inspections and provide direct access to source data 
documents.  
• Monitoring details describing strategy  including definition of study critical data 
items and processes  (e.g., risk -based initiatives in operations and quality such as 
Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (ce ntral, remote, or on -site 
monitoring) are provided in the Monitoring Plan.  
• The sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
• The sponsor assumes accountability for actions delegated to oth er individuals 
(e.g., Contract Research Organi sations  [CRO ]). 
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 25 years from the issue of the final 
Clinical Study Report (CSR)/ eq uivalent summary  unless local regulations or 
institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. 
No records may be transferred to another location or  party without written 
notification to the sponsor.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 101 
 10.1.8.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data r eported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, dep ending on the study. Also, current medical records must be 
available.  
• Definition of what constitutes source data and its origin can be found in the RAP . 
• The investigator must maintain accurate documentation (source data) that 
supports the information enter ed in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_31855], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agr eements, ICH GCP, and all 
applicable regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open a nd will be the study start date.  
Study/Site Termination  
[COMPANY_004] or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of [COMPANY_004]. Study sites will be closed upon study 
completion. A study si te is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient no tice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_103086]:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
• Inadequate or no recruitment of participants (evaluated after a reasonable amount 
of time) by [CONTACT_093]  
• Discontinuation of further study intervention development  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 102 
 If the study is prematurely terminated or suspended, the sponsor shall promptly inform 
the investigators, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the 
study of the reason for termination or suspension, as specified by [CONTACT_76542] e 
regulatory requirements. The investigator shall promptly inform the participant  and 
should assure appropriate participant  therapy and/or follow -up 
10.1.10.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary 
information and to provide comments.   
• The sponsor will comply with the requirements for publication  of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicentre  studies only in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_1317] d esignated by 
[CONTACT_11402].  
• Authorship will be determined by [CONTACT_14346].  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 103 
 10.2.  Appendix 2: Clinical Laboratory Tests  
The tests detailed in Table [ADDRESS_937039] be available prior to dosing.  A sample for central analysis is obtained in parallel . 
Otherwise, local laboratory results are only required in the event that the central laboratory 
results are not available in time for either  study intervention administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central analysis 
is obtained in parallel.  
Protocol -specific requirements for inclusion or exclusion of participants are detai led in 
Section  5 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_690659].  
Pregnancy Testing:  
Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria .  Pregnancy 
testing (urine or serum as required by [CONTACT_427]) should be conducted according to 
the Schedule of Assessments (Section 1.3) during the study.  Additional  serum or urine 
pregnancy tests may be performed, as determined necessary by [CONTACT_170492], to establish the absence of pregnancy at any time during 
participation in the study.  
Table 17 Protocol -Required Safety Laboratory Tests  
Laboratory 
Assessments  Parameters  
Haematology  Platelet Count1  RBC Indices:  
mean corpuscular volume  
mean corpuscular 
haemoglobin  WBC count (with Differential if WBC 
abnormal) : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC Count  
Haemoglobin  
Haematocrit  
Clinical 
Chemistry  Blood Urea 
Nitrogen  Potassium  Aspartate 
Aminotransferase  
/ Serum Glutamic -
Oxaloacetic 
Transaminase  Total, indirect and direct 
bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase / 
Serum Glutamic -
Pyruvic 
Transaminase  Total Protein  
Glucose  Calcium  Alkaline 
phosphatase  Albumin  
Routine 
Urinalysis  • By [CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal)  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 104 
 Laboratory 
Assessments  Parameters  
Pregnancy 
testing  • Highly sensitive urine or serum human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)2 
Other Tests  • Follicle -stimulating hormone and oestradiol  (as needed only)  
• Serology (HIV antibody, hepatitis C virus antibody, and hepatitis D virus antibody)  
• Hepatitis B serology (H BsAg, anti -HBsAg, anti -HBeAg, HBV DNA, HBV RNA , HBcrAg)  
• Other laboratory: TSH/T4, prothrombin time ( PT), INR, activated partial 
thromboplastin time ( aPTT ), Alpha -fetoprotein, ANCA (MPO -ANCA, PR3 -ANCA), 
APRI/Fibrosure, Complement factors C3, C4, C5a, and Bb, hs -CRP, MCP -1, 
angiopoietin  II, PBMC, soluble protein, PAX Gene  
• Urine ACR  
• Optional collections: Genetic sample  
• Viral Sequencing: HBV Genotype, HBV DNA, HBV RNA  
 
All study -required laboratory assessments will be performed by a central laboratory, with the 
exception:  
• Platelet counts for investigator decisions may be drawn at local laboratory  
 
Additional tests 
listed under 
safety follow -up 
processes  Liver Chemistry Stoppi[INVESTIGATOR_2121]3 
• Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody  
o Hepatitis B virus DNA load  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• PK sample  
• Serum CPK LDH.  
• Fractionated bilirubin, Anti -nuclear antibody, anti -smooth muscle antibody, Type 1 
anti-liver kidney microsomal antibodies and quantitative t otal immunoglobulin G (IgG 
or gamma globulins).  
• Serum acetaminophen adduct HPLC assay  
Drug Induced Vascular Inflammation and Complement Stoppi[INVESTIGATOR_2121]  
• CH50  
• Factor B level  
• Factor H level  
• sC5b -9 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 105 
 Laboratory 
Assessments  Parameters  
Haematological  Stoppi[INVESTIGATOR_2121]  
• anti-platelet antibodies  
Drug Induced Kidney Injury Stoppi[INVESTIGATOR_2121]  
• 24-hour urine analysis  
• renal ultrasound  
• urine microscopy  
• serum urea and creatinine  
• platelets  
• urgent serum vasculitis screen [including ANCA, ANA, dsDNA, cryoglobulins]  
•  SPEP/  UPEP  
• complement panel (C3, C4, C5a and Bb ) 
NOTES:  
1. Platelets will require local/central lab collection while participants are [COMPANY_004]3228836 on-treatment . The blood 
draw can be taken the day before [COMPANY_004]3228836 dosing.  Results must be available prior to dosing.    
2. Urine testing will be standard for the protocol unless serum testing is required by [CONTACT_18039]/IEC or 
if urine testing is unavailable  
3. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver stoppi[INVESTIGATOR_103031] 7.1 and Appendix 6 .  All events of ALT 3 × upper limi t of normal 
(ULN) and bilirubin >2 × ULN  (>35% direct bilirubin) or ALT 3 × ULN and international normali sed ratio (INR) 
>1.5, if INR measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis).  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 106 
 10.3.  Appendix 3: AEs and SAEs : Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study  intervention, whether or not 
considered related to the study intervention.  
NOTE: An AE can therefore be any unfavourable  and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study intervention.  
 
Definition of Unsolicited and Solicited AE  
• An unsolicited adverse event is an adverse e vent that was not solicited using a 
Participant Diary and that is communicated by a participant/  legally acceptable 
representative  (LAR(s) ) who has signed the informed consent. Unsolicited A Es 
include serious and non -serious A Es. 
• Potential unsolicited A Es may be medically attended (i.e., symptoms or illnesses 
requiring a hospi[INVESTIGATOR_11956], or emergency room visit, or visit to/by a health care 
provider). The participants/LAR(s)  will be instructed to contact [CONTACT_690660](s), as well as any events that, though 
not medically attended, are of participant /LAR’s  concern. Detailed information 
about reported unsolicited A Es will be collected by [CONTACT_377360]’s records.  
• Unsolicited A Es that are not medically attended nor perceived as a concern by 
[CONTACT_3445]/LAR(s)  will be collected during interview with the participants/  LAR(s)  
and by [CONTACT_458664].  
• Solicited A Es are predefined local  at the injection site  and systemic events for 
which the participant is specifically questioned, and which are noted by [CONTACT_14350].  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (h aematology, clinical chemistry, or 
urinalysis) or other safety assessments ( e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( i.e., not 
related to progression or part of underlying disease).  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 107 
 • Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdo se of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• “Lack of efficacy ” or “failure of expected pharmacological action ” per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of effic acy will be reported as AE or SAE if they fulfil  the definition of an AE 
or SAE.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying  disease, unless judged by [CONTACT_11009]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admiss ion to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
 
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE  even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_690608]/symptoms of the disease under study, 
death due to progression of disease).  
An SAE is defined as any serious adverse event  that, at any dose:  
a. Results in death  
b. Is life -threatening  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 108 
 The term ‘life-threatening ’ in the definition of ‘serious ’ refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_218747]  
• In general, hospi[INVESTIGATOR_690609]  
(usually involving at least an overnight stay) at the hospi[INVESTIGATOR_53107] /or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_690610]. If a complication prolongs hospi[INVESTIGATOR_690611], the event is serio us. When in doubt as to whether 
“hospi[INVESTIGATOR_343639] ” occurred or was necessary, the AE should be considered 
serious.  
• Hospi[INVESTIGATOR_690612] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
d. Results in pers istent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
This definition is not intended to include experiences of relatively minor medical 
significance such as u ncomplicated headache, nausea, vomiting, diarrhoea , 
influenza, and accidental trauma ( e.g., sprained ankle) which may interfere with 
or prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised  by [CONTACT_690661] s urgical intervention to prevent one of the other outcomes listed in 
the above definition. These events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, 
intensive treatment for allergic bronchospasm, blood  dyscrasias , 
convulsions, or development of intervention dependency or intervention 
abuse.  
 
10.3.3.  Definition of Cardiovascular Events  
Cardiovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following A Es and SAEs:  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 109 
 • Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revasculari sation  
 
10.3.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004]  required form . 
• There may be instances when copi[INVESTIGATOR_31784]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_690613].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should  not be confused with an SAE. Severe is a category utilised for 
rating the intensity of an event; and both AE and SAE can be assessed as severe.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 110 
 • An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the defini tion of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), conc omitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Informat ion, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occu rred an d the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] . 
• The inves tigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirement s. 
 
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_31859]/or causality of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recogni sed 
follow -up period, the investigator will provide [COMPANY_004] with a copy of any 
post-mortem findings including histopathology.  
• New or updated information will be recorded in the originally submitted 
documents . 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 111 
 • The investigator will submit any updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.  
The DAIDS Table [ DAIDS , 2017] is used for grading AEs and provided as a guidance 
for patient management for th e consideration of the PI.  The DAIDS table will be used to 
grade the severity of an AE that is not specifically identified in the grading table. In 
addition, all deaths related to an AE are to be classified as grade 5.  
The DAIDS Table is available at the  following link:  
https://rsc.niaid.nih.gov/clinical -research -sites/grading -severity -adult -pediatric -adverse -
events -corrected -version -two-one 
10.3.5.  Reporting of SAE to [COMPANY_004]  
SAE Reporting to [COMPANY_004]  via Electronic Data Collection Tool  
• The primary mechanism for reporti ng SAE to [COMPANY_004] will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new S AE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by [CONTACT_756].  
• Contacts for SAE reporting can be found in the SRM . 
 
SAE Reporting to [COMPANY_004] via Paper Data Collection Tool  
• Facsimile transmission of the SAE paper data collection tool  is the preferred 
method to transmit this information to the medical monitor or the SAE coordinator . 
• In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telepho ne does not replace the need for the investigator to 
complete and sign the SAE data collection tool  within the designated reporting time 
frames.  
• Contacts for SAE reporting can be found in the SRM . 
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 112 
 10.4.  Appendix  4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions:  
Woman of Childbearing Potential (WOCBP)  
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming post -menopausal unless permanently 
sterile (see below)  
Notes : 
• A postmenopausa l state is defined as no menses for 12 months without an 
alternative medical cause.  
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormo nal replacement therapy (HRT). However, in the 
absence of [ADDRESS_937040] discontinue HRT to allow confirmation of postmenopausal status before 
study enrollment.  
• Permanent sterili sation  methods (for the purpose of t his study) include:  
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above,  (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry.  
 
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview . 
 
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.  
Woman of Nonchildbearing Potential (WONCBP)  
Women in the  following categories are considered WONCBP:  
• Premenopausal female with permanent infertility due to one of the following (for 
the purpose of this study):  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 113 
 • Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
For indiv iduals with permanent infertility due to an alternate medical cause other than the 
above,  (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry.  
Note : Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
• Postmenopausal female  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
o A high f ollicle stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the 
absence of [ADDRESS_937041] discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.  
10.4.2.  Contraception Guidance:  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year 
when used consistently and correctly.  
Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationb 
Intrauterine device  
Intrauterine hormone -releasing system b 
Bilateral tubal occlusion  
Azoospermic partner (vasectomi sed or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is 
the sole sexual partner of the woman of childbearing potential and the absence of 
sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia fo r a male participant can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview.)  
Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used 
consistently and correctly.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 114 
 Combined ( oestrogen - and progestogen -containing) hormonal contraception associated 
with inhibition of ovulationc 
• oral 
• intravaginal  
• transdermal  
• injectable  
Progestogen -only hormone contraception associated with inhibition of ovulationc 
• oral 
• injectable  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.  
Effective Methodsd That Are Not Considered Highly Effective Failure rate of ≥1% per year when 
used consistently and correct ly. 
Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary mode of action  
Male or female condom with or without spermicidee 
Cervical cap, diaphragm, or sponge with spermicide  
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods)c 
a. Contraceptive use by [CONTACT_103092].  
b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_17964].  
c. If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contracept ive 
methods are limited to those which inhibit ovulation as the primary mode of action.  
d. Considered effective, but not highly effective - failure rate of ≥1% per year.  Periodic abstinence (calendar, 
sympto -thermal, post -ovulation methods), withdrawal (coit us interruptus), spermicides only, and lactational 
amenorrhea method are not acceptable methods of contraception.  
e. Male condom and female condom should not be used together (due to risk of failure from friction).  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 115 
 Collection of Pregnancy Information:  
Fema le Participants who become pregnant  
Investigator will collect pregnancy information on any female participant, who becomes 
pregnant while participating in this study.  
The initial information will be recorded on the appropriate form and submitted to [COMPANY_004]  
within 24 hours of learning of a participant's pregnancy.  
Participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow up information on participant and neonate, which will be forwarded to 
[COMPANY_004]  Generally, fol low-up will not be required for longer than 6 to 8 weeks beyond the 
estimated delivery date.   
Any termination of pregnancy will be reported, regardless of foetal  status (presence or 
absence of anomalies) or indication for procedure.  
While pregnancy itsel f is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy for medical reasons will be reported as an AE or 
SAE.  
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring 
at >2 2 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study pregnancy which is considered reasonably 
related to the study intervention by [CONTACT_093], will be reported to [COMPANY_004]  as described 
in Appendix 3 . While the investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
Any female participant who b ecomes pregnant while participating will discontinue study 
intervention or be withdrawn from the study . 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 116 
 10.5.  Appendix  5: Genetics  
USE/ANALYSIS OF DNA  
• Genetic variation may impact a participant’s response to study intervention , 
susceptibility, severity and progr ession of disease. Variable response to study 
intervention  may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease b eing treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis . 
• DNA samples will be used for research related to [COMPANY_004]3228836  or chronic 
hepatitis B and related diseases. They may also be used to develop  tests/assays 
including diagnostic tests) related to [COMPANY_004]3228836  or other 2’ -MOE ASOs , and 
CHB . Genetic research may consist of the analysis of one or more candidate 
genes or the analysis of genetic markers throughout the genome or analysis of the 
entire genome (as appropriate ). 
• Additional analyses may be conducted if it is hypothesi sed that this may help 
further understand the clinical data.  
• The samples may be analysed  as part of a multi -study assessment of genetic 
factors involved in the response to [COMPANY_004] 3228836 or study interventions of this 
class. The results of genetic analyses may be reported in the clinical study report 
or in a separate study summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect co nfidentiality.  
• The samples will be retained while research on [COMPANY_004]3228836  (or study 
interventions of this class) or chronic hepati tis B continues but no longer than 
[ADDRESS_937042] visit or other period as per local 
requirements . 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 117 
 10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart  Guidelines  
Phase [ADDRESS_937043] been 
designed to assure participant safety and evaluate liver event etiology.  
The procedures listed below are to be followed if a participant meets any of the liver 
chemistry stoppi[INVESTIGATOR_103034]  7.1. 
If criteria for permanent discontinuation of IP are met, immediately withdraw the 
participant from study treatment.  
Notify the Medical Monitor within 24  hours of learning of the abnormality to con firm 
the participant’s study treatment cessation and follow -up. 
Complete the Liver Event CRF.  
Complete the “Safety Follow -up Procedures” listed below.  
Safety Follow -up Procedures for Participants Who Meet Any of The 
Stoppi[INVESTIGATOR_2121]:  
Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody.  
o Hepatitis C virus RNA load  
o Hepatiti s D virus antibody  
• Obtain a blood sample for PK analysis as soon as possible following the 
occurrence of an event. Record the date/time of the PK blood sample collection 
and the date/time of the last dose of study treatment prior to blood sample 
collection  on the CRF. If the date or time of the last dose is unclear, provide the 
participant’s best approximation. Instructions for sample handling and shippi[INVESTIGATOR_690614].  
o CPK and LDH.  
o Review fractionated bilirubin  
o Assess eosinophilia  
o Record the app earance or worsening of clinical symptoms of hepatitis 
(fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, 
rash or eosinophilia) as relevant on the AE  CRF.  
o Record use of concomitant medications, acetaminophen, herbal remedies, 
other  over the counter medications, or putative hepatotoxins on the 
Concomitant Medications CRF.  
TMF-[ADDRESS_937044] alcohol use on the Liver Events CRF.  
The following are required for participants who meet the ALT and bilirubin 
stoppi[INVESTIGATOR_165746] . 
 
• Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies and quantitative total immunoglobulin G (IgG or gamma 
globulins).  
• Serum acetaminophen HPLC assay (quantifies potential acetamino phen 
contribution to liver injury in participants with definite or likely acetaminophen 
use in the preceding week [ James , 2009]).  
• Liver imaging (ultrasound, magnetic resonance, or computeri sed tomography) or 
Liver biopsy to evaluate liver disease.  
• The Liver Imaging and/or Liver Biopsy CRFs are also to be completed if these 
tests are performed.  
 
[COMPANY_004]3228836 rechallenge after stoppi[INVESTIGATOR_007] c riteria are met (i.e., study treatment 
discontinued) by [CONTACT_103070].  
[COMPANY_004]3228836 restart may be considered only for liver events as follows:  
Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_690605]3228836  
Restart refers to resuming study intervention following liver stoppi[INVESTIGATOR_90570] a clear underlying cause (other than  DILI]) of the liver event (e.g. , biliary obstruction, 
pancreatic events, hypotension, acute viral hepatitis). Fu rthermore, restart is not permitted 
following liver stoppi[INVESTIGATOR_42257] -related hepatitis.  
• Approval by [CONTACT_103071]:  
o Investigator requests consideration for study intervention r estart if liver 
chemistries have a clear underlying cause (e.g., biliary obstruction, 
hypotension and liver chemistries have improved to normal or are within 
1.5 x baseline and ALT  <[ADDRESS_937045]).  
o Possible study intervention -induced liver injury has been exclud ed by [CONTACT_103072]. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eosinophilia). Where 
a study intervention has a confirmed genetic marker associated with liver 
injury, the presence of t he marker should be excluded. If study 
intervention -related liver injury cannot be excluded, the guidance on 
rechallenge will apply.  
o There is no evidence of alcohol -related hepatitis.  
o IRB/IEC approval of study intervention restart , if required, has been 
obtained.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 119 
 If restart of study intervention is approved by [CONTACT_90652]:  
• The participant must be provided with a clear description of the possible benefits 
and risks of study intervention administration including the possibility of recurr ent, 
more severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the 
restart of study intervention. Documentation of informed consent must be recorded 
in the study file.  
• Study intervention must be adminis tered at the dose specified by [CONTACT_23983]  
• Participants approved by [CONTACT_165779] a week for liver function tests until stable liver function tests have been 
demonstrated and then standard laboratory monitori ng may resume as per protocol.  
• If the participant meets protocol -defined liver chemistry stoppi[INVESTIGATOR_165755], study intervention should be permanently discontinued.  
• The Medical Monitor and the IRB/IEC must be informed of the outcome for the 
participant following study intervention restart.  
• [COMPANY_004] must be notified of any adverse events.  
 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 120 
 10.7.  Appendix 7: Country -specific requirements  
10.7.1.  China  
The following sections outline China -specific changes from the main protocol. In China, 
collection of exploratory/biomarker labs will be contingent on agreements with China 
regulatory , Human Genetics Resources Administration of China (HGRAC).  
[IP_ADDRESS].  China Schedule of Activities  
The SoA in China will be completed as per Section 1.3, however collection of the  
following  laboratory assessments  will be contingent on agreements with CHINA 
regulatory (HGRAC) and will be optional for Chinese participa nts: 
• PBMC Collection for immunophenotypi[INVESTIGATOR_007]  
• Soluble Protein (Immunology)  
• PAXGene RNA for expression analysis in whole blood  
[IP_ADDRESS].  China Biomarkers and Archived Samples  
For China, collection of PBMCs, plasma protein, PAXgene RNA, and genetic samples 
will be contin gent on agreements with China regulatory (HGRAC) and will be optional 
for Chinese participants. Depending on the agreements with China regulatory and ethics 
committees, all or some of these biomarkers will be made optional for Chinese 
participants.  
• Blood samples, includ ing serum, plasma, PBMCs and PAXgene tubes, will be 
collected to evaluate virologic and immune biomarkers related to the pathogenesis 
of CHB and the participant’s response to [COMPANY_004]3228836. Samples will be collected 
according to the schedule described in the SoA and as detailed in the laboratory 
manual provided separately to sites.  
 
• For China -stored samples (e.g., archived samples) may be used for the purposes 
of follow -up exploration of laboratory findings and/or AEs (e.g., see Section 7 for 
additional analyses in case of an AE or SAE).  
CCI
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 121 
 10.8.  Appendix  8: Abbreviations  and Trademarks  
ACR  albumin to creatinine ratio  
AE adverse event  
ALT alanine aminotransferase  
ANA antinuclear antibody  
ANC  absolute neutrophil count  
ANCA  anti-neutrophil cytoplasmic antibody  
cANCA  classical anti -neutrophil cytoplasmic antibodies  
pANCA  perinuclear anti -neutrophil cytoplasmic antibodies  
APRI  aspartate aminotransferase -platelet index  
aPTT  activated partial thromboplastin time  
ASO  antisense oligonucleotide  
AST aspartate aminotransferase  
BDI-II Beck Depression Inventory -II 
cccDNA  covalently closed circular DNA  
CHB  chronic hepatitis B  
Ct concentration  
CNS  central nervous system  
COVID -[ADDRESS_937046] research organi sation  
C-SSRS  Columbia Suicide -Severity Rating Scale  
CV cardiovascular  
DAIDS  Division of Acquired Immune Deficiency Syndrome  
DIVI drug induced vascular inflammation  
DILI drug induced liver injury  
dL decilitres  
DNA  deoxyribonucleic acid  
dsDNA  double stranded deoxyribonucleic acid  
eCRF  electronic case report form  
ECG  electrocardiogram  
ET early termination  
FDA Food and Drug Administration  
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
eGFR  Estimated glomerular filtration rate  
[COMPANY_004]  GlaxoSmithKline  
HBcrAg  hepatitis B core -related antigen  
Anti-HBeAg  hepatitis B virus e -antigen  antibody  
HBeAg  hepatitis B virus e -antigen  
Anti- HBsAg  hepatitis B virus surface antibody  
HBsAg  hepatitis B virus surface antigen  
HBV hepatitis B virus  
HCC  hepatocellular carcinoma  
hCG human chorionic gonadotropin  
HCV  hepatitis C virus  
HDV  hepatitis D virus  
HGRAC  human Genetics Resources Administration of China  
HIV human immunodeficiency virus  
HPF high-power field  
HPLC  high performance liquid chromatography  
HRT hormonal replacement therapy  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 122 
 hs-CRP  high sensitivity  C-reactive protein  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
IDMC  independent data monitoring committee  
IDO indoleamine 2,[ADDRESS_937047]  
ISR injection site reaction  
IVRS/IWRS  Interactive Voice/Web Response System  
ITT Intent -to-Treat  
IU international units  
IP Investigational Product  
Kg kilograms  
kPa kilopascals  
L litres  
LAR(s)  Legally acceptable representative  
LDH lactate dehydrogenase  
LLN lower limit of normal  
LLOQ  lower limit of quantification  
m2 square meters  
MCP  monocyte chemoattractant protein  
mEq milliequivalents  
mcg microgram  
mg milligrams  
Min minutes  
mL millilitres  
mm3 cubic millimetres  
MOE  methoxyethyl  
msec milliseconds  
MSDS  Material Safety Data Sheet  
NA nucleos(t)ide analogue  
Ng nanograms  
Nucleos(t)ide  nucleoside or nucleotide  
OAT organic anion transporter  
OCT  organic cation transporter  
PBMC  peripheral blood mononuclear cells  
PD pharmacodynamics(s)  
PEG  pegylated  
PegIFN  peginterferon  
PK pharmacokinetic(s)  
POC  proof of concept  
PT prothrombin time  
QTcF  Fridericia’s QT correction formula  
QTLs  quality tolerance limits  
RAP reporting and Analysis Plan  
RBC  red blood cell  
RNA  ribonucleic acid  
RNAse H  Ribonuclease H  
mRNA  Messenger RNA  
RPGN  rapi[INVESTIGATOR_690615]-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 123 
 RR response rate  
SAE serious adverse event  
SC subcutaneous(ly)  
siRNA  small interfering ribonucleic acid  
SoA Schedule of Activities  
SPEP  serum protein electrophoresis  
SRM  Study Reference Manual  
SRT Safety Review Team  
SVR Sustained Virologic Response  
t½ terminal half -life 
TCM  traditional Chinese medicine  
TSH thyroid stimulating hormone  
U units  
UA urinalysis  
µg micrograms  
ULN upper limit of normal  
UPEP  urine protein electrophoresis  
mol micromole  
WBC  white blood cell  
WOCBP  women of childbearing potential  
WONCBP  woman of non-childbearing potential  
 
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by [CONTACT_690662]-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 124 
 11. REFERENCES  
Baraclude (Entecavir) [package insert]. Bristol -Myers Squibb Company. Princeton (NJ); 
2015.  
Bennett CF and Swayze EE. RNA targeting therapeutics: molecular mechanisms of 
antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 
50:259 -93.  
Bertoletti A, Ferrari C. I nnate and adaptive immune responses in chronic hepatitis B virus 
infections: towards restoration of immune control of viral infection. Postgrad Med J  
2013;89:294 -304. 
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M et. al. Care 
of pat ients with liver disease during the COVID -19 pandemic: EASL -ESCMID position 
paper. JHEP Reports . 2020;2(3):100113  
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. 
Characterization of hepatitis B virus (HBV) -specific T -cell dysfun ction in chronic HBV 
infection. J Virol . 2007;81:4215 -25. 
Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored 
function of HBV -specific T cells after long -term effective therapy with nucleos(t)ide 
analogues. Gastroenterolo gy. 2012;143:963 -73. 
Bristol -Myers Squibb Company. Baraclude prescribing information ([LOCATION_003]). 12/[ADDRESS_937048] HBsAg 
seroclearance in patients with inactive chronic hepatitis B virus infe ction. Clin 
Gastroenterol Hepatol . 2012;10:297 -302. 
Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA -based 
therapeutics . Drug Discovery Today . 2017 ;22(5):823 -33. ISSN 1359 -6446, 
https://doi.org/10.1016/j.drudis.2017.01.[ADDRESS_937049] J. Abstr. 44th Intersci. Conf. Antimicrob. Agents 
Chemother., abstr. A448, 2004.  
Cihlar T, Ho ES, Lin DC. Human renal organic anion transporter 1 (hOAT1) and its role 
in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic 
Acids  2001;20:641 -8.  
Cornberg, M., Lok, A.S. ‐F., Terrault, N.A., Zoulim, F. (2019), Guidance for Design and 
Endpoints of Clinical Trials in Chronic Hepatitis B —Report From the 2019 EASL ‐
AASLD HBV Treatment Endpoints Conferenc e. Hepatology . 71: 1070 -1092. doi:  
10.1002/hep.[ADDRESS_937050], Baker BF, Wiztum JL, Kwoh TJ, Pham NC, Salgado et al.  The effects of 2’ -
O-Methoxyethyl containgin antisense oligonucleotides on platelets in human clinical 
trials.  Nucleic Acid Ther . 2017; 2 7(3):121 -129.  
Division of AIDS. Division of AIDS (DAIDS ) Table for Grading the Severity of Adult 
and Pediatric Adverse Events Version 2.0. National Institutes of Health; Institute of 
Allergy and Infectious Diseases, Bethesda, MD; 2017. Available at: http://rsc.tech -
res.com/Document/safetyandpharmacovigilance/D AIDS_AE_Grading_Table_v2.1_2017
.pdf  
Epi[INVESTIGATOR_54736] (Lamivudine) [package insert]. GlaxoSmithKline. Research Triangle Park (NC); 
2002.  
European Association for the Study of the Liver (EASL). EASL clinical practice 
guidelines: Management of chronic hepatitis B viru s infection. J Hepatol . 
2012;57:167 -85. 
Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. 
Hepatology . 2009;49([ADDRESS_937051]):S96 -S102.  
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et. al. Clinical 
Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID -
19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology . 2020; 
10.1002/hep.[ZIP_CODE]. doi:  10.1002/hep.[ZIP_CODE]. Online ahead of print.  
Geary RS, Yu RZ, Siwkowski A, Levin AA. Pharmacokinetic/pharmacodynamics 
properties of phosphorothioate 2ʹ -O-(2-methoxyethyl) -modified antisense 
oligonucleotides in animals and man. In Crooke ST, editor. Antisense  Drug Technology: 
Principles, Strategies and Applications, 2nd Edition. Boca Raton, FL. Taylor & Francis 
Group 2008; 305 -326.  
[COMPANY_009] Sciences Inc. Viread prescribing information ([LOCATION_003]). 12/2018 revision  
[COMPANY_004] Document Number 2019N425040_00.  [COMPANY_004]3228836 Inves tigator’s Brochure. 
Version 1. Feb 2020.  
[COMPANY_004] Document Number 2020N429086_00. ISIS 505358 -CS3 Study Report. Clinical 
Study Report:  A Phase 2, Double -Blinded, Randomized, Placebo -Controlled, Dose -
Escalation Study to Examine the Safety, Tolerability, Pharmac okinetics and Antiviral 
Activity of ISIS 505358 in Treatment -Naïve Patients with Chronic Hepatitis B Virus 
Infection.  June 2020.  
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, et al. Contraceptive 
Technology. 20th ed. Atlanta, Georgia:  Ardent Media Inc; 2011.  
Henry SP, Kim TW, Kramer -Strickland K, Zanardi TA, Fey RA, Levin AA. Antisense 
Drug Technology: Principles, Strategies and Applications; Toxicologic properties of 2' -
O-methoxyethyl chimeric antisense inhibitors in animals and man. Crooke ST editor. 2nd 
ed. Boca Raton, [LOCATION_012]:Taylor & Francis Group; 2008.  
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 126 
 Hepsera (Adefovir dipi[INVESTIGATOR_96471]) [package insert]. [COMPANY_009] Sciences, Inc. Foster City (CA); 
2012.  
Höner Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current 
managemen t of chronic HBV infection. Ann Gastroenterol . 2014;27(2):[ADDRESS_937052] in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab  Dispos . 2009;37:1779 -84. 
Jaroszewicz J, Ho H, Markova A, Deterding K, Schlue K, Raupach R, et al. Hepatitis B 
surface antigen (HBsAg) decrease and serum interferon -inducible protein -10 levels as 
predictive markers for HBsAg loss during treatment with nucl eoside/nucleotide 
analogues. Antivir Ther . 2011; 16(6): 915 -924. 
Jones HE, OhlssenDI, NeuenschwanderB, Racine A, Branson M.Bayesian models for 
subgroup analysis in clinical trials.Clin Trials. 2011 Apr; 8(2): 129 –143. Published online 
2011 Jan 31. doi: 10. 1177/1740774510396933  
Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet . 2004;439:595 ‐612 
Kim GA, Lee HC, Kim MJ. (2014) Incidence of hepatocellular carcinoma after HBsAg 
serocleara nce in chronic hepatitis B patients: A need for surveillance.  J Hepato l. Vol 62, 
Issue 5, 1092 –1099.  https://doi.org/10.1016/j.jhep.2014.11.[ADDRESS_937053] a Functional Cure for Hepatitis B Virus Infection. 
Gastroenterol Hepatol (N Y) . 2018;14(7):439 ‐442. 
Lee IC, Yang SS, Lee CJ, Su CW, Wang YJ, Lan KH, et al. 2018. 'Incidence and 
Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg -Negative Chronic 
Hepatitis B: A Multicenter, Long -term Follow -up Study', J Infect Dis . 2018: 10 75-84. 
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian 
Lamivudine Multicenter Study Group. Lamivudine for patients with chronic hepatitis B 
and advanced liver disease. N Engl J Med . 2004;351:1521 -31. 
Lok AS, Zoulim F, Dusheiko G, Ghany MG. 2017. 'Hepatitis B cure: From discovery to 
regulatory approval', Hepatology . 
Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. AASLD practice guidelines. 
Hepatol . 2009;50:1 -36. 
Marcellin P, Ahn SH, Ma X. Combination of Tenofovir Disoproxi l Fumarate and 
Peginterferon α -2a Increases Loss of Hepatitis B Surface Antigen in Patients With 
Chronic Hepatitis B. Gastroenterology . 2016;150(1):134 -144.e10. 
doi:10.1053/j.gastro.2015.09.[ADDRESS_937054] . 1993; 91:[ADDRESS_937055], Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can 
modulate the immune response to the nucleocapsid: a mechanism for pers istence. J 
Immunol . 1998;160:2013 -21. 
Minuesa G, Volk C, Molina -Arcas M, Gorboulev V, Erkizia I, Arndt P, et al. Transport 
of lamivudine [( -)-beta-L-2’,3’ -dideoxy -3’-thiacytidine] and high -affinity interaction of 
nucleoside reverse transcriptase inhibitors  with human organic cation transporters 1, 2, 
and 3. J Pharmacol Exp Ther . 2009;329:252 –61. 
Op den Brouw M L, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van de 
Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell 
funct ion: a possible immune escape mechanism of hepatitis B virus. Immunol . 
2009;126:280 -89. 
Pegasys (peginterferon alfa -2a) injection [Package insert] Hoffmann -La [COMPANY_002], Inc. c/o 
Genentech, Inc. South San Francisco, CA [ZIP_CODE] -4990. U.S. License No. 0136. Revise d: 
October 2017.  
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification 
Algorithm of Suicide Assessment (C -CASA): classification of suicidal events in the 
FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry . 
2007;164(7):1035 -1043.  
Ren H, Huang Y. 2019. 'Effects of pegylated interferon -alpha based therapi[INVESTIGATOR_690616] B', J Viral Hepat . [ADDRESS_937056] 1: [ADDRESS_937057] G, Jaudon MC, et al. Tubular transporters 
and clearance of adefovir. Eur J Pharmacol . 2006;540:168 -74. 
Shemesh  CS, Yu RZ, Warren MS. Assessment of the drug interaction potential of 
unconjugated and galNAc3 -conjugated 2’ -MOE ASOs. Mol Therapy: Nuc Acids . 2017; 
9: 34 -47. 
Tyzeka (Telbivudine) [package insert]. [COMPANY_001] Pharmaceuticals Corporation. East 
Hanover (NJ); 2013.  
Uwai Y, Ida H, Tsuji Y. Renal transport of adefovir, cidofovir, and tenofovir by [CONTACT_103095]22A 
family members (hOAT1, hOAT3, and hOCT2). Pharm Res . 2007; 24: 811 -815. 
Vanlandschoot P, Leroux -Roels G. Viral apoptotic mimicry: an immune evasion strategy 
deve loped by [CONTACT_91292] B virus? Trends  Immunol . 2003;24:144 -47. 
Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux -Roels G. Hepatitis B 
virus surface antigen suppresses the activation of monocytes through interaction with a 
serum protein and a monocyte -specific receptor. J Gen Virol . 2002;83:1281 -89. 
TMF-13966464  CONFIDENTIAL   
  209348  
 Protocol Amd 01  
 128 
 Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic 
promise. Yonsei Med J . 2012;53:875 -85. 
World Health Organization (WHO). Guidelines for the prevention, care an d treatment of 
persons with chronic hepatitis B infection. March 2015.  
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R. Hepatitis B virus suppresses toll -
like receptor -mediated innate immune responses in murine parenchymal and 
nonparenchymal liver cel ls. Hepatology . 2009;49:1132 -40. 
Wursthorn K, Jung M, Riva A. Kinetics of hepatitis B surface antigen decline during 3 
years of telbivudine treatment in hepatitis B e antigen -positive patients. Hepatology . 
2010; 52(5): 1611 -20. 
Xu Q, Wang C, Meng Q. OAT1 a nd OAT3: targets of drug -drug interaction between 
entecavir and JBP485. Eur J Pharm Sci . 2013; 48: 650 -7.  
Yanxiao C, Ruijuan X, Jin Y, Lei C, Qian W, Xuefen Y, et al. Organic anion and cation 
transporters are possibly involved in renal excretion of enteca vir in rats. Life Sci . 
2011;89:1 –6. 
Yeo YH, Ho HJ, Yang H, Tseng TC, Hosaka T, Trinh HN, et al. Factors associated with 
rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review 
and meta-analysis. Gasteroenterology . 2019;156:[ADDRESS_937058] survival 
outcome in patients with hepatitis B related hepatocellular carcinoma?  Transl 
Gastroenterol Hepatol . 2016 ;1:51 
Yu RZ, Warren MS, Watanabe T. Lack of interactions between an antisense 
oligonucleotide with 2' -O-(2- methoxyethyl) modifications and major drug transporters. 
Nucleic Acid Ther . 2016;26:111 -7.  
Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, et al. 2019. RNA interference 
therapy with ARC -520 results i n prolonged HBsAg response in patients with chronic 
hepatitis B infection . Hepatology . 2020 ;72:1(19 -31). 
 